Datasets:
bio-datasets
/
bigbio-ner-merged

Dataset card Data Studio Files
xet
Community
answer
stringlengths
1
16.1k
id
stringlengths
7
56
instruction
stringlengths
106
72.6k
ner_tags
list
text
stringlengths
5
72.4k
tokens
list
types
list
adaptations, human, pregnancy, ovulation, heart rate, blood pressure, stroke volume, cardiac output, peripheral resistance, compliance, standard, menstrual cycle, conception, conception, Techniques, EKG, blood pressure, measurement, plethysmography, conception, conception, time, human chorionic gonadotropin, estradiol, progesterone
DerGynaekologe.90320360.eng.abstr_task2
Sentence: To test the hypothesis that cardiovascular adaptations to human pregnancy begin in the first 4 weeks post ovulation ( PO ) we obtained estimates of resting heart rate ( HR ) , blood pressure ( BP ) , stroke volume ( SV ) , cardiac output ( CO ) , peripheral resistance ( TPR ) , and venous capacity ( VC ) and compliance ( VCom ) weekly under standard conditions beginning on day 3 of the menstrual cycle . The data obtained in cycles with conception were compared to those in which conception did not occur . Techniques utilized included EKG , automated blood pressure measurement ( Dynamap ) , echocardiography , and plethysmography . No directional changes were observed in any parameter during the cycles in which conception did not occur . However , in cycles in which conception occurred HR increased 10 bpm within 1 week PO and remained at that level for the next 7 weeks . BP did not fall significantly until the 5th week PO . SV rose significantly between the 2nd and 3rd week PO and plateaued 10 % above pre ovulatory levels thereafter . As a result , CO rose and TPR fell significantly within 1 week PO and plateaued 1.5 l/min above and 300 dyne/cm/s-5 below pre ovulatory levels by the 3rd PO week . VC increased and followed a similar time course . These changes were associated with rapid increases in human chorionic gonadotropin , a fourfold increase in estradiol , and a twofold increase in progesterone . We conclude that the hypothesis is correct and speculate that the cardiovascular changes are initiated by the rapidly changing hormonal milieu . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
To test the hypothesis that cardiovascular adaptations to human pregnancy begin in the first 4 weeks post ovulation ( PO ) we obtained estimates of resting heart rate ( HR ) , blood pressure ( BP ) , stroke volume ( SV ) , cardiac output ( CO ) , peripheral resistance ( TPR ) , and venous capacity ( VC ) and compliance ( VCom ) weekly under standard conditions beginning on day 3 of the menstrual cycle . The data obtained in cycles with conception were compared to those in which conception did not occur . Techniques utilized included EKG , automated blood pressure measurement ( Dynamap ) , echocardiography , and plethysmography . No directional changes were observed in any parameter during the cycles in which conception did not occur . However , in cycles in which conception occurred HR increased 10 bpm within 1 week PO and remained at that level for the next 7 weeks . BP did not fall significantly until the 5th week PO . SV rose significantly between the 2nd and 3rd week PO and plateaued 10 % above pre ovulatory levels thereafter . As a result , CO rose and TPR fell significantly within 1 week PO and plateaued 1.5 l/min above and 300 dyne/cm/s-5 below pre ovulatory levels by the 3rd PO week . VC increased and followed a similar time course . These changes were associated with rapid increases in human chorionic gonadotropin , a fourfold increase in estradiol , and a twofold increase in progesterone . We conclude that the hypothesis is correct and speculate that the cardiovascular changes are initiated by the rapidly changing hormonal milieu .
[ "To", "test", "the", "hypothesis", "that", "cardiovascular", "adaptations", "to", "human", "pregnancy", "begin", "in", "the", "first", "4", "weeks", "post", "ovulation", "(", "PO", ")", "we", "obtained", "estimates", "of", "resting", "heart", "rate", "(", "HR", ")", ",", "blood", "pressure", "(", "BP", ")", ",", "stroke", "volume", "(", "SV", ")", ",", "cardiac", "output", "(", "CO", ")", ",", "peripheral", "resistance", "(", "TPR", ")", ",", "and", "venous", "capacity", "(", "VC", ")", "and", "compliance", "(", "VCom", ")", "weekly", "under", "standard", "conditions", "beginning", "on", "day", "3", "of", "the", "menstrual", "cycle", ".", "The", "data", "obtained", "in", "cycles", "with", "conception", "were", "compared", "to", "those", "in", "which", "conception", "did", "not", "occur", ".", "Techniques", "utilized", "included", "EKG", ",", "automated", "blood", "pressure", "measurement", "(", "Dynamap", ")", ",", "echocardiography", ",", "and", "plethysmography", ".", "No", "directional", "changes", "were", "observed", "in", "any", "parameter", "during", "the", "cycles", "in", "which", "conception", "did", "not", "occur", ".", "However", ",", "in", "cycles", "in", "which", "conception", "occurred", "HR", "increased", "10", "bpm", "within", "1", "week", "PO", "and", "remained", "at", "that", "level", "for", "the", "next", "7", "weeks", ".", "BP", "did", "not", "fall", "significantly", "until", "the", "5th", "week", "PO", ".", "SV", "rose", "significantly", "between", "the", "2nd", "and", "3rd", "week", "PO", "and", "plateaued", "10", "%", "above", "pre", "ovulatory", "levels", "thereafter", ".", "As", "a", "result", ",", "CO", "rose", "and", "TPR", "fell", "significantly", "within", "1", "week", "PO", "and", "plateaued", "1.5", "l", "/", "min", "above", "and", "300", "dyne", "/", "cm", "/", "s-5", "below", "pre", "ovulatory", "levels", "by", "the", "3rd", "PO", "week", ".", "VC", "increased", "and", "followed", "a", "similar", "time", "course", ".", "These", "changes", "were", "associated", "with", "rapid", "increases", "in", "human", "chorionic", "gonadotropin", ",", "a", "fourfold", "increase", "in", "estradiol", ",", "and", "a", "twofold", "increase", "in", "progesterone", ".", "We", "conclude", "that", "the", "hypothesis", "is", "correct", "and", "speculate", "that", "the", "cardiovascular", "changes", "are", "initiated", "by", "the", "rapidly", "changing", "hormonal", "milieu", "." ]
[ "umlsterm" ]
TiO2 is a CHEMICAL, Ag is a CHEMICAL, graphitic is a CHEMICAL, carbon is a CHEMICAL, Ag is a CHEMICAL, TiO2 is a CHEMICAL, RhB is a CHEMICAL, phenol is a CHEMICAL, carbon is a CHEMICAL
23058_task0
Sentence: The design and realization of a large-area flexible nanofiber-based mat for pollutant degradation: an application in photocatalysis. This work demonstrates a novel multifunctional nanofibrous mat for photocatalytic applications based on TiO2 nanocables functionalized by Ag nanoparticles and coated with a thin (∼2 nm) graphitic shell. In this mat, which was realized by an electrospinning technique, each component serves a unique function: the carbon coating acts as both an adsorption material for capturing pollutants and as a charge-transfer material, the Ag nanoparticles act as a visible-light sensitizing agent and also as a charge-transfer material, finally the TiO2 nanocable mat acts as a UV sensitive photocatalytic matrix and as the flexible substrate for the other functional components. This multicomponent nanocable mat exhibits excellent photocatalytic activity under simulated solar irradiation for the degradation of model pollutants including RhB and phenol. The significant photocatalytic properties are attributed to the synergetic effect of the three functional components and the unique charge transport "freeway" property of the nanofibrous mat. In addition, the porous carbon coating infiltrated into the nanocable matrix endows the mat with excellent flexibility and enables robust, large-area (10 × 10 cm) fabrication, representing a significant advantage over previous brittle ceramic nanofibrous mat photocatalyst substrates. This study provides new insight into the design and preparation of an advanced, yet commercially practical and scaleable photocatalytic composite membrane material. The as-prepared photocatalytic mat might also be of interest in solar cell, catalysis, separation technology, biomedical engineering, and nanotechnology. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
The design and realization of a large-area flexible nanofiber-based mat for pollutant degradation: an application in photocatalysis. This work demonstrates a novel multifunctional nanofibrous mat for photocatalytic applications based on TiO2 nanocables functionalized by Ag nanoparticles and coated with a thin (∼2 nm) graphitic shell. In this mat, which was realized by an electrospinning technique, each component serves a unique function: the carbon coating acts as both an adsorption material for capturing pollutants and as a charge-transfer material, the Ag nanoparticles act as a visible-light sensitizing agent and also as a charge-transfer material, finally the TiO2 nanocable mat acts as a UV sensitive photocatalytic matrix and as the flexible substrate for the other functional components. This multicomponent nanocable mat exhibits excellent photocatalytic activity under simulated solar irradiation for the degradation of model pollutants including RhB and phenol. The significant photocatalytic properties are attributed to the synergetic effect of the three functional components and the unique charge transport "freeway" property of the nanofibrous mat. In addition, the porous carbon coating infiltrated into the nanocable matrix endows the mat with excellent flexibility and enables robust, large-area (10 × 10 cm) fabrication, representing a significant advantage over previous brittle ceramic nanofibrous mat photocatalyst substrates. This study provides new insight into the design and preparation of an advanced, yet commercially practical and scaleable photocatalytic composite membrane material. The as-prepared photocatalytic mat might also be of interest in solar cell, catalysis, separation technology, biomedical engineering, and nanotechnology.
[ "The", "design", "and", "realization", "of", "a", "large", "-", "area", "flexible", "nanofiber", "-", "based", "mat", "for", "pollutant", "degradation", ":", "an", "application", "in", "photocatalysis", ".", "\n", "This", "work", "demonstrates", "a", "novel", "multifunctional", "nanofibrous", "mat", "for", "photocatalytic", "applications", "based", "on", "TiO2", "nanocables", "functionalized", "by", "Ag", "nanoparticles", "and", "coated", "with", "a", "thin", "(", "∼2", "nm", ")", "graphitic", "shell", ".", "In", "this", "mat", ",", "which", "was", "realized", "by", "an", "electrospinning", "technique", ",", "each", "component", "serves", "a", "unique", "function", ":", "the", "carbon", "coating", "acts", "as", "both", "an", "adsorption", "material", "for", "capturing", "pollutants", "and", "as", "a", "charge", "-", "transfer", "material", ",", "the", "Ag", "nanoparticles", "act", "as", "a", "visible", "-", "light", "sensitizing", "agent", "and", "also", "as", "a", "charge", "-", "transfer", "material", ",", "finally", "the", "TiO2", "nanocable", "mat", "acts", "as", "a", "UV", "sensitive", "photocatalytic", "matrix", "and", "as", "the", "flexible", "substrate", "for", "the", "other", "functional", "components", ".", "This", "multicomponent", "nanocable", "mat", "exhibits", "excellent", "photocatalytic", "activity", "under", "simulated", "solar", "irradiation", "for", "the", "degradation", "of", "model", "pollutants", "including", "RhB", "and", "phenol", ".", "The", "significant", "photocatalytic", "properties", "are", "attributed", "to", "the", "synergetic", "effect", "of", "the", "three", "functional", "components", "and", "the", "unique", "charge", "transport", "\"", "freeway", "\"", "property", "of", "the", "nanofibrous", "mat", ".", "In", "addition", ",", "the", "porous", "carbon", "coating", "infiltrated", "into", "the", "nanocable", "matrix", "endows", "the", "mat", "with", "excellent", "flexibility", "and", "enables", "robust", ",", "large", "-", "area", "(", "10", "×", "10", "cm", ")", "fabrication", ",", "representing", "a", "significant", "advantage", "over", "previous", "brittle", "ceramic", "nanofibrous", "mat", "photocatalyst", "substrates", ".", "This", "study", "provides", "new", "insight", "into", "the", "design", "and", "preparation", "of", "an", "advanced", ",", "yet", "commercially", "practical", "and", "scaleable", "photocatalytic", "composite", "membrane", "material", ".", "The", "as", "-", "prepared", "photocatalytic", "mat", "might", "also", "be", "of", "interest", "in", "solar", "cell", ",", "catalysis", ",", "separation", "technology", ",", "biomedical", "engineering", ",", "and", "nanotechnology", "." ]
[ "CHEMICAL" ]
TiO2 is a CHEMICAL, Ag is a CHEMICAL, graphitic is a CHEMICAL, carbon is a CHEMICAL, Ag is a CHEMICAL, TiO2 is a CHEMICAL, RhB is a CHEMICAL, phenol is a CHEMICAL, carbon is a CHEMICAL
23058_task1
Sentence: The design and realization of a large-area flexible nanofiber-based mat for pollutant degradation: an application in photocatalysis. This work demonstrates a novel multifunctional nanofibrous mat for photocatalytic applications based on TiO2 nanocables functionalized by Ag nanoparticles and coated with a thin (∼2 nm) graphitic shell. In this mat, which was realized by an electrospinning technique, each component serves a unique function: the carbon coating acts as both an adsorption material for capturing pollutants and as a charge-transfer material, the Ag nanoparticles act as a visible-light sensitizing agent and also as a charge-transfer material, finally the TiO2 nanocable mat acts as a UV sensitive photocatalytic matrix and as the flexible substrate for the other functional components. This multicomponent nanocable mat exhibits excellent photocatalytic activity under simulated solar irradiation for the degradation of model pollutants including RhB and phenol. The significant photocatalytic properties are attributed to the synergetic effect of the three functional components and the unique charge transport "freeway" property of the nanofibrous mat. In addition, the porous carbon coating infiltrated into the nanocable matrix endows the mat with excellent flexibility and enables robust, large-area (10 × 10 cm) fabrication, representing a significant advantage over previous brittle ceramic nanofibrous mat photocatalyst substrates. This study provides new insight into the design and preparation of an advanced, yet commercially practical and scaleable photocatalytic composite membrane material. The as-prepared photocatalytic mat might also be of interest in solar cell, catalysis, separation technology, biomedical engineering, and nanotechnology. Instructions: please typing these entity words according to sentence: TiO2, Ag, graphitic, carbon, Ag, TiO2, RhB, phenol, carbon Options: CHEMICAL
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
The design and realization of a large-area flexible nanofiber-based mat for pollutant degradation: an application in photocatalysis. This work demonstrates a novel multifunctional nanofibrous mat for photocatalytic applications based on TiO2 nanocables functionalized by Ag nanoparticles and coated with a thin (∼2 nm) graphitic shell. In this mat, which was realized by an electrospinning technique, each component serves a unique function: the carbon coating acts as both an adsorption material for capturing pollutants and as a charge-transfer material, the Ag nanoparticles act as a visible-light sensitizing agent and also as a charge-transfer material, finally the TiO2 nanocable mat acts as a UV sensitive photocatalytic matrix and as the flexible substrate for the other functional components. This multicomponent nanocable mat exhibits excellent photocatalytic activity under simulated solar irradiation for the degradation of model pollutants including RhB and phenol. The significant photocatalytic properties are attributed to the synergetic effect of the three functional components and the unique charge transport "freeway" property of the nanofibrous mat. In addition, the porous carbon coating infiltrated into the nanocable matrix endows the mat with excellent flexibility and enables robust, large-area (10 × 10 cm) fabrication, representing a significant advantage over previous brittle ceramic nanofibrous mat photocatalyst substrates. This study provides new insight into the design and preparation of an advanced, yet commercially practical and scaleable photocatalytic composite membrane material. The as-prepared photocatalytic mat might also be of interest in solar cell, catalysis, separation technology, biomedical engineering, and nanotechnology.
[ "The", "design", "and", "realization", "of", "a", "large", "-", "area", "flexible", "nanofiber", "-", "based", "mat", "for", "pollutant", "degradation", ":", "an", "application", "in", "photocatalysis", ".", "\n", "This", "work", "demonstrates", "a", "novel", "multifunctional", "nanofibrous", "mat", "for", "photocatalytic", "applications", "based", "on", "TiO2", "nanocables", "functionalized", "by", "Ag", "nanoparticles", "and", "coated", "with", "a", "thin", "(", "∼2", "nm", ")", "graphitic", "shell", ".", "In", "this", "mat", ",", "which", "was", "realized", "by", "an", "electrospinning", "technique", ",", "each", "component", "serves", "a", "unique", "function", ":", "the", "carbon", "coating", "acts", "as", "both", "an", "adsorption", "material", "for", "capturing", "pollutants", "and", "as", "a", "charge", "-", "transfer", "material", ",", "the", "Ag", "nanoparticles", "act", "as", "a", "visible", "-", "light", "sensitizing", "agent", "and", "also", "as", "a", "charge", "-", "transfer", "material", ",", "finally", "the", "TiO2", "nanocable", "mat", "acts", "as", "a", "UV", "sensitive", "photocatalytic", "matrix", "and", "as", "the", "flexible", "substrate", "for", "the", "other", "functional", "components", ".", "This", "multicomponent", "nanocable", "mat", "exhibits", "excellent", "photocatalytic", "activity", "under", "simulated", "solar", "irradiation", "for", "the", "degradation", "of", "model", "pollutants", "including", "RhB", "and", "phenol", ".", "The", "significant", "photocatalytic", "properties", "are", "attributed", "to", "the", "synergetic", "effect", "of", "the", "three", "functional", "components", "and", "the", "unique", "charge", "transport", "\"", "freeway", "\"", "property", "of", "the", "nanofibrous", "mat", ".", "In", "addition", ",", "the", "porous", "carbon", "coating", "infiltrated", "into", "the", "nanocable", "matrix", "endows", "the", "mat", "with", "excellent", "flexibility", "and", "enables", "robust", ",", "large", "-", "area", "(", "10", "×", "10", "cm", ")", "fabrication", ",", "representing", "a", "significant", "advantage", "over", "previous", "brittle", "ceramic", "nanofibrous", "mat", "photocatalyst", "substrates", ".", "This", "study", "provides", "new", "insight", "into", "the", "design", "and", "preparation", "of", "an", "advanced", ",", "yet", "commercially", "practical", "and", "scaleable", "photocatalytic", "composite", "membrane", "material", ".", "The", "as", "-", "prepared", "photocatalytic", "mat", "might", "also", "be", "of", "interest", "in", "solar", "cell", ",", "catalysis", ",", "separation", "technology", ",", "biomedical", "engineering", ",", "and", "nanotechnology", "." ]
[ "CHEMICAL" ]
TiO2, Ag, graphitic, carbon, Ag, TiO2, RhB, phenol, carbon
23058_task2
Sentence: The design and realization of a large-area flexible nanofiber-based mat for pollutant degradation: an application in photocatalysis. This work demonstrates a novel multifunctional nanofibrous mat for photocatalytic applications based on TiO2 nanocables functionalized by Ag nanoparticles and coated with a thin (∼2 nm) graphitic shell. In this mat, which was realized by an electrospinning technique, each component serves a unique function: the carbon coating acts as both an adsorption material for capturing pollutants and as a charge-transfer material, the Ag nanoparticles act as a visible-light sensitizing agent and also as a charge-transfer material, finally the TiO2 nanocable mat acts as a UV sensitive photocatalytic matrix and as the flexible substrate for the other functional components. This multicomponent nanocable mat exhibits excellent photocatalytic activity under simulated solar irradiation for the degradation of model pollutants including RhB and phenol. The significant photocatalytic properties are attributed to the synergetic effect of the three functional components and the unique charge transport "freeway" property of the nanofibrous mat. In addition, the porous carbon coating infiltrated into the nanocable matrix endows the mat with excellent flexibility and enables robust, large-area (10 × 10 cm) fabrication, representing a significant advantage over previous brittle ceramic nanofibrous mat photocatalyst substrates. This study provides new insight into the design and preparation of an advanced, yet commercially practical and scaleable photocatalytic composite membrane material. The as-prepared photocatalytic mat might also be of interest in solar cell, catalysis, separation technology, biomedical engineering, and nanotechnology. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
The design and realization of a large-area flexible nanofiber-based mat for pollutant degradation: an application in photocatalysis. This work demonstrates a novel multifunctional nanofibrous mat for photocatalytic applications based on TiO2 nanocables functionalized by Ag nanoparticles and coated with a thin (∼2 nm) graphitic shell. In this mat, which was realized by an electrospinning technique, each component serves a unique function: the carbon coating acts as both an adsorption material for capturing pollutants and as a charge-transfer material, the Ag nanoparticles act as a visible-light sensitizing agent and also as a charge-transfer material, finally the TiO2 nanocable mat acts as a UV sensitive photocatalytic matrix and as the flexible substrate for the other functional components. This multicomponent nanocable mat exhibits excellent photocatalytic activity under simulated solar irradiation for the degradation of model pollutants including RhB and phenol. The significant photocatalytic properties are attributed to the synergetic effect of the three functional components and the unique charge transport "freeway" property of the nanofibrous mat. In addition, the porous carbon coating infiltrated into the nanocable matrix endows the mat with excellent flexibility and enables robust, large-area (10 × 10 cm) fabrication, representing a significant advantage over previous brittle ceramic nanofibrous mat photocatalyst substrates. This study provides new insight into the design and preparation of an advanced, yet commercially practical and scaleable photocatalytic composite membrane material. The as-prepared photocatalytic mat might also be of interest in solar cell, catalysis, separation technology, biomedical engineering, and nanotechnology.
[ "The", "design", "and", "realization", "of", "a", "large", "-", "area", "flexible", "nanofiber", "-", "based", "mat", "for", "pollutant", "degradation", ":", "an", "application", "in", "photocatalysis", ".", "\n", "This", "work", "demonstrates", "a", "novel", "multifunctional", "nanofibrous", "mat", "for", "photocatalytic", "applications", "based", "on", "TiO2", "nanocables", "functionalized", "by", "Ag", "nanoparticles", "and", "coated", "with", "a", "thin", "(", "∼2", "nm", ")", "graphitic", "shell", ".", "In", "this", "mat", ",", "which", "was", "realized", "by", "an", "electrospinning", "technique", ",", "each", "component", "serves", "a", "unique", "function", ":", "the", "carbon", "coating", "acts", "as", "both", "an", "adsorption", "material", "for", "capturing", "pollutants", "and", "as", "a", "charge", "-", "transfer", "material", ",", "the", "Ag", "nanoparticles", "act", "as", "a", "visible", "-", "light", "sensitizing", "agent", "and", "also", "as", "a", "charge", "-", "transfer", "material", ",", "finally", "the", "TiO2", "nanocable", "mat", "acts", "as", "a", "UV", "sensitive", "photocatalytic", "matrix", "and", "as", "the", "flexible", "substrate", "for", "the", "other", "functional", "components", ".", "This", "multicomponent", "nanocable", "mat", "exhibits", "excellent", "photocatalytic", "activity", "under", "simulated", "solar", "irradiation", "for", "the", "degradation", "of", "model", "pollutants", "including", "RhB", "and", "phenol", ".", "The", "significant", "photocatalytic", "properties", "are", "attributed", "to", "the", "synergetic", "effect", "of", "the", "three", "functional", "components", "and", "the", "unique", "charge", "transport", "\"", "freeway", "\"", "property", "of", "the", "nanofibrous", "mat", ".", "In", "addition", ",", "the", "porous", "carbon", "coating", "infiltrated", "into", "the", "nanocable", "matrix", "endows", "the", "mat", "with", "excellent", "flexibility", "and", "enables", "robust", ",", "large", "-", "area", "(", "10", "×", "10", "cm", ")", "fabrication", ",", "representing", "a", "significant", "advantage", "over", "previous", "brittle", "ceramic", "nanofibrous", "mat", "photocatalyst", "substrates", ".", "This", "study", "provides", "new", "insight", "into", "the", "design", "and", "preparation", "of", "an", "advanced", ",", "yet", "commercially", "practical", "and", "scaleable", "photocatalytic", "composite", "membrane", "material", ".", "The", "as", "-", "prepared", "photocatalytic", "mat", "might", "also", "be", "of", "interest", "in", "solar", "cell", ",", "catalysis", ",", "separation", "technology", ",", "biomedical", "engineering", ",", "and", "nanotechnology", "." ]
[ "CHEMICAL" ]
fine - needle is an umlsterm, aspiration biopsy is an umlsterm, prostate is an umlsterm, control is an umlsterm, method is an umlsterm, diagnostic is an umlsterm, evaluation is an umlsterm, sensitivity is an umlsterm, complication is an umlsterm, specificity is an umlsterm, method is an umlsterm, cytology is an umlsterm, prostate is an umlsterm, forms is an umlsterm, prostatitis is an umlsterm, cancer is an umlsterm, PIN is an umlsterm, diagnoses is an umlsterm, adenocarcinomas is an umlsterm, prostate is an umlsterm, proven is an umlsterm, histologic is an umlsterm, lymph nodes is an umlsterm, sensitivity is an umlsterm, specificity is an umlsterm, prostatectomies is an umlsterm, tumor is an umlsterm, proven is an umlsterm, Diagnostic is an umlsterm, DNA is an umlsterm, prostatic cancer is an umlsterm, patients is an umlsterm, risk of is an umlsterm, tumor is an umlsterm, survival is an umlsterm, probability is an umlsterm, therapy is an umlsterm, Patients is an umlsterm, DNA is an umlsterm, prognosis is an umlsterm, therapy is an umlsterm, prostatic cancers is an umlsterm, therapy is an umlsterm
DerPathologe.80190053.eng.abstr_task0
Sentence: Transrectal fine-needle aspiration biopsy ( FNAB ) of the prostate under digital control is a cheap and rapid method for diagnostic evaluation of palpable and non-palpable nodules , yielding high sensitivity ( ca. 95% ) and a low complication rate ( 1% ) . Its specificity amounts to > 97% . The scarcity of urologists trained in the FNAB method and of pathologists experienced in cytology of the prostate limit the clinical application so far . Besides various forms of prostatitis , five different types of cancer can cytologically be differentiated . While PIN I cannot be cytologically identified , PIN II/III lesions may lead to false-positive diagnoses . Cytologic grading of adenocarcinomas of the prostate is of statistically proven prognostic validity and strictly correlated with its histologic counterpart . Preoperative , radiologically controlled FNAB of pelvic and paraortal lymph nodes has sensitivity of ca. 86% and specificity of 100% . It thus helps to avoid unnecessary prostatectomies if nodal tumor spread has preoperatively been proven . Diagnostic DNA cytometry is able to identify those prostatic cancer patients who do not reveal significantly increased risk of tumor progression or decreased survival probability , even without therapy ( constantly and representatively diploid and tetraploid patterns ) . Patients with DNA tetraplid histograms may show detoriation of prognosis under hormonal therapy . DNA-aneuploid prostatic cancers should not be subjected to a " wait and see " strategy ; they do not respond to hormonal therapy . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]
Transrectal fine-needle aspiration biopsy ( FNAB ) of the prostate under digital control is a cheap and rapid method for diagnostic evaluation of palpable and non-palpable nodules , yielding high sensitivity ( ca. 95% ) and a low complication rate ( 1% ) . Its specificity amounts to > 97% . The scarcity of urologists trained in the FNAB method and of pathologists experienced in cytology of the prostate limit the clinical application so far . Besides various forms of prostatitis , five different types of cancer can cytologically be differentiated . While PIN I cannot be cytologically identified , PIN II/III lesions may lead to false-positive diagnoses . Cytologic grading of adenocarcinomas of the prostate is of statistically proven prognostic validity and strictly correlated with its histologic counterpart . Preoperative , radiologically controlled FNAB of pelvic and paraortal lymph nodes has sensitivity of ca. 86% and specificity of 100% . It thus helps to avoid unnecessary prostatectomies if nodal tumor spread has preoperatively been proven . Diagnostic DNA cytometry is able to identify those prostatic cancer patients who do not reveal significantly increased risk of tumor progression or decreased survival probability , even without therapy ( constantly and representatively diploid and tetraploid patterns ) . Patients with DNA tetraplid histograms may show detoriation of prognosis under hormonal therapy . DNA-aneuploid prostatic cancers should not be subjected to a " wait and see " strategy ; they do not respond to hormonal therapy .
[ "Transrectal", "fine", "-", "needle", "aspiration", "biopsy", "(", "FNAB", ")", "of", "the", "prostate", "under", "digital", "control", "is", "a", "cheap", "and", "rapid", "method", "for", "diagnostic", "evaluation", "of", "palpable", "and", "non", "-", "palpable", "nodules", ",", "yielding", "high", "sensitivity", "(", "ca", ".", "95", "%", ")", "and", "a", "low", "complication", "rate", "(", "1", "%", ")", ".", "Its", "specificity", "amounts", "to", ">", "97", "%", ".", "The", "scarcity", "of", "urologists", "trained", "in", "the", "FNAB", "method", "and", "of", "pathologists", "experienced", "in", "cytology", "of", "the", "prostate", "limit", "the", "clinical", "application", "so", "far", ".", "Besides", "various", "forms", "of", "prostatitis", ",", "five", "different", "types", "of", "cancer", "can", "cytologically", "be", "differentiated", ".", "While", "PIN", "I", "cannot", "be", "cytologically", "identified", ",", "PIN", "II", "/", "III", "lesions", "may", "lead", "to", "false", "-", "positive", "diagnoses", ".", "Cytologic", "grading", "of", "adenocarcinomas", "of", "the", "prostate", "is", "of", "statistically", "proven", "prognostic", "validity", "and", "strictly", "correlated", "with", "its", "histologic", "counterpart", ".", "Preoperative", ",", "radiologically", "controlled", "FNAB", "of", "pelvic", "and", "paraortal", "lymph", "nodes", "has", "sensitivity", "of", "ca", ".", "86", "%", "and", "specificity", "of", "100", "%", ".", "It", "thus", "helps", "to", "avoid", "unnecessary", "prostatectomies", "if", "nodal", "tumor", "spread", "has", "preoperatively", "been", "proven", ".", "Diagnostic", "DNA", "cytometry", "is", "able", "to", "identify", "those", "prostatic", "cancer", "patients", "who", "do", "not", "reveal", "significantly", "increased", "risk", "of", "tumor", "progression", "or", "decreased", "survival", "probability", ",", "even", "without", "therapy", "(", "constantly", "and", "representatively", "diploid", "and", "tetraploid", "patterns", ")", ".", "Patients", "with", "DNA", "tetraplid", "histograms", "may", "show", "detoriation", "of", "prognosis", "under", "hormonal", "therapy", ".", "DNA", "-", "aneuploid", "prostatic", "cancers", "should", "not", "be", "subjected", "to", "a", "\"", "wait", "and", "see", "\"", "strategy", ";", "they", "do", "not", "respond", "to", "hormonal", "therapy", "." ]
[ "umlsterm" ]
fine - needle is an umlsterm, aspiration biopsy is an umlsterm, prostate is an umlsterm, control is an umlsterm, method is an umlsterm, diagnostic is an umlsterm, evaluation is an umlsterm, sensitivity is an umlsterm, complication is an umlsterm, specificity is an umlsterm, method is an umlsterm, cytology is an umlsterm, prostate is an umlsterm, forms is an umlsterm, prostatitis is an umlsterm, cancer is an umlsterm, PIN is an umlsterm, diagnoses is an umlsterm, adenocarcinomas is an umlsterm, prostate is an umlsterm, proven is an umlsterm, histologic is an umlsterm, lymph nodes is an umlsterm, sensitivity is an umlsterm, specificity is an umlsterm, prostatectomies is an umlsterm, tumor is an umlsterm, proven is an umlsterm, Diagnostic is an umlsterm, DNA is an umlsterm, prostatic cancer is an umlsterm, patients is an umlsterm, risk of is an umlsterm, tumor is an umlsterm, survival is an umlsterm, probability is an umlsterm, therapy is an umlsterm, Patients is an umlsterm, DNA is an umlsterm, prognosis is an umlsterm, therapy is an umlsterm, prostatic cancers is an umlsterm, therapy is an umlsterm
DerPathologe.80190053.eng.abstr_task1
Sentence: Transrectal fine-needle aspiration biopsy ( FNAB ) of the prostate under digital control is a cheap and rapid method for diagnostic evaluation of palpable and non-palpable nodules , yielding high sensitivity ( ca. 95% ) and a low complication rate ( 1% ) . Its specificity amounts to > 97% . The scarcity of urologists trained in the FNAB method and of pathologists experienced in cytology of the prostate limit the clinical application so far . Besides various forms of prostatitis , five different types of cancer can cytologically be differentiated . While PIN I cannot be cytologically identified , PIN II/III lesions may lead to false-positive diagnoses . Cytologic grading of adenocarcinomas of the prostate is of statistically proven prognostic validity and strictly correlated with its histologic counterpart . Preoperative , radiologically controlled FNAB of pelvic and paraortal lymph nodes has sensitivity of ca. 86% and specificity of 100% . It thus helps to avoid unnecessary prostatectomies if nodal tumor spread has preoperatively been proven . Diagnostic DNA cytometry is able to identify those prostatic cancer patients who do not reveal significantly increased risk of tumor progression or decreased survival probability , even without therapy ( constantly and representatively diploid and tetraploid patterns ) . Patients with DNA tetraplid histograms may show detoriation of prognosis under hormonal therapy . DNA-aneuploid prostatic cancers should not be subjected to a " wait and see " strategy ; they do not respond to hormonal therapy . Instructions: please typing these entity words according to sentence: fine - needle, aspiration biopsy, prostate, control, method, diagnostic, evaluation, sensitivity, complication, specificity, method, cytology, prostate, forms, prostatitis, cancer, PIN, diagnoses, adenocarcinomas, prostate, proven, histologic, lymph nodes, sensitivity, specificity, prostatectomies, tumor, proven, Diagnostic, DNA, prostatic cancer, patients, risk of, tumor, survival, probability, therapy, Patients, DNA, prognosis, therapy, prostatic cancers, therapy Options: umlsterm
[ "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]
Transrectal fine-needle aspiration biopsy ( FNAB ) of the prostate under digital control is a cheap and rapid method for diagnostic evaluation of palpable and non-palpable nodules , yielding high sensitivity ( ca. 95% ) and a low complication rate ( 1% ) . Its specificity amounts to > 97% . The scarcity of urologists trained in the FNAB method and of pathologists experienced in cytology of the prostate limit the clinical application so far . Besides various forms of prostatitis , five different types of cancer can cytologically be differentiated . While PIN I cannot be cytologically identified , PIN II/III lesions may lead to false-positive diagnoses . Cytologic grading of adenocarcinomas of the prostate is of statistically proven prognostic validity and strictly correlated with its histologic counterpart . Preoperative , radiologically controlled FNAB of pelvic and paraortal lymph nodes has sensitivity of ca. 86% and specificity of 100% . It thus helps to avoid unnecessary prostatectomies if nodal tumor spread has preoperatively been proven . Diagnostic DNA cytometry is able to identify those prostatic cancer patients who do not reveal significantly increased risk of tumor progression or decreased survival probability , even without therapy ( constantly and representatively diploid and tetraploid patterns ) . Patients with DNA tetraplid histograms may show detoriation of prognosis under hormonal therapy . DNA-aneuploid prostatic cancers should not be subjected to a " wait and see " strategy ; they do not respond to hormonal therapy .
[ "Transrectal", "fine", "-", "needle", "aspiration", "biopsy", "(", "FNAB", ")", "of", "the", "prostate", "under", "digital", "control", "is", "a", "cheap", "and", "rapid", "method", "for", "diagnostic", "evaluation", "of", "palpable", "and", "non", "-", "palpable", "nodules", ",", "yielding", "high", "sensitivity", "(", "ca", ".", "95", "%", ")", "and", "a", "low", "complication", "rate", "(", "1", "%", ")", ".", "Its", "specificity", "amounts", "to", ">", "97", "%", ".", "The", "scarcity", "of", "urologists", "trained", "in", "the", "FNAB", "method", "and", "of", "pathologists", "experienced", "in", "cytology", "of", "the", "prostate", "limit", "the", "clinical", "application", "so", "far", ".", "Besides", "various", "forms", "of", "prostatitis", ",", "five", "different", "types", "of", "cancer", "can", "cytologically", "be", "differentiated", ".", "While", "PIN", "I", "cannot", "be", "cytologically", "identified", ",", "PIN", "II", "/", "III", "lesions", "may", "lead", "to", "false", "-", "positive", "diagnoses", ".", "Cytologic", "grading", "of", "adenocarcinomas", "of", "the", "prostate", "is", "of", "statistically", "proven", "prognostic", "validity", "and", "strictly", "correlated", "with", "its", "histologic", "counterpart", ".", "Preoperative", ",", "radiologically", "controlled", "FNAB", "of", "pelvic", "and", "paraortal", "lymph", "nodes", "has", "sensitivity", "of", "ca", ".", "86", "%", "and", "specificity", "of", "100", "%", ".", "It", "thus", "helps", "to", "avoid", "unnecessary", "prostatectomies", "if", "nodal", "tumor", "spread", "has", "preoperatively", "been", "proven", ".", "Diagnostic", "DNA", "cytometry", "is", "able", "to", "identify", "those", "prostatic", "cancer", "patients", "who", "do", "not", "reveal", "significantly", "increased", "risk", "of", "tumor", "progression", "or", "decreased", "survival", "probability", ",", "even", "without", "therapy", "(", "constantly", "and", "representatively", "diploid", "and", "tetraploid", "patterns", ")", ".", "Patients", "with", "DNA", "tetraplid", "histograms", "may", "show", "detoriation", "of", "prognosis", "under", "hormonal", "therapy", ".", "DNA", "-", "aneuploid", "prostatic", "cancers", "should", "not", "be", "subjected", "to", "a", "\"", "wait", "and", "see", "\"", "strategy", ";", "they", "do", "not", "respond", "to", "hormonal", "therapy", "." ]
[ "umlsterm" ]
fine - needle, aspiration biopsy, prostate, control, method, diagnostic, evaluation, sensitivity, complication, specificity, method, cytology, prostate, forms, prostatitis, cancer, PIN, diagnoses, adenocarcinomas, prostate, proven, histologic, lymph nodes, sensitivity, specificity, prostatectomies, tumor, proven, Diagnostic, DNA, prostatic cancer, patients, risk of, tumor, survival, probability, therapy, Patients, DNA, prognosis, therapy, prostatic cancers, therapy
DerPathologe.80190053.eng.abstr_task2
Sentence: Transrectal fine-needle aspiration biopsy ( FNAB ) of the prostate under digital control is a cheap and rapid method for diagnostic evaluation of palpable and non-palpable nodules , yielding high sensitivity ( ca. 95% ) and a low complication rate ( 1% ) . Its specificity amounts to > 97% . The scarcity of urologists trained in the FNAB method and of pathologists experienced in cytology of the prostate limit the clinical application so far . Besides various forms of prostatitis , five different types of cancer can cytologically be differentiated . While PIN I cannot be cytologically identified , PIN II/III lesions may lead to false-positive diagnoses . Cytologic grading of adenocarcinomas of the prostate is of statistically proven prognostic validity and strictly correlated with its histologic counterpart . Preoperative , radiologically controlled FNAB of pelvic and paraortal lymph nodes has sensitivity of ca. 86% and specificity of 100% . It thus helps to avoid unnecessary prostatectomies if nodal tumor spread has preoperatively been proven . Diagnostic DNA cytometry is able to identify those prostatic cancer patients who do not reveal significantly increased risk of tumor progression or decreased survival probability , even without therapy ( constantly and representatively diploid and tetraploid patterns ) . Patients with DNA tetraplid histograms may show detoriation of prognosis under hormonal therapy . DNA-aneuploid prostatic cancers should not be subjected to a " wait and see " strategy ; they do not respond to hormonal therapy . Instructions: please extract entity words from the input sentence
[ "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]
Transrectal fine-needle aspiration biopsy ( FNAB ) of the prostate under digital control is a cheap and rapid method for diagnostic evaluation of palpable and non-palpable nodules , yielding high sensitivity ( ca. 95% ) and a low complication rate ( 1% ) . Its specificity amounts to > 97% . The scarcity of urologists trained in the FNAB method and of pathologists experienced in cytology of the prostate limit the clinical application so far . Besides various forms of prostatitis , five different types of cancer can cytologically be differentiated . While PIN I cannot be cytologically identified , PIN II/III lesions may lead to false-positive diagnoses . Cytologic grading of adenocarcinomas of the prostate is of statistically proven prognostic validity and strictly correlated with its histologic counterpart . Preoperative , radiologically controlled FNAB of pelvic and paraortal lymph nodes has sensitivity of ca. 86% and specificity of 100% . It thus helps to avoid unnecessary prostatectomies if nodal tumor spread has preoperatively been proven . Diagnostic DNA cytometry is able to identify those prostatic cancer patients who do not reveal significantly increased risk of tumor progression or decreased survival probability , even without therapy ( constantly and representatively diploid and tetraploid patterns ) . Patients with DNA tetraplid histograms may show detoriation of prognosis under hormonal therapy . DNA-aneuploid prostatic cancers should not be subjected to a " wait and see " strategy ; they do not respond to hormonal therapy .
[ "Transrectal", "fine", "-", "needle", "aspiration", "biopsy", "(", "FNAB", ")", "of", "the", "prostate", "under", "digital", "control", "is", "a", "cheap", "and", "rapid", "method", "for", "diagnostic", "evaluation", "of", "palpable", "and", "non", "-", "palpable", "nodules", ",", "yielding", "high", "sensitivity", "(", "ca", ".", "95", "%", ")", "and", "a", "low", "complication", "rate", "(", "1", "%", ")", ".", "Its", "specificity", "amounts", "to", ">", "97", "%", ".", "The", "scarcity", "of", "urologists", "trained", "in", "the", "FNAB", "method", "and", "of", "pathologists", "experienced", "in", "cytology", "of", "the", "prostate", "limit", "the", "clinical", "application", "so", "far", ".", "Besides", "various", "forms", "of", "prostatitis", ",", "five", "different", "types", "of", "cancer", "can", "cytologically", "be", "differentiated", ".", "While", "PIN", "I", "cannot", "be", "cytologically", "identified", ",", "PIN", "II", "/", "III", "lesions", "may", "lead", "to", "false", "-", "positive", "diagnoses", ".", "Cytologic", "grading", "of", "adenocarcinomas", "of", "the", "prostate", "is", "of", "statistically", "proven", "prognostic", "validity", "and", "strictly", "correlated", "with", "its", "histologic", "counterpart", ".", "Preoperative", ",", "radiologically", "controlled", "FNAB", "of", "pelvic", "and", "paraortal", "lymph", "nodes", "has", "sensitivity", "of", "ca", ".", "86", "%", "and", "specificity", "of", "100", "%", ".", "It", "thus", "helps", "to", "avoid", "unnecessary", "prostatectomies", "if", "nodal", "tumor", "spread", "has", "preoperatively", "been", "proven", ".", "Diagnostic", "DNA", "cytometry", "is", "able", "to", "identify", "those", "prostatic", "cancer", "patients", "who", "do", "not", "reveal", "significantly", "increased", "risk", "of", "tumor", "progression", "or", "decreased", "survival", "probability", ",", "even", "without", "therapy", "(", "constantly", "and", "representatively", "diploid", "and", "tetraploid", "patterns", ")", ".", "Patients", "with", "DNA", "tetraplid", "histograms", "may", "show", "detoriation", "of", "prognosis", "under", "hormonal", "therapy", ".", "DNA", "-", "aneuploid", "prostatic", "cancers", "should", "not", "be", "subjected", "to", "a", "\"", "wait", "and", "see", "\"", "strategy", ";", "they", "do", "not", "respond", "to", "hormonal", "therapy", "." ]
[ "umlsterm" ]
May is an umlsterm, operations is an umlsterm, injuries is an umlsterm, pathologic fractures is an umlsterm, bone is an umlsterm, crest is an umlsterm, implantation is an umlsterm, titanium is an umlsterm, plate is an umlsterm, complications is an umlsterm, infection is an umlsterm, graft is an umlsterm, literature is an umlsterm, complications is an umlsterm, open is an umlsterm, surgery is an umlsterm, morbidity is an umlsterm, surgical is an umlsterm, patient is an umlsterm, population is an umlsterm, postoperative is an umlsterm, analgesic is an umlsterm, convalescence is an umlsterm
Trauma+Berufskrankheit.0002s251.eng.abstr_task0
Sentence: Between May 1996 and 1999 , a total of 186 endoscopic spinal operations were performed to treat unstable injuries and pathologic fractures . The operative spinal interventions followed the classic sequence of excision of part of a vertebral body , partial replacement of the vertebral body with bone harvested from the iliac crest , and implantation of a titanium plate to stabilize the part to be fused . In 62% of these cases we performed primary dorsal straightening with a fixateur interne . The serious complications were aortic leakage and deep infection in the area of the graft and the implant , each of which occurred in 1 case . Comparisons with the literature showed approximately the same rate of spinal complications as with open surgery , while the rate of morbidity connected with the surgical approach was reduced to a third in the patient population treated endoscopically , with correspondingly positive implications for the postoperative analgesic requirement and for convalescence . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O" ]
Between May 1996 and 1999 , a total of 186 endoscopic spinal operations were performed to treat unstable injuries and pathologic fractures . The operative spinal interventions followed the classic sequence of excision of part of a vertebral body , partial replacement of the vertebral body with bone harvested from the iliac crest , and implantation of a titanium plate to stabilize the part to be fused . In 62% of these cases we performed primary dorsal straightening with a fixateur interne . The serious complications were aortic leakage and deep infection in the area of the graft and the implant , each of which occurred in 1 case . Comparisons with the literature showed approximately the same rate of spinal complications as with open surgery , while the rate of morbidity connected with the surgical approach was reduced to a third in the patient population treated endoscopically , with correspondingly positive implications for the postoperative analgesic requirement and for convalescence .
[ "Between", "May", "1996", "and", "1999", ",", "a", "total", "of", "186", "endoscopic", "spinal", "operations", "were", "performed", "to", "treat", "unstable", "injuries", "and", "pathologic", "fractures", ".", "The", "operative", "spinal", "interventions", "followed", "the", "classic", "sequence", "of", "excision", "of", "part", "of", "a", "vertebral", "body", ",", "partial", "replacement", "of", "the", "vertebral", "body", "with", "bone", "harvested", "from", "the", "iliac", "crest", ",", "and", "implantation", "of", "a", "titanium", "plate", "to", "stabilize", "the", "part", "to", "be", "fused", ".", "In", "62", "%", "of", "these", "cases", "we", "performed", "primary", "dorsal", "straightening", "with", "a", "fixateur", "interne", ".", "The", "serious", "complications", "were", "aortic", "leakage", "and", "deep", "infection", "in", "the", "area", "of", "the", "graft", "and", "the", "implant", ",", "each", "of", "which", "occurred", "in", "1", "case", ".", "Comparisons", "with", "the", "literature", "showed", "approximately", "the", "same", "rate", "of", "spinal", "complications", "as", "with", "open", "surgery", ",", "while", "the", "rate", "of", "morbidity", "connected", "with", "the", "surgical", "approach", "was", "reduced", "to", "a", "third", "in", "the", "patient", "population", "treated", "endoscopically", ",", "with", "correspondingly", "positive", "implications", "for", "the", "postoperative", "analgesic", "requirement", "and", "for", "convalescence", "." ]
[ "umlsterm" ]
May is an umlsterm, operations is an umlsterm, injuries is an umlsterm, pathologic fractures is an umlsterm, bone is an umlsterm, crest is an umlsterm, implantation is an umlsterm, titanium is an umlsterm, plate is an umlsterm, complications is an umlsterm, infection is an umlsterm, graft is an umlsterm, literature is an umlsterm, complications is an umlsterm, open is an umlsterm, surgery is an umlsterm, morbidity is an umlsterm, surgical is an umlsterm, patient is an umlsterm, population is an umlsterm, postoperative is an umlsterm, analgesic is an umlsterm, convalescence is an umlsterm
Trauma+Berufskrankheit.0002s251.eng.abstr_task1
Sentence: Between May 1996 and 1999 , a total of 186 endoscopic spinal operations were performed to treat unstable injuries and pathologic fractures . The operative spinal interventions followed the classic sequence of excision of part of a vertebral body , partial replacement of the vertebral body with bone harvested from the iliac crest , and implantation of a titanium plate to stabilize the part to be fused . In 62% of these cases we performed primary dorsal straightening with a fixateur interne . The serious complications were aortic leakage and deep infection in the area of the graft and the implant , each of which occurred in 1 case . Comparisons with the literature showed approximately the same rate of spinal complications as with open surgery , while the rate of morbidity connected with the surgical approach was reduced to a third in the patient population treated endoscopically , with correspondingly positive implications for the postoperative analgesic requirement and for convalescence . Instructions: please typing these entity words according to sentence: May, operations, injuries, pathologic fractures, bone, crest, implantation, titanium, plate, complications, infection, graft, literature, complications, open, surgery, morbidity, surgical, patient, population, postoperative, analgesic, convalescence Options: umlsterm
[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O" ]
Between May 1996 and 1999 , a total of 186 endoscopic spinal operations were performed to treat unstable injuries and pathologic fractures . The operative spinal interventions followed the classic sequence of excision of part of a vertebral body , partial replacement of the vertebral body with bone harvested from the iliac crest , and implantation of a titanium plate to stabilize the part to be fused . In 62% of these cases we performed primary dorsal straightening with a fixateur interne . The serious complications were aortic leakage and deep infection in the area of the graft and the implant , each of which occurred in 1 case . Comparisons with the literature showed approximately the same rate of spinal complications as with open surgery , while the rate of morbidity connected with the surgical approach was reduced to a third in the patient population treated endoscopically , with correspondingly positive implications for the postoperative analgesic requirement and for convalescence .
[ "Between", "May", "1996", "and", "1999", ",", "a", "total", "of", "186", "endoscopic", "spinal", "operations", "were", "performed", "to", "treat", "unstable", "injuries", "and", "pathologic", "fractures", ".", "The", "operative", "spinal", "interventions", "followed", "the", "classic", "sequence", "of", "excision", "of", "part", "of", "a", "vertebral", "body", ",", "partial", "replacement", "of", "the", "vertebral", "body", "with", "bone", "harvested", "from", "the", "iliac", "crest", ",", "and", "implantation", "of", "a", "titanium", "plate", "to", "stabilize", "the", "part", "to", "be", "fused", ".", "In", "62", "%", "of", "these", "cases", "we", "performed", "primary", "dorsal", "straightening", "with", "a", "fixateur", "interne", ".", "The", "serious", "complications", "were", "aortic", "leakage", "and", "deep", "infection", "in", "the", "area", "of", "the", "graft", "and", "the", "implant", ",", "each", "of", "which", "occurred", "in", "1", "case", ".", "Comparisons", "with", "the", "literature", "showed", "approximately", "the", "same", "rate", "of", "spinal", "complications", "as", "with", "open", "surgery", ",", "while", "the", "rate", "of", "morbidity", "connected", "with", "the", "surgical", "approach", "was", "reduced", "to", "a", "third", "in", "the", "patient", "population", "treated", "endoscopically", ",", "with", "correspondingly", "positive", "implications", "for", "the", "postoperative", "analgesic", "requirement", "and", "for", "convalescence", "." ]
[ "umlsterm" ]
May, operations, injuries, pathologic fractures, bone, crest, implantation, titanium, plate, complications, infection, graft, literature, complications, open, surgery, morbidity, surgical, patient, population, postoperative, analgesic, convalescence
Trauma+Berufskrankheit.0002s251.eng.abstr_task2
Sentence: Between May 1996 and 1999 , a total of 186 endoscopic spinal operations were performed to treat unstable injuries and pathologic fractures . The operative spinal interventions followed the classic sequence of excision of part of a vertebral body , partial replacement of the vertebral body with bone harvested from the iliac crest , and implantation of a titanium plate to stabilize the part to be fused . In 62% of these cases we performed primary dorsal straightening with a fixateur interne . The serious complications were aortic leakage and deep infection in the area of the graft and the implant , each of which occurred in 1 case . Comparisons with the literature showed approximately the same rate of spinal complications as with open surgery , while the rate of morbidity connected with the surgical approach was reduced to a third in the patient population treated endoscopically , with correspondingly positive implications for the postoperative analgesic requirement and for convalescence . Instructions: please extract entity words from the input sentence
[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O" ]
Between May 1996 and 1999 , a total of 186 endoscopic spinal operations were performed to treat unstable injuries and pathologic fractures . The operative spinal interventions followed the classic sequence of excision of part of a vertebral body , partial replacement of the vertebral body with bone harvested from the iliac crest , and implantation of a titanium plate to stabilize the part to be fused . In 62% of these cases we performed primary dorsal straightening with a fixateur interne . The serious complications were aortic leakage and deep infection in the area of the graft and the implant , each of which occurred in 1 case . Comparisons with the literature showed approximately the same rate of spinal complications as with open surgery , while the rate of morbidity connected with the surgical approach was reduced to a third in the patient population treated endoscopically , with correspondingly positive implications for the postoperative analgesic requirement and for convalescence .
[ "Between", "May", "1996", "and", "1999", ",", "a", "total", "of", "186", "endoscopic", "spinal", "operations", "were", "performed", "to", "treat", "unstable", "injuries", "and", "pathologic", "fractures", ".", "The", "operative", "spinal", "interventions", "followed", "the", "classic", "sequence", "of", "excision", "of", "part", "of", "a", "vertebral", "body", ",", "partial", "replacement", "of", "the", "vertebral", "body", "with", "bone", "harvested", "from", "the", "iliac", "crest", ",", "and", "implantation", "of", "a", "titanium", "plate", "to", "stabilize", "the", "part", "to", "be", "fused", ".", "In", "62", "%", "of", "these", "cases", "we", "performed", "primary", "dorsal", "straightening", "with", "a", "fixateur", "interne", ".", "The", "serious", "complications", "were", "aortic", "leakage", "and", "deep", "infection", "in", "the", "area", "of", "the", "graft", "and", "the", "implant", ",", "each", "of", "which", "occurred", "in", "1", "case", ".", "Comparisons", "with", "the", "literature", "showed", "approximately", "the", "same", "rate", "of", "spinal", "complications", "as", "with", "open", "surgery", ",", "while", "the", "rate", "of", "morbidity", "connected", "with", "the", "surgical", "approach", "was", "reduced", "to", "a", "third", "in", "the", "patient", "population", "treated", "endoscopically", ",", "with", "correspondingly", "positive", "implications", "for", "the", "postoperative", "analgesic", "requirement", "and", "for", "convalescence", "." ]
[ "umlsterm" ]
Erythropoietin is a Protein, hemoglobin is a Entity, erythropoietin is a Protein, EPO is a Protein, granulocyte - macrophage colony - stimulating factor is a Protein, GM - CSF is a Protein, stem cell factor is a Protein, SCF is a Protein, Hemoglobin is a Entity, erythroid delta - aminolevulinate synthase is a Protein, EPO is a Protein, GM - CSF is a Protein, GM - CSF is a Protein, EPO is a Protein, hemoglobin is a Entity, GM - CSF is a Protein, GATA-1 is a Protein, GM - CSF is a Protein, EPO is a Protein, hemoglobin is a Entity, EPO is a Protein, EPO is a Protein, GM - CSF is a Protein, EPO is a Protein, GM - CSF is a Protein, EPO is a Protein
667_task0
Sentence: Erythropoietin-dependent induction of hemoglobin synthesis in a cytokine-dependent cell line M-TAT. M-TAT is a cytokine-dependent cell line with the potential to differentiate along the erythroid and megakaryocytic lineages. We cultured M-TAT cells long term (> 1 year) in the continuous presence of erythropoietin (EPO), granulocyte-macrophage colony-stimulating factor (GM-CSF), or stem cell factor (SCF). These long term cultures are referred to as M-TAT/EPO, M-TAT/GM-CSF, and M-TAT/SCF cells, respectively. Hemoglobin concentration and gamma-globin and erythroid delta-aminolevulinate synthase mRNA levels were significantly higher in M-TAT/EPO cells than in M-TAT/GM-CSF cells. When the supplemented cytokine was switched from GM-CSF to EPO, hemoglobin synthesis in M-TAT/GM-CSF cells increased rapidly (within 5 h), and the level of GATA-1 mRNA increased. In contrast, the addition of GM-CSF to the M-TAT/EPO cell culture decreased the amount of hemoglobin, even in the presence of EPO, indicating that the EPO signal for erythroid differentiation is suppressed by GM-CSF. Thus, erythroid development of M-TAT cells is promoted by EPO and suppressed by GM-CSF. These results support the hypothesis that EPO actively influences the programming of gene expression required for erythroid progenitor cell differentiation. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein
[ "B-Protein", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Erythropoietin-dependent induction of hemoglobin synthesis in a cytokine-dependent cell line M-TAT. M-TAT is a cytokine-dependent cell line with the potential to differentiate along the erythroid and megakaryocytic lineages. We cultured M-TAT cells long term (> 1 year) in the continuous presence of erythropoietin (EPO), granulocyte-macrophage colony-stimulating factor (GM-CSF), or stem cell factor (SCF). These long term cultures are referred to as M-TAT/EPO, M-TAT/GM-CSF, and M-TAT/SCF cells, respectively. Hemoglobin concentration and gamma-globin and erythroid delta-aminolevulinate synthase mRNA levels were significantly higher in M-TAT/EPO cells than in M-TAT/GM-CSF cells. When the supplemented cytokine was switched from GM-CSF to EPO, hemoglobin synthesis in M-TAT/GM-CSF cells increased rapidly (within 5 h), and the level of GATA-1 mRNA increased. In contrast, the addition of GM-CSF to the M-TAT/EPO cell culture decreased the amount of hemoglobin, even in the presence of EPO, indicating that the EPO signal for erythroid differentiation is suppressed by GM-CSF. Thus, erythroid development of M-TAT cells is promoted by EPO and suppressed by GM-CSF. These results support the hypothesis that EPO actively influences the programming of gene expression required for erythroid progenitor cell differentiation.
[ "Erythropoietin", "-", "dependent", "induction", "of", "hemoglobin", "synthesis", "in", "a", "cytokine", "-", "dependent", "cell", "line", "M", "-", "TAT", ".", "\n", "M", "-", "TAT", "is", "a", "cytokine", "-", "dependent", "cell", "line", "with", "the", "potential", "to", "differentiate", "along", "the", "erythroid", "and", "megakaryocytic", "lineages", ".", "We", "cultured", "M", "-", "TAT", "cells", "long", "term", "(", ">", "1", "year", ")", "in", "the", "continuous", "presence", "of", "erythropoietin", "(", "EPO", ")", ",", "granulocyte", "-", "macrophage", "colony", "-", "stimulating", "factor", "(", "GM", "-", "CSF", ")", ",", "or", "stem", "cell", "factor", "(", "SCF", ")", ".", "These", "long", "term", "cultures", "are", "referred", "to", "as", "M", "-", "TAT", "/", "EPO", ",", "M", "-", "TAT", "/", "GM", "-", "CSF", ",", "and", "M", "-", "TAT", "/", "SCF", "cells", ",", "respectively", ".", "Hemoglobin", "concentration", "and", "gamma", "-", "globin", "and", "erythroid", "delta", "-", "aminolevulinate", "synthase", "mRNA", "levels", "were", "significantly", "higher", "in", "M", "-", "TAT", "/", "EPO", "cells", "than", "in", "M", "-", "TAT", "/", "GM", "-", "CSF", "cells", ".", "When", "the", "supplemented", "cytokine", "was", "switched", "from", "GM", "-", "CSF", "to", "EPO", ",", "hemoglobin", "synthesis", "in", "M", "-", "TAT", "/", "GM", "-", "CSF", "cells", "increased", "rapidly", "(", "within", "5", "h", ")", ",", "and", "the", "level", "of", "GATA-1", "mRNA", "increased", ".", "In", "contrast", ",", "the", "addition", "of", "GM", "-", "CSF", "to", "the", "M", "-", "TAT", "/", "EPO", "cell", "culture", "decreased", "the", "amount", "of", "hemoglobin", ",", "even", "in", "the", "presence", "of", "EPO", ",", "indicating", "that", "the", "EPO", "signal", "for", "erythroid", "differentiation", "is", "suppressed", "by", "GM", "-", "CSF", ".", "Thus", ",", "erythroid", "development", "of", "M", "-", "TAT", "cells", "is", "promoted", "by", "EPO", "and", "suppressed", "by", "GM", "-", "CSF", ".", "These", "results", "support", "the", "hypothesis", "that", "EPO", "actively", "influences", "the", "programming", "of", "gene", "expression", "required", "for", "erythroid", "progenitor", "cell", "differentiation", ".", "\n" ]
[ "Protein", "Entity" ]
Erythropoietin is a Protein, hemoglobin is a Entity, erythropoietin is a Protein, EPO is a Protein, granulocyte - macrophage colony - stimulating factor is a Protein, GM - CSF is a Protein, stem cell factor is a Protein, SCF is a Protein, Hemoglobin is a Entity, erythroid delta - aminolevulinate synthase is a Protein, EPO is a Protein, GM - CSF is a Protein, GM - CSF is a Protein, EPO is a Protein, hemoglobin is a Entity, GM - CSF is a Protein, GATA-1 is a Protein, GM - CSF is a Protein, EPO is a Protein, hemoglobin is a Entity, EPO is a Protein, EPO is a Protein, GM - CSF is a Protein, EPO is a Protein, GM - CSF is a Protein, EPO is a Protein
667_task1
Sentence: Erythropoietin-dependent induction of hemoglobin synthesis in a cytokine-dependent cell line M-TAT. M-TAT is a cytokine-dependent cell line with the potential to differentiate along the erythroid and megakaryocytic lineages. We cultured M-TAT cells long term (> 1 year) in the continuous presence of erythropoietin (EPO), granulocyte-macrophage colony-stimulating factor (GM-CSF), or stem cell factor (SCF). These long term cultures are referred to as M-TAT/EPO, M-TAT/GM-CSF, and M-TAT/SCF cells, respectively. Hemoglobin concentration and gamma-globin and erythroid delta-aminolevulinate synthase mRNA levels were significantly higher in M-TAT/EPO cells than in M-TAT/GM-CSF cells. When the supplemented cytokine was switched from GM-CSF to EPO, hemoglobin synthesis in M-TAT/GM-CSF cells increased rapidly (within 5 h), and the level of GATA-1 mRNA increased. In contrast, the addition of GM-CSF to the M-TAT/EPO cell culture decreased the amount of hemoglobin, even in the presence of EPO, indicating that the EPO signal for erythroid differentiation is suppressed by GM-CSF. Thus, erythroid development of M-TAT cells is promoted by EPO and suppressed by GM-CSF. These results support the hypothesis that EPO actively influences the programming of gene expression required for erythroid progenitor cell differentiation. Instructions: please typing these entity words according to sentence: Erythropoietin, hemoglobin, erythropoietin, EPO, granulocyte - macrophage colony - stimulating factor, GM - CSF, stem cell factor, SCF, Hemoglobin, erythroid delta - aminolevulinate synthase, EPO, GM - CSF, GM - CSF, EPO, hemoglobin, GM - CSF, GATA-1, GM - CSF, EPO, hemoglobin, EPO, EPO, GM - CSF, EPO, GM - CSF, EPO Options: Entity, Protein
[ "B-Protein", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Erythropoietin-dependent induction of hemoglobin synthesis in a cytokine-dependent cell line M-TAT. M-TAT is a cytokine-dependent cell line with the potential to differentiate along the erythroid and megakaryocytic lineages. We cultured M-TAT cells long term (> 1 year) in the continuous presence of erythropoietin (EPO), granulocyte-macrophage colony-stimulating factor (GM-CSF), or stem cell factor (SCF). These long term cultures are referred to as M-TAT/EPO, M-TAT/GM-CSF, and M-TAT/SCF cells, respectively. Hemoglobin concentration and gamma-globin and erythroid delta-aminolevulinate synthase mRNA levels were significantly higher in M-TAT/EPO cells than in M-TAT/GM-CSF cells. When the supplemented cytokine was switched from GM-CSF to EPO, hemoglobin synthesis in M-TAT/GM-CSF cells increased rapidly (within 5 h), and the level of GATA-1 mRNA increased. In contrast, the addition of GM-CSF to the M-TAT/EPO cell culture decreased the amount of hemoglobin, even in the presence of EPO, indicating that the EPO signal for erythroid differentiation is suppressed by GM-CSF. Thus, erythroid development of M-TAT cells is promoted by EPO and suppressed by GM-CSF. These results support the hypothesis that EPO actively influences the programming of gene expression required for erythroid progenitor cell differentiation.
[ "Erythropoietin", "-", "dependent", "induction", "of", "hemoglobin", "synthesis", "in", "a", "cytokine", "-", "dependent", "cell", "line", "M", "-", "TAT", ".", "\n", "M", "-", "TAT", "is", "a", "cytokine", "-", "dependent", "cell", "line", "with", "the", "potential", "to", "differentiate", "along", "the", "erythroid", "and", "megakaryocytic", "lineages", ".", "We", "cultured", "M", "-", "TAT", "cells", "long", "term", "(", ">", "1", "year", ")", "in", "the", "continuous", "presence", "of", "erythropoietin", "(", "EPO", ")", ",", "granulocyte", "-", "macrophage", "colony", "-", "stimulating", "factor", "(", "GM", "-", "CSF", ")", ",", "or", "stem", "cell", "factor", "(", "SCF", ")", ".", "These", "long", "term", "cultures", "are", "referred", "to", "as", "M", "-", "TAT", "/", "EPO", ",", "M", "-", "TAT", "/", "GM", "-", "CSF", ",", "and", "M", "-", "TAT", "/", "SCF", "cells", ",", "respectively", ".", "Hemoglobin", "concentration", "and", "gamma", "-", "globin", "and", "erythroid", "delta", "-", "aminolevulinate", "synthase", "mRNA", "levels", "were", "significantly", "higher", "in", "M", "-", "TAT", "/", "EPO", "cells", "than", "in", "M", "-", "TAT", "/", "GM", "-", "CSF", "cells", ".", "When", "the", "supplemented", "cytokine", "was", "switched", "from", "GM", "-", "CSF", "to", "EPO", ",", "hemoglobin", "synthesis", "in", "M", "-", "TAT", "/", "GM", "-", "CSF", "cells", "increased", "rapidly", "(", "within", "5", "h", ")", ",", "and", "the", "level", "of", "GATA-1", "mRNA", "increased", ".", "In", "contrast", ",", "the", "addition", "of", "GM", "-", "CSF", "to", "the", "M", "-", "TAT", "/", "EPO", "cell", "culture", "decreased", "the", "amount", "of", "hemoglobin", ",", "even", "in", "the", "presence", "of", "EPO", ",", "indicating", "that", "the", "EPO", "signal", "for", "erythroid", "differentiation", "is", "suppressed", "by", "GM", "-", "CSF", ".", "Thus", ",", "erythroid", "development", "of", "M", "-", "TAT", "cells", "is", "promoted", "by", "EPO", "and", "suppressed", "by", "GM", "-", "CSF", ".", "These", "results", "support", "the", "hypothesis", "that", "EPO", "actively", "influences", "the", "programming", "of", "gene", "expression", "required", "for", "erythroid", "progenitor", "cell", "differentiation", ".", "\n" ]
[ "Protein", "Entity" ]
Erythropoietin, hemoglobin, erythropoietin, EPO, granulocyte - macrophage colony - stimulating factor, GM - CSF, stem cell factor, SCF, Hemoglobin, erythroid delta - aminolevulinate synthase, EPO, GM - CSF, GM - CSF, EPO, hemoglobin, GM - CSF, GATA-1, GM - CSF, EPO, hemoglobin, EPO, EPO, GM - CSF, EPO, GM - CSF, EPO
667_task2
Sentence: Erythropoietin-dependent induction of hemoglobin synthesis in a cytokine-dependent cell line M-TAT. M-TAT is a cytokine-dependent cell line with the potential to differentiate along the erythroid and megakaryocytic lineages. We cultured M-TAT cells long term (> 1 year) in the continuous presence of erythropoietin (EPO), granulocyte-macrophage colony-stimulating factor (GM-CSF), or stem cell factor (SCF). These long term cultures are referred to as M-TAT/EPO, M-TAT/GM-CSF, and M-TAT/SCF cells, respectively. Hemoglobin concentration and gamma-globin and erythroid delta-aminolevulinate synthase mRNA levels were significantly higher in M-TAT/EPO cells than in M-TAT/GM-CSF cells. When the supplemented cytokine was switched from GM-CSF to EPO, hemoglobin synthesis in M-TAT/GM-CSF cells increased rapidly (within 5 h), and the level of GATA-1 mRNA increased. In contrast, the addition of GM-CSF to the M-TAT/EPO cell culture decreased the amount of hemoglobin, even in the presence of EPO, indicating that the EPO signal for erythroid differentiation is suppressed by GM-CSF. Thus, erythroid development of M-TAT cells is promoted by EPO and suppressed by GM-CSF. These results support the hypothesis that EPO actively influences the programming of gene expression required for erythroid progenitor cell differentiation. Instructions: please extract entity words from the input sentence
[ "B-Protein", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Erythropoietin-dependent induction of hemoglobin synthesis in a cytokine-dependent cell line M-TAT. M-TAT is a cytokine-dependent cell line with the potential to differentiate along the erythroid and megakaryocytic lineages. We cultured M-TAT cells long term (> 1 year) in the continuous presence of erythropoietin (EPO), granulocyte-macrophage colony-stimulating factor (GM-CSF), or stem cell factor (SCF). These long term cultures are referred to as M-TAT/EPO, M-TAT/GM-CSF, and M-TAT/SCF cells, respectively. Hemoglobin concentration and gamma-globin and erythroid delta-aminolevulinate synthase mRNA levels were significantly higher in M-TAT/EPO cells than in M-TAT/GM-CSF cells. When the supplemented cytokine was switched from GM-CSF to EPO, hemoglobin synthesis in M-TAT/GM-CSF cells increased rapidly (within 5 h), and the level of GATA-1 mRNA increased. In contrast, the addition of GM-CSF to the M-TAT/EPO cell culture decreased the amount of hemoglobin, even in the presence of EPO, indicating that the EPO signal for erythroid differentiation is suppressed by GM-CSF. Thus, erythroid development of M-TAT cells is promoted by EPO and suppressed by GM-CSF. These results support the hypothesis that EPO actively influences the programming of gene expression required for erythroid progenitor cell differentiation.
[ "Erythropoietin", "-", "dependent", "induction", "of", "hemoglobin", "synthesis", "in", "a", "cytokine", "-", "dependent", "cell", "line", "M", "-", "TAT", ".", "\n", "M", "-", "TAT", "is", "a", "cytokine", "-", "dependent", "cell", "line", "with", "the", "potential", "to", "differentiate", "along", "the", "erythroid", "and", "megakaryocytic", "lineages", ".", "We", "cultured", "M", "-", "TAT", "cells", "long", "term", "(", ">", "1", "year", ")", "in", "the", "continuous", "presence", "of", "erythropoietin", "(", "EPO", ")", ",", "granulocyte", "-", "macrophage", "colony", "-", "stimulating", "factor", "(", "GM", "-", "CSF", ")", ",", "or", "stem", "cell", "factor", "(", "SCF", ")", ".", "These", "long", "term", "cultures", "are", "referred", "to", "as", "M", "-", "TAT", "/", "EPO", ",", "M", "-", "TAT", "/", "GM", "-", "CSF", ",", "and", "M", "-", "TAT", "/", "SCF", "cells", ",", "respectively", ".", "Hemoglobin", "concentration", "and", "gamma", "-", "globin", "and", "erythroid", "delta", "-", "aminolevulinate", "synthase", "mRNA", "levels", "were", "significantly", "higher", "in", "M", "-", "TAT", "/", "EPO", "cells", "than", "in", "M", "-", "TAT", "/", "GM", "-", "CSF", "cells", ".", "When", "the", "supplemented", "cytokine", "was", "switched", "from", "GM", "-", "CSF", "to", "EPO", ",", "hemoglobin", "synthesis", "in", "M", "-", "TAT", "/", "GM", "-", "CSF", "cells", "increased", "rapidly", "(", "within", "5", "h", ")", ",", "and", "the", "level", "of", "GATA-1", "mRNA", "increased", ".", "In", "contrast", ",", "the", "addition", "of", "GM", "-", "CSF", "to", "the", "M", "-", "TAT", "/", "EPO", "cell", "culture", "decreased", "the", "amount", "of", "hemoglobin", ",", "even", "in", "the", "presence", "of", "EPO", ",", "indicating", "that", "the", "EPO", "signal", "for", "erythroid", "differentiation", "is", "suppressed", "by", "GM", "-", "CSF", ".", "Thus", ",", "erythroid", "development", "of", "M", "-", "TAT", "cells", "is", "promoted", "by", "EPO", "and", "suppressed", "by", "GM", "-", "CSF", ".", "These", "results", "support", "the", "hypothesis", "that", "EPO", "actively", "influences", "the", "programming", "of", "gene", "expression", "required", "for", "erythroid", "progenitor", "cell", "differentiation", ".", "\n" ]
[ "Protein", "Entity" ]
microsatellite instable is a Disorder, tumours is a cohort-patient, 90 % is a size, absence of hMLH1 expression is a Physiology, sporadic is a Concepts_Ideas, colorectal cancers is a disease, promoter region of hMLH1 is hypermethylated is a Physiology, sporadic is a Concepts_Ideas, colorectal cancer is a disease, absent hMLH1 expression is a Physiology, mutations is a mutation, APC is a gene, K - ras is a gene, groups is a cohort-patient, HNPCC is a disease, sporadic is a Concepts_Ideas, colorectal cancer is a disease, patients is a cohort-patient, hMLH1 deficiency is a Physiology, APC is a gene, K - ras is a gene, mutation is a mutation, small number is a size, tumours is a cohort-patient, hMLH1 deficiency is a Physiology, mutations is a mutation, APC is a gene, K - ras is a gene, tumours is a disease, APC is a gene, K - ras is a gene, mutations is a mutation, absence of hMLH1 expression is a Physiology, tumour is a disease, hMLH1 deficient is a Disorder, tumours is a disease, proximal colon is a body-part
0_task0
Sentence: Of the microsatellite instable tumours, approximately 90% show absence of hMLH1 expression [24]. In most sporadic colorectal cancers, the promoter region of hMLH1 is hypermethylated, resulting in absence of the protein [53-55]. BAT-26 was previously shown to identify microsatellite instability in sporadic colorectal cancer [56] and results from our study showed a good agreement between unstable BAT-26 and absent hMLH1 expression. Several studies have shown that microsatellite instability and mutations in APC and K-ras occur almost mutually exclusively [18,19,21,57], suggesting that these characteristics represent separate pathways. However, others have observed aberrations in both pathways, but these studies have been performed in relatively small groups of HNPCC and sporadic colorectal cancer patients [14,20,58] and this may have given rise to a relative overrepresentation of mutation detection in both pathways. Although in our study the simultaneous occurrence of hMLH1 deficiency as well as an APC or K-ras mutation was observed in a small number of tumours, the mutually exclusive occurrence of hMLH1 deficiency and mutations in APC and/or K-ras seemed to predominate. Moreover, after exclusion of tumours displaying this overlap, a striking difference between occurrences of APC and/or K-ras mutations versus absence of hMLH1 expression was observed. The differences were most pronounced with regard to tumour sub-localisation and differentiation. hMLH1 deficient tumours occur almost exclusively in the proximal colon and are relatively more frequently poorly differentiated, which is in accordance with reports from other studies [22-25]. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Concepts_Ideas, disease, mutation, cohort-patient, Physiology, body-part, Disorder, size, gene
[ "O", "O", "B-Disorder", "I-Disorder", "B-cohort-patient", "O", "O", "B-size", "I-size", "O", "B-Physiology", "I-Physiology", "I-Physiology", "I-Physiology", "O", "O", "O", "O", "O", "O", "B-Concepts_Ideas", "B-disease", "I-disease", "O", "O", "B-Physiology", "I-Physiology", "I-Physiology", "I-Physiology", "I-Physiology", "I-Physiology", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Concepts_Ideas", "B-disease", "I-disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Physiology", "I-Physiology", "I-Physiology", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-mutation", "O", "B-gene", "O", "B-gene", "I-gene", "I-gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-cohort-patient", "O", "B-disease", "O", "B-Concepts_Ideas", "B-disease", "I-disease", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Physiology", "I-Physiology", "O", "O", "O", "O", "B-gene", "O", "B-gene", "I-gene", "I-gene", "B-mutation", "O", "O", "O", "O", "B-size", "I-size", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "B-Physiology", "I-Physiology", "O", "B-mutation", "O", "B-gene", "O", "O", "O", "B-gene", "I-gene", "I-gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-gene", "O", "O", "O", "B-gene", "I-gene", "I-gene", "B-mutation", "O", "B-Physiology", "I-Physiology", "I-Physiology", "I-Physiology", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O", "O", "O", "O", "O", "O", "B-Disorder", "I-Disorder", "B-disease", "O", "O", "O", "O", "O", "B-body-part", "I-body-part", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Of the microsatellite instable tumours, approximately 90% show absence of hMLH1 expression [24]. In most sporadic colorectal cancers, the promoter region of hMLH1 is hypermethylated, resulting in absence of the protein [53-55]. BAT-26 was previously shown to identify microsatellite instability in sporadic colorectal cancer [56] and results from our study showed a good agreement between unstable BAT-26 and absent hMLH1 expression. Several studies have shown that microsatellite instability and mutations in APC and K-ras occur almost mutually exclusively [18,19,21,57], suggesting that these characteristics represent separate pathways. However, others have observed aberrations in both pathways, but these studies have been performed in relatively small groups of HNPCC and sporadic colorectal cancer patients [14,20,58] and this may have given rise to a relative overrepresentation of mutation detection in both pathways. Although in our study the simultaneous occurrence of hMLH1 deficiency as well as an APC or K-ras mutation was observed in a small number of tumours, the mutually exclusive occurrence of hMLH1 deficiency and mutations in APC and/or K-ras seemed to predominate. Moreover, after exclusion of tumours displaying this overlap, a striking difference between occurrences of APC and/or K-ras mutations versus absence of hMLH1 expression was observed. The differences were most pronounced with regard to tumour sub-localisation and differentiation. hMLH1 deficient tumours occur almost exclusively in the proximal colon and are relatively more frequently poorly differentiated, which is in accordance with reports from other studies [22-25].
[ "Of", "the", "microsatellite", "instable", "tumours", ",", "approximately", "90", "%", "show", "absence", "of", "hMLH1", "expression", "[", "24", "]", ".", "In", "most", "sporadic", "colorectal", "cancers", ",", "the", "promoter", "region", "of", "hMLH1", "is", "hypermethylated", ",", "resulting", "in", "absence", "of", "the", "protein", "[", "53", "-", "55", "]", ".", "BAT-26", "was", "previously", "shown", "to", "identify", "microsatellite", "instability", "in", "sporadic", "colorectal", "cancer", "[", "56", "]", "and", "results", "from", "our", "study", "showed", "a", "good", "agreement", "between", "unstable", "BAT-26", "and", "absent", "hMLH1", "expression", ".", "\n\n", "Several", "studies", "have", "shown", "that", "microsatellite", "instability", "and", "mutations", "in", "APC", "and", "K", "-", "ras", "occur", "almost", "mutually", "exclusively", "[", "18,19,21,57", "]", ",", "suggesting", "that", "these", "characteristics", "represent", "separate", "pathways", ".", "However", ",", "others", "have", "observed", "aberrations", "in", "both", "pathways", ",", "but", "these", "studies", "have", "been", "performed", "in", "relatively", "small", "groups", "of", "HNPCC", "and", "sporadic", "colorectal", "cancer", "patients", "[", "14,20,58", "]", "and", "this", "may", "have", "given", "rise", "to", "a", "relative", "overrepresentation", "of", "mutation", "detection", "in", "both", "pathways", ".", "Although", "in", "our", "study", "the", "simultaneous", "occurrence", "of", "hMLH1", "deficiency", "as", "well", "as", "an", "APC", "or", "K", "-", "ras", "mutation", "was", "observed", "in", "a", "small", "number", "of", "tumours", ",", "the", "mutually", "exclusive", "occurrence", "of", "hMLH1", "deficiency", "and", "mutations", "in", "APC", "and", "/", "or", "K", "-", "ras", "seemed", "to", "predominate", ".", "\n\n", "Moreover", ",", "after", "exclusion", "of", "tumours", "displaying", "this", "overlap", ",", "a", "striking", "difference", "between", "occurrences", "of", "APC", "and", "/", "or", "K", "-", "ras", "mutations", "versus", "absence", "of", "hMLH1", "expression", "was", "observed", ".", "The", "differences", "were", "most", "pronounced", "with", "regard", "to", "tumour", "sub", "-", "localisation", "and", "differentiation", ".", "hMLH1", "deficient", "tumours", "occur", "almost", "exclusively", "in", "the", "proximal", "colon", "and", "are", "relatively", "more", "frequently", "poorly", "differentiated", ",", "which", "is", "in", "accordance", "with", "reports", "from", "other", "studies", "[", "22", "-", "25", "]", ".", "\n\n" ]
[ "Physiology", "Disorder", "disease", "body-part", "size", "mutation", "cohort-patient", "Concepts_Ideas", "gene" ]
microsatellite instable is a Disorder, tumours is a cohort-patient, 90 % is a size, absence of hMLH1 expression is a Physiology, sporadic is a Concepts_Ideas, colorectal cancers is a disease, promoter region of hMLH1 is hypermethylated is a Physiology, sporadic is a Concepts_Ideas, colorectal cancer is a disease, absent hMLH1 expression is a Physiology, mutations is a mutation, APC is a gene, K - ras is a gene, groups is a cohort-patient, HNPCC is a disease, sporadic is a Concepts_Ideas, colorectal cancer is a disease, patients is a cohort-patient, hMLH1 deficiency is a Physiology, APC is a gene, K - ras is a gene, mutation is a mutation, small number is a size, tumours is a cohort-patient, hMLH1 deficiency is a Physiology, mutations is a mutation, APC is a gene, K - ras is a gene, tumours is a disease, APC is a gene, K - ras is a gene, mutations is a mutation, absence of hMLH1 expression is a Physiology, tumour is a disease, hMLH1 deficient is a Disorder, tumours is a disease, proximal colon is a body-part
0_task1
Sentence: Of the microsatellite instable tumours, approximately 90% show absence of hMLH1 expression [24]. In most sporadic colorectal cancers, the promoter region of hMLH1 is hypermethylated, resulting in absence of the protein [53-55]. BAT-26 was previously shown to identify microsatellite instability in sporadic colorectal cancer [56] and results from our study showed a good agreement between unstable BAT-26 and absent hMLH1 expression. Several studies have shown that microsatellite instability and mutations in APC and K-ras occur almost mutually exclusively [18,19,21,57], suggesting that these characteristics represent separate pathways. However, others have observed aberrations in both pathways, but these studies have been performed in relatively small groups of HNPCC and sporadic colorectal cancer patients [14,20,58] and this may have given rise to a relative overrepresentation of mutation detection in both pathways. Although in our study the simultaneous occurrence of hMLH1 deficiency as well as an APC or K-ras mutation was observed in a small number of tumours, the mutually exclusive occurrence of hMLH1 deficiency and mutations in APC and/or K-ras seemed to predominate. Moreover, after exclusion of tumours displaying this overlap, a striking difference between occurrences of APC and/or K-ras mutations versus absence of hMLH1 expression was observed. The differences were most pronounced with regard to tumour sub-localisation and differentiation. hMLH1 deficient tumours occur almost exclusively in the proximal colon and are relatively more frequently poorly differentiated, which is in accordance with reports from other studies [22-25]. Instructions: please typing these entity words according to sentence: microsatellite instable, tumours, 90 %, absence of hMLH1 expression, sporadic, colorectal cancers, promoter region of hMLH1 is hypermethylated, sporadic, colorectal cancer, absent hMLH1 expression, mutations, APC, K - ras, groups, HNPCC, sporadic, colorectal cancer, patients, hMLH1 deficiency, APC, K - ras, mutation, small number, tumours, hMLH1 deficiency, mutations, APC, K - ras, tumours, APC, K - ras, mutations, absence of hMLH1 expression, tumour, hMLH1 deficient, tumours, proximal colon Options: Concepts_Ideas, disease, mutation, cohort-patient, Physiology, body-part, Disorder, size, gene
[ "O", "O", "B-Disorder", "I-Disorder", "B-cohort-patient", "O", "O", "B-size", "I-size", "O", "B-Physiology", "I-Physiology", "I-Physiology", "I-Physiology", "O", "O", "O", "O", "O", "O", "B-Concepts_Ideas", "B-disease", "I-disease", "O", "O", "B-Physiology", "I-Physiology", "I-Physiology", "I-Physiology", "I-Physiology", "I-Physiology", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Concepts_Ideas", "B-disease", "I-disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Physiology", "I-Physiology", "I-Physiology", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-mutation", "O", "B-gene", "O", "B-gene", "I-gene", "I-gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-cohort-patient", "O", "B-disease", "O", "B-Concepts_Ideas", "B-disease", "I-disease", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Physiology", "I-Physiology", "O", "O", "O", "O", "B-gene", "O", "B-gene", "I-gene", "I-gene", "B-mutation", "O", "O", "O", "O", "B-size", "I-size", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "B-Physiology", "I-Physiology", "O", "B-mutation", "O", "B-gene", "O", "O", "O", "B-gene", "I-gene", "I-gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-gene", "O", "O", "O", "B-gene", "I-gene", "I-gene", "B-mutation", "O", "B-Physiology", "I-Physiology", "I-Physiology", "I-Physiology", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O", "O", "O", "O", "O", "O", "B-Disorder", "I-Disorder", "B-disease", "O", "O", "O", "O", "O", "B-body-part", "I-body-part", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Of the microsatellite instable tumours, approximately 90% show absence of hMLH1 expression [24]. In most sporadic colorectal cancers, the promoter region of hMLH1 is hypermethylated, resulting in absence of the protein [53-55]. BAT-26 was previously shown to identify microsatellite instability in sporadic colorectal cancer [56] and results from our study showed a good agreement between unstable BAT-26 and absent hMLH1 expression. Several studies have shown that microsatellite instability and mutations in APC and K-ras occur almost mutually exclusively [18,19,21,57], suggesting that these characteristics represent separate pathways. However, others have observed aberrations in both pathways, but these studies have been performed in relatively small groups of HNPCC and sporadic colorectal cancer patients [14,20,58] and this may have given rise to a relative overrepresentation of mutation detection in both pathways. Although in our study the simultaneous occurrence of hMLH1 deficiency as well as an APC or K-ras mutation was observed in a small number of tumours, the mutually exclusive occurrence of hMLH1 deficiency and mutations in APC and/or K-ras seemed to predominate. Moreover, after exclusion of tumours displaying this overlap, a striking difference between occurrences of APC and/or K-ras mutations versus absence of hMLH1 expression was observed. The differences were most pronounced with regard to tumour sub-localisation and differentiation. hMLH1 deficient tumours occur almost exclusively in the proximal colon and are relatively more frequently poorly differentiated, which is in accordance with reports from other studies [22-25].
[ "Of", "the", "microsatellite", "instable", "tumours", ",", "approximately", "90", "%", "show", "absence", "of", "hMLH1", "expression", "[", "24", "]", ".", "In", "most", "sporadic", "colorectal", "cancers", ",", "the", "promoter", "region", "of", "hMLH1", "is", "hypermethylated", ",", "resulting", "in", "absence", "of", "the", "protein", "[", "53", "-", "55", "]", ".", "BAT-26", "was", "previously", "shown", "to", "identify", "microsatellite", "instability", "in", "sporadic", "colorectal", "cancer", "[", "56", "]", "and", "results", "from", "our", "study", "showed", "a", "good", "agreement", "between", "unstable", "BAT-26", "and", "absent", "hMLH1", "expression", ".", "\n\n", "Several", "studies", "have", "shown", "that", "microsatellite", "instability", "and", "mutations", "in", "APC", "and", "K", "-", "ras", "occur", "almost", "mutually", "exclusively", "[", "18,19,21,57", "]", ",", "suggesting", "that", "these", "characteristics", "represent", "separate", "pathways", ".", "However", ",", "others", "have", "observed", "aberrations", "in", "both", "pathways", ",", "but", "these", "studies", "have", "been", "performed", "in", "relatively", "small", "groups", "of", "HNPCC", "and", "sporadic", "colorectal", "cancer", "patients", "[", "14,20,58", "]", "and", "this", "may", "have", "given", "rise", "to", "a", "relative", "overrepresentation", "of", "mutation", "detection", "in", "both", "pathways", ".", "Although", "in", "our", "study", "the", "simultaneous", "occurrence", "of", "hMLH1", "deficiency", "as", "well", "as", "an", "APC", "or", "K", "-", "ras", "mutation", "was", "observed", "in", "a", "small", "number", "of", "tumours", ",", "the", "mutually", "exclusive", "occurrence", "of", "hMLH1", "deficiency", "and", "mutations", "in", "APC", "and", "/", "or", "K", "-", "ras", "seemed", "to", "predominate", ".", "\n\n", "Moreover", ",", "after", "exclusion", "of", "tumours", "displaying", "this", "overlap", ",", "a", "striking", "difference", "between", "occurrences", "of", "APC", "and", "/", "or", "K", "-", "ras", "mutations", "versus", "absence", "of", "hMLH1", "expression", "was", "observed", ".", "The", "differences", "were", "most", "pronounced", "with", "regard", "to", "tumour", "sub", "-", "localisation", "and", "differentiation", ".", "hMLH1", "deficient", "tumours", "occur", "almost", "exclusively", "in", "the", "proximal", "colon", "and", "are", "relatively", "more", "frequently", "poorly", "differentiated", ",", "which", "is", "in", "accordance", "with", "reports", "from", "other", "studies", "[", "22", "-", "25", "]", ".", "\n\n" ]
[ "Physiology", "Disorder", "disease", "body-part", "size", "mutation", "cohort-patient", "Concepts_Ideas", "gene" ]
microsatellite instable, tumours, 90 %, absence of hMLH1 expression, sporadic, colorectal cancers, promoter region of hMLH1 is hypermethylated, sporadic, colorectal cancer, absent hMLH1 expression, mutations, APC, K - ras, groups, HNPCC, sporadic, colorectal cancer, patients, hMLH1 deficiency, APC, K - ras, mutation, small number, tumours, hMLH1 deficiency, mutations, APC, K - ras, tumours, APC, K - ras, mutations, absence of hMLH1 expression, tumour, hMLH1 deficient, tumours, proximal colon
0_task2
Sentence: Of the microsatellite instable tumours, approximately 90% show absence of hMLH1 expression [24]. In most sporadic colorectal cancers, the promoter region of hMLH1 is hypermethylated, resulting in absence of the protein [53-55]. BAT-26 was previously shown to identify microsatellite instability in sporadic colorectal cancer [56] and results from our study showed a good agreement between unstable BAT-26 and absent hMLH1 expression. Several studies have shown that microsatellite instability and mutations in APC and K-ras occur almost mutually exclusively [18,19,21,57], suggesting that these characteristics represent separate pathways. However, others have observed aberrations in both pathways, but these studies have been performed in relatively small groups of HNPCC and sporadic colorectal cancer patients [14,20,58] and this may have given rise to a relative overrepresentation of mutation detection in both pathways. Although in our study the simultaneous occurrence of hMLH1 deficiency as well as an APC or K-ras mutation was observed in a small number of tumours, the mutually exclusive occurrence of hMLH1 deficiency and mutations in APC and/or K-ras seemed to predominate. Moreover, after exclusion of tumours displaying this overlap, a striking difference between occurrences of APC and/or K-ras mutations versus absence of hMLH1 expression was observed. The differences were most pronounced with regard to tumour sub-localisation and differentiation. hMLH1 deficient tumours occur almost exclusively in the proximal colon and are relatively more frequently poorly differentiated, which is in accordance with reports from other studies [22-25]. Instructions: please extract entity words from the input sentence
[ "O", "O", "B-Disorder", "I-Disorder", "B-cohort-patient", "O", "O", "B-size", "I-size", "O", "B-Physiology", "I-Physiology", "I-Physiology", "I-Physiology", "O", "O", "O", "O", "O", "O", "B-Concepts_Ideas", "B-disease", "I-disease", "O", "O", "B-Physiology", "I-Physiology", "I-Physiology", "I-Physiology", "I-Physiology", "I-Physiology", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Concepts_Ideas", "B-disease", "I-disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Physiology", "I-Physiology", "I-Physiology", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-mutation", "O", "B-gene", "O", "B-gene", "I-gene", "I-gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-cohort-patient", "O", "B-disease", "O", "B-Concepts_Ideas", "B-disease", "I-disease", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Physiology", "I-Physiology", "O", "O", "O", "O", "B-gene", "O", "B-gene", "I-gene", "I-gene", "B-mutation", "O", "O", "O", "O", "B-size", "I-size", "O", "B-cohort-patient", "O", "O", "O", "O", "O", "O", "B-Physiology", "I-Physiology", "O", "B-mutation", "O", "B-gene", "O", "O", "O", "B-gene", "I-gene", "I-gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-gene", "O", "O", "O", "B-gene", "I-gene", "I-gene", "B-mutation", "O", "B-Physiology", "I-Physiology", "I-Physiology", "I-Physiology", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O", "O", "O", "O", "O", "O", "B-Disorder", "I-Disorder", "B-disease", "O", "O", "O", "O", "O", "B-body-part", "I-body-part", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Of the microsatellite instable tumours, approximately 90% show absence of hMLH1 expression [24]. In most sporadic colorectal cancers, the promoter region of hMLH1 is hypermethylated, resulting in absence of the protein [53-55]. BAT-26 was previously shown to identify microsatellite instability in sporadic colorectal cancer [56] and results from our study showed a good agreement between unstable BAT-26 and absent hMLH1 expression. Several studies have shown that microsatellite instability and mutations in APC and K-ras occur almost mutually exclusively [18,19,21,57], suggesting that these characteristics represent separate pathways. However, others have observed aberrations in both pathways, but these studies have been performed in relatively small groups of HNPCC and sporadic colorectal cancer patients [14,20,58] and this may have given rise to a relative overrepresentation of mutation detection in both pathways. Although in our study the simultaneous occurrence of hMLH1 deficiency as well as an APC or K-ras mutation was observed in a small number of tumours, the mutually exclusive occurrence of hMLH1 deficiency and mutations in APC and/or K-ras seemed to predominate. Moreover, after exclusion of tumours displaying this overlap, a striking difference between occurrences of APC and/or K-ras mutations versus absence of hMLH1 expression was observed. The differences were most pronounced with regard to tumour sub-localisation and differentiation. hMLH1 deficient tumours occur almost exclusively in the proximal colon and are relatively more frequently poorly differentiated, which is in accordance with reports from other studies [22-25].
[ "Of", "the", "microsatellite", "instable", "tumours", ",", "approximately", "90", "%", "show", "absence", "of", "hMLH1", "expression", "[", "24", "]", ".", "In", "most", "sporadic", "colorectal", "cancers", ",", "the", "promoter", "region", "of", "hMLH1", "is", "hypermethylated", ",", "resulting", "in", "absence", "of", "the", "protein", "[", "53", "-", "55", "]", ".", "BAT-26", "was", "previously", "shown", "to", "identify", "microsatellite", "instability", "in", "sporadic", "colorectal", "cancer", "[", "56", "]", "and", "results", "from", "our", "study", "showed", "a", "good", "agreement", "between", "unstable", "BAT-26", "and", "absent", "hMLH1", "expression", ".", "\n\n", "Several", "studies", "have", "shown", "that", "microsatellite", "instability", "and", "mutations", "in", "APC", "and", "K", "-", "ras", "occur", "almost", "mutually", "exclusively", "[", "18,19,21,57", "]", ",", "suggesting", "that", "these", "characteristics", "represent", "separate", "pathways", ".", "However", ",", "others", "have", "observed", "aberrations", "in", "both", "pathways", ",", "but", "these", "studies", "have", "been", "performed", "in", "relatively", "small", "groups", "of", "HNPCC", "and", "sporadic", "colorectal", "cancer", "patients", "[", "14,20,58", "]", "and", "this", "may", "have", "given", "rise", "to", "a", "relative", "overrepresentation", "of", "mutation", "detection", "in", "both", "pathways", ".", "Although", "in", "our", "study", "the", "simultaneous", "occurrence", "of", "hMLH1", "deficiency", "as", "well", "as", "an", "APC", "or", "K", "-", "ras", "mutation", "was", "observed", "in", "a", "small", "number", "of", "tumours", ",", "the", "mutually", "exclusive", "occurrence", "of", "hMLH1", "deficiency", "and", "mutations", "in", "APC", "and", "/", "or", "K", "-", "ras", "seemed", "to", "predominate", ".", "\n\n", "Moreover", ",", "after", "exclusion", "of", "tumours", "displaying", "this", "overlap", ",", "a", "striking", "difference", "between", "occurrences", "of", "APC", "and", "/", "or", "K", "-", "ras", "mutations", "versus", "absence", "of", "hMLH1", "expression", "was", "observed", ".", "The", "differences", "were", "most", "pronounced", "with", "regard", "to", "tumour", "sub", "-", "localisation", "and", "differentiation", ".", "hMLH1", "deficient", "tumours", "occur", "almost", "exclusively", "in", "the", "proximal", "colon", "and", "are", "relatively", "more", "frequently", "poorly", "differentiated", ",", "which", "is", "in", "accordance", "with", "reports", "from", "other", "studies", "[", "22", "-", "25", "]", ".", "\n\n" ]
[ "Physiology", "Disorder", "disease", "body-part", "size", "mutation", "cohort-patient", "Concepts_Ideas", "gene" ]
Above 18 years is a Value, age is a Person, Symptomatic , permanent is a Scope, AF is a Condition, at least three months duration is a Multiplier, Resting heart rate is a Measurement, = 80 bpm is a Value
NCT02695992_inc_task0
Sentence: Above 18 years of age Symptomatic, permanent AF of at least three months duration Resting heart rate =80 bpm Signed informed consent Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Condition, Value, Person, Multiplier, Scope, Measurement
[ "B-Value", "I-Value", "I-Value", "O", "B-Person", "O", "B-Scope", "I-Scope", "I-Scope", "B-Condition", "O", "B-Multiplier", "I-Multiplier", "I-Multiplier", "I-Multiplier", "I-Multiplier", "O", "B-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O" ]
Above 18 years of age Symptomatic, permanent AF of at least three months duration Resting heart rate =80 bpm Signed informed consent
[ "Above", "18", "years", "of", "age", "\n", "Symptomatic", ",", "permanent", "AF", "of", "at", "least", "three", "months", "duration", "\n", "Resting", "heart", "rate", "=", "80", "bpm", "\n", "Signed", "informed", "consent", "\n" ]
[ "Multiplier", "Scope", "Measurement", "Value", "Qualifier", "Person", "Condition" ]
Above 18 years is a Value, age is a Person, Symptomatic , permanent is a Scope, AF is a Condition, at least three months duration is a Multiplier, Resting heart rate is a Measurement, = 80 bpm is a Value
NCT02695992_inc_task1
Sentence: Above 18 years of age Symptomatic, permanent AF of at least three months duration Resting heart rate =80 bpm Signed informed consent Instructions: please typing these entity words according to sentence: Above 18 years, age, Symptomatic , permanent, AF, at least three months duration, Resting heart rate, = 80 bpm Options: Condition, Value, Person, Multiplier, Scope, Measurement
[ "B-Value", "I-Value", "I-Value", "O", "B-Person", "O", "B-Scope", "I-Scope", "I-Scope", "B-Condition", "O", "B-Multiplier", "I-Multiplier", "I-Multiplier", "I-Multiplier", "I-Multiplier", "O", "B-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O" ]
Above 18 years of age Symptomatic, permanent AF of at least three months duration Resting heart rate =80 bpm Signed informed consent
[ "Above", "18", "years", "of", "age", "\n", "Symptomatic", ",", "permanent", "AF", "of", "at", "least", "three", "months", "duration", "\n", "Resting", "heart", "rate", "=", "80", "bpm", "\n", "Signed", "informed", "consent", "\n" ]
[ "Multiplier", "Scope", "Measurement", "Value", "Qualifier", "Person", "Condition" ]
Above 18 years, age, Symptomatic , permanent, AF, at least three months duration, Resting heart rate, = 80 bpm
NCT02695992_inc_task2
Sentence: Above 18 years of age Symptomatic, permanent AF of at least three months duration Resting heart rate =80 bpm Signed informed consent Instructions: please extract entity words from the input sentence
[ "B-Value", "I-Value", "I-Value", "O", "B-Person", "O", "B-Scope", "I-Scope", "I-Scope", "B-Condition", "O", "B-Multiplier", "I-Multiplier", "I-Multiplier", "I-Multiplier", "I-Multiplier", "O", "B-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O" ]
Above 18 years of age Symptomatic, permanent AF of at least three months duration Resting heart rate =80 bpm Signed informed consent
[ "Above", "18", "years", "of", "age", "\n", "Symptomatic", ",", "permanent", "AF", "of", "at", "least", "three", "months", "duration", "\n", "Resting", "heart", "rate", "=", "80", "bpm", "\n", "Signed", "informed", "consent", "\n" ]
[ "Multiplier", "Scope", "Measurement", "Value", "Qualifier", "Person", "Condition" ]
old is an umlsterm, patient is an umlsterm, purpura is an umlsterm, therapeutic is an umlsterm, steroids is an umlsterm, azathioprine is an umlsterm, arthralgias is an umlsterm, symptoms is an umlsterm, skin is an umlsterm, dapsone is an umlsterm, therapy is an umlsterm, control is an umlsterm, blood is an umlsterm, methemoglobin is an umlsterm, symptoms is an umlsterm, dapsone is an umlsterm, therapy is an umlsterm, purpura is an umlsterm
DerHautarzt.90500809.eng.abstr_task0
Sentence: A 26-year old patient who suffered from purpura for four years evolved into the complete clinical picture of Henoch-Schoenlein-purpura in the past two years . A causative agent was never found . Multiple therapeutic approaches including systemic steroids , azathioprine as well as pentoxyfylline failed to control the arthralgias , intestinal symptoms and skin lesions . Therefore dapsone therapy was initiated at a dosage of 100 mg daily after checking the glucose-6-phosphate-dehydrogenase and with regular control of the blood methemoglobin level . Within two weeks , the patient's symptoms completetly cleared , he has now been in remission for the past six months . As noted elsewhere , dapsone is an effective therapy for severe cases of Henoch-Schoenlein- purpura . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]
A 26-year old patient who suffered from purpura for four years evolved into the complete clinical picture of Henoch-Schoenlein-purpura in the past two years . A causative agent was never found . Multiple therapeutic approaches including systemic steroids , azathioprine as well as pentoxyfylline failed to control the arthralgias , intestinal symptoms and skin lesions . Therefore dapsone therapy was initiated at a dosage of 100 mg daily after checking the glucose-6-phosphate-dehydrogenase and with regular control of the blood methemoglobin level . Within two weeks , the patient's symptoms completetly cleared , he has now been in remission for the past six months . As noted elsewhere , dapsone is an effective therapy for severe cases of Henoch-Schoenlein- purpura .
[ "A", "26-year", "old", "patient", "who", "suffered", "from", "purpura", "for", "four", "years", "evolved", "into", "the", "complete", "clinical", "picture", "of", "Henoch", "-", "Schoenlein", "-", "purpura", "in", "the", "past", "two", "years", ".", "A", "causative", "agent", "was", "never", "found", ".", "Multiple", "therapeutic", "approaches", "including", "systemic", "steroids", ",", "azathioprine", "as", "well", "as", "pentoxyfylline", "failed", "to", "control", "the", "arthralgias", ",", "intestinal", "symptoms", "and", "skin", "lesions", ".", "Therefore", "dapsone", "therapy", "was", "initiated", "at", "a", "dosage", "of", "100", "mg", "daily", "after", "checking", "the", "glucose-6-phosphate", "-", "dehydrogenase", "and", "with", "regular", "control", "of", "the", "blood", "methemoglobin", "level", ".", "Within", "two", "weeks", ",", "the", "patient", "'s", "symptoms", "completetly", "cleared", ",", "he", "has", "now", "been", "in", "remission", "for", "the", "past", "six", "months", ".", "As", "noted", "elsewhere", ",", "dapsone", "is", "an", "effective", "therapy", "for", "severe", "cases", "of", "Henoch", "-", "Schoenlein-", "purpura", "." ]
[ "umlsterm" ]
old is an umlsterm, patient is an umlsterm, purpura is an umlsterm, therapeutic is an umlsterm, steroids is an umlsterm, azathioprine is an umlsterm, arthralgias is an umlsterm, symptoms is an umlsterm, skin is an umlsterm, dapsone is an umlsterm, therapy is an umlsterm, control is an umlsterm, blood is an umlsterm, methemoglobin is an umlsterm, symptoms is an umlsterm, dapsone is an umlsterm, therapy is an umlsterm, purpura is an umlsterm
DerHautarzt.90500809.eng.abstr_task1
Sentence: A 26-year old patient who suffered from purpura for four years evolved into the complete clinical picture of Henoch-Schoenlein-purpura in the past two years . A causative agent was never found . Multiple therapeutic approaches including systemic steroids , azathioprine as well as pentoxyfylline failed to control the arthralgias , intestinal symptoms and skin lesions . Therefore dapsone therapy was initiated at a dosage of 100 mg daily after checking the glucose-6-phosphate-dehydrogenase and with regular control of the blood methemoglobin level . Within two weeks , the patient's symptoms completetly cleared , he has now been in remission for the past six months . As noted elsewhere , dapsone is an effective therapy for severe cases of Henoch-Schoenlein- purpura . Instructions: please typing these entity words according to sentence: old, patient, purpura, therapeutic, steroids, azathioprine, arthralgias, symptoms, skin, dapsone, therapy, control, blood, methemoglobin, symptoms, dapsone, therapy, purpura Options: umlsterm
[ "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]
A 26-year old patient who suffered from purpura for four years evolved into the complete clinical picture of Henoch-Schoenlein-purpura in the past two years . A causative agent was never found . Multiple therapeutic approaches including systemic steroids , azathioprine as well as pentoxyfylline failed to control the arthralgias , intestinal symptoms and skin lesions . Therefore dapsone therapy was initiated at a dosage of 100 mg daily after checking the glucose-6-phosphate-dehydrogenase and with regular control of the blood methemoglobin level . Within two weeks , the patient's symptoms completetly cleared , he has now been in remission for the past six months . As noted elsewhere , dapsone is an effective therapy for severe cases of Henoch-Schoenlein- purpura .
[ "A", "26-year", "old", "patient", "who", "suffered", "from", "purpura", "for", "four", "years", "evolved", "into", "the", "complete", "clinical", "picture", "of", "Henoch", "-", "Schoenlein", "-", "purpura", "in", "the", "past", "two", "years", ".", "A", "causative", "agent", "was", "never", "found", ".", "Multiple", "therapeutic", "approaches", "including", "systemic", "steroids", ",", "azathioprine", "as", "well", "as", "pentoxyfylline", "failed", "to", "control", "the", "arthralgias", ",", "intestinal", "symptoms", "and", "skin", "lesions", ".", "Therefore", "dapsone", "therapy", "was", "initiated", "at", "a", "dosage", "of", "100", "mg", "daily", "after", "checking", "the", "glucose-6-phosphate", "-", "dehydrogenase", "and", "with", "regular", "control", "of", "the", "blood", "methemoglobin", "level", ".", "Within", "two", "weeks", ",", "the", "patient", "'s", "symptoms", "completetly", "cleared", ",", "he", "has", "now", "been", "in", "remission", "for", "the", "past", "six", "months", ".", "As", "noted", "elsewhere", ",", "dapsone", "is", "an", "effective", "therapy", "for", "severe", "cases", "of", "Henoch", "-", "Schoenlein-", "purpura", "." ]
[ "umlsterm" ]
old, patient, purpura, therapeutic, steroids, azathioprine, arthralgias, symptoms, skin, dapsone, therapy, control, blood, methemoglobin, symptoms, dapsone, therapy, purpura
DerHautarzt.90500809.eng.abstr_task2
Sentence: A 26-year old patient who suffered from purpura for four years evolved into the complete clinical picture of Henoch-Schoenlein-purpura in the past two years . A causative agent was never found . Multiple therapeutic approaches including systemic steroids , azathioprine as well as pentoxyfylline failed to control the arthralgias , intestinal symptoms and skin lesions . Therefore dapsone therapy was initiated at a dosage of 100 mg daily after checking the glucose-6-phosphate-dehydrogenase and with regular control of the blood methemoglobin level . Within two weeks , the patient's symptoms completetly cleared , he has now been in remission for the past six months . As noted elsewhere , dapsone is an effective therapy for severe cases of Henoch-Schoenlein- purpura . Instructions: please extract entity words from the input sentence
[ "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]
A 26-year old patient who suffered from purpura for four years evolved into the complete clinical picture of Henoch-Schoenlein-purpura in the past two years . A causative agent was never found . Multiple therapeutic approaches including systemic steroids , azathioprine as well as pentoxyfylline failed to control the arthralgias , intestinal symptoms and skin lesions . Therefore dapsone therapy was initiated at a dosage of 100 mg daily after checking the glucose-6-phosphate-dehydrogenase and with regular control of the blood methemoglobin level . Within two weeks , the patient's symptoms completetly cleared , he has now been in remission for the past six months . As noted elsewhere , dapsone is an effective therapy for severe cases of Henoch-Schoenlein- purpura .
[ "A", "26-year", "old", "patient", "who", "suffered", "from", "purpura", "for", "four", "years", "evolved", "into", "the", "complete", "clinical", "picture", "of", "Henoch", "-", "Schoenlein", "-", "purpura", "in", "the", "past", "two", "years", ".", "A", "causative", "agent", "was", "never", "found", ".", "Multiple", "therapeutic", "approaches", "including", "systemic", "steroids", ",", "azathioprine", "as", "well", "as", "pentoxyfylline", "failed", "to", "control", "the", "arthralgias", ",", "intestinal", "symptoms", "and", "skin", "lesions", ".", "Therefore", "dapsone", "therapy", "was", "initiated", "at", "a", "dosage", "of", "100", "mg", "daily", "after", "checking", "the", "glucose-6-phosphate", "-", "dehydrogenase", "and", "with", "regular", "control", "of", "the", "blood", "methemoglobin", "level", ".", "Within", "two", "weeks", ",", "the", "patient", "'s", "symptoms", "completetly", "cleared", ",", "he", "has", "now", "been", "in", "remission", "for", "the", "past", "six", "months", ".", "As", "noted", "elsewhere", ",", "dapsone", "is", "an", "effective", "therapy", "for", "severe", "cases", "of", "Henoch", "-", "Schoenlein-", "purpura", "." ]
[ "umlsterm" ]
gold is an umlsterm, standard is an umlsterm, diagnosis is an umlsterm, glycogen storage disease is an umlsterm, enzyme is an umlsterm, liver is an umlsterm, tissue is an umlsterm, gene is an umlsterm, human is an umlsterm, phosphatase is an umlsterm, mutations is an umlsterm, glycogen storage disease is an umlsterm, patients is an umlsterm, gene is an umlsterm, patients is an umlsterm, glycogen storage disease is an umlsterm, diagnosis is an umlsterm, enzyme is an umlsterm, assay is an umlsterm, patients is an umlsterm, patients is an umlsterm
MonatsschriftKinderheilkunde.81460660.eng.abstr_task0
Sentence: Background : The gold standard for the diagnosis of glycogen storage disease type Ia is still the enzyme assay necessitating fresh liver tissue . In 1993 , the gene encoding for the human phosphatase ( G-6-Pase) of the glucose-6-phosphatase system was isolated and consequently , mutations have been identified in glycogen storage disease type Ia patients . We analysed the G-6-Pase gene of 18 patients with glycogen storage disease type Ia . The diagnosis had previously been established by the enzyme assay in 13 patients . The remaining 5 patients were diagnosed on the basis of the clinical presentation . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Background : The gold standard for the diagnosis of glycogen storage disease type Ia is still the enzyme assay necessitating fresh liver tissue . In 1993 , the gene encoding for the human phosphatase ( G-6-Pase) of the glucose-6-phosphatase system was isolated and consequently , mutations have been identified in glycogen storage disease type Ia patients . We analysed the G-6-Pase gene of 18 patients with glycogen storage disease type Ia . The diagnosis had previously been established by the enzyme assay in 13 patients . The remaining 5 patients were diagnosed on the basis of the clinical presentation .
[ "Background", ":", "The", "gold", "standard", "for", "the", "diagnosis", "of", "glycogen", "storage", "disease", "type", "Ia", "is", "still", "the", "enzyme", "assay", "necessitating", "fresh", "liver", "tissue", ".", "In", "1993", ",", "the", "gene", "encoding", "for", "the", "human", "phosphatase", "(", "G-6-Pase", ")", "of", "the", "glucose-6-phosphatase", "system", "was", "isolated", "and", "consequently", ",", "mutations", "have", "been", "identified", "in", "glycogen", "storage", "disease", "type", "Ia", "patients", ".", "We", "analysed", "the", "G-6-Pase", "gene", "of", "18", "patients", "with", "glycogen", "storage", "disease", "type", "Ia", ".", "The", "diagnosis", "had", "previously", "been", "established", "by", "the", "enzyme", "assay", "in", "13", "patients", ".", "The", "remaining", "5", "patients", "were", "diagnosed", "on", "the", "basis", "of", "the", "clinical", "presentation", "." ]
[ "umlsterm" ]
gold is an umlsterm, standard is an umlsterm, diagnosis is an umlsterm, glycogen storage disease is an umlsterm, enzyme is an umlsterm, liver is an umlsterm, tissue is an umlsterm, gene is an umlsterm, human is an umlsterm, phosphatase is an umlsterm, mutations is an umlsterm, glycogen storage disease is an umlsterm, patients is an umlsterm, gene is an umlsterm, patients is an umlsterm, glycogen storage disease is an umlsterm, diagnosis is an umlsterm, enzyme is an umlsterm, assay is an umlsterm, patients is an umlsterm, patients is an umlsterm
MonatsschriftKinderheilkunde.81460660.eng.abstr_task1
Sentence: Background : The gold standard for the diagnosis of glycogen storage disease type Ia is still the enzyme assay necessitating fresh liver tissue . In 1993 , the gene encoding for the human phosphatase ( G-6-Pase) of the glucose-6-phosphatase system was isolated and consequently , mutations have been identified in glycogen storage disease type Ia patients . We analysed the G-6-Pase gene of 18 patients with glycogen storage disease type Ia . The diagnosis had previously been established by the enzyme assay in 13 patients . The remaining 5 patients were diagnosed on the basis of the clinical presentation . Instructions: please typing these entity words according to sentence: gold, standard, diagnosis, glycogen storage disease, enzyme, liver, tissue, gene, human, phosphatase, mutations, glycogen storage disease, patients, gene, patients, glycogen storage disease, diagnosis, enzyme, assay, patients, patients Options: umlsterm
[ "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Background : The gold standard for the diagnosis of glycogen storage disease type Ia is still the enzyme assay necessitating fresh liver tissue . In 1993 , the gene encoding for the human phosphatase ( G-6-Pase) of the glucose-6-phosphatase system was isolated and consequently , mutations have been identified in glycogen storage disease type Ia patients . We analysed the G-6-Pase gene of 18 patients with glycogen storage disease type Ia . The diagnosis had previously been established by the enzyme assay in 13 patients . The remaining 5 patients were diagnosed on the basis of the clinical presentation .
[ "Background", ":", "The", "gold", "standard", "for", "the", "diagnosis", "of", "glycogen", "storage", "disease", "type", "Ia", "is", "still", "the", "enzyme", "assay", "necessitating", "fresh", "liver", "tissue", ".", "In", "1993", ",", "the", "gene", "encoding", "for", "the", "human", "phosphatase", "(", "G-6-Pase", ")", "of", "the", "glucose-6-phosphatase", "system", "was", "isolated", "and", "consequently", ",", "mutations", "have", "been", "identified", "in", "glycogen", "storage", "disease", "type", "Ia", "patients", ".", "We", "analysed", "the", "G-6-Pase", "gene", "of", "18", "patients", "with", "glycogen", "storage", "disease", "type", "Ia", ".", "The", "diagnosis", "had", "previously", "been", "established", "by", "the", "enzyme", "assay", "in", "13", "patients", ".", "The", "remaining", "5", "patients", "were", "diagnosed", "on", "the", "basis", "of", "the", "clinical", "presentation", "." ]
[ "umlsterm" ]
gold, standard, diagnosis, glycogen storage disease, enzyme, liver, tissue, gene, human, phosphatase, mutations, glycogen storage disease, patients, gene, patients, glycogen storage disease, diagnosis, enzyme, assay, patients, patients
MonatsschriftKinderheilkunde.81460660.eng.abstr_task2
Sentence: Background : The gold standard for the diagnosis of glycogen storage disease type Ia is still the enzyme assay necessitating fresh liver tissue . In 1993 , the gene encoding for the human phosphatase ( G-6-Pase) of the glucose-6-phosphatase system was isolated and consequently , mutations have been identified in glycogen storage disease type Ia patients . We analysed the G-6-Pase gene of 18 patients with glycogen storage disease type Ia . The diagnosis had previously been established by the enzyme assay in 13 patients . The remaining 5 patients were diagnosed on the basis of the clinical presentation . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Background : The gold standard for the diagnosis of glycogen storage disease type Ia is still the enzyme assay necessitating fresh liver tissue . In 1993 , the gene encoding for the human phosphatase ( G-6-Pase) of the glucose-6-phosphatase system was isolated and consequently , mutations have been identified in glycogen storage disease type Ia patients . We analysed the G-6-Pase gene of 18 patients with glycogen storage disease type Ia . The diagnosis had previously been established by the enzyme assay in 13 patients . The remaining 5 patients were diagnosed on the basis of the clinical presentation .
[ "Background", ":", "The", "gold", "standard", "for", "the", "diagnosis", "of", "glycogen", "storage", "disease", "type", "Ia", "is", "still", "the", "enzyme", "assay", "necessitating", "fresh", "liver", "tissue", ".", "In", "1993", ",", "the", "gene", "encoding", "for", "the", "human", "phosphatase", "(", "G-6-Pase", ")", "of", "the", "glucose-6-phosphatase", "system", "was", "isolated", "and", "consequently", ",", "mutations", "have", "been", "identified", "in", "glycogen", "storage", "disease", "type", "Ia", "patients", ".", "We", "analysed", "the", "G-6-Pase", "gene", "of", "18", "patients", "with", "glycogen", "storage", "disease", "type", "Ia", ".", "The", "diagnosis", "had", "previously", "been", "established", "by", "the", "enzyme", "assay", "in", "13", "patients", ".", "The", "remaining", "5", "patients", "were", "diagnosed", "on", "the", "basis", "of", "the", "clinical", "presentation", "." ]
[ "umlsterm" ]
N - alkylcarbazole is a CHEMICAL, STAT3 is a GENE-Y
23287056_task0
Sentence: Synthesis and biological evaluation of new N-alkylcarbazole derivatives as STAT3 inhibitors: preliminary study. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL
[ "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O" ]
Synthesis and biological evaluation of new N-alkylcarbazole derivatives as STAT3 inhibitors: preliminary study.
[ "Synthesis", "and", "biological", "evaluation", "of", "new", "N", "-", "alkylcarbazole", "derivatives", "as", "STAT3", "inhibitors", ":", "preliminary", "study", "." ]
[ "GENE-N", "CHEMICAL", "GENE-Y" ]
N - alkylcarbazole is a CHEMICAL, STAT3 is a GENE-Y
23287056_task1
Sentence: Synthesis and biological evaluation of new N-alkylcarbazole derivatives as STAT3 inhibitors: preliminary study. Instructions: please typing these entity words according to sentence: N - alkylcarbazole, STAT3 Options: GENE-Y, CHEMICAL
[ "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O" ]
Synthesis and biological evaluation of new N-alkylcarbazole derivatives as STAT3 inhibitors: preliminary study.
[ "Synthesis", "and", "biological", "evaluation", "of", "new", "N", "-", "alkylcarbazole", "derivatives", "as", "STAT3", "inhibitors", ":", "preliminary", "study", "." ]
[ "GENE-N", "CHEMICAL", "GENE-Y" ]
N - alkylcarbazole, STAT3
23287056_task2
Sentence: Synthesis and biological evaluation of new N-alkylcarbazole derivatives as STAT3 inhibitors: preliminary study. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O" ]
Synthesis and biological evaluation of new N-alkylcarbazole derivatives as STAT3 inhibitors: preliminary study.
[ "Synthesis", "and", "biological", "evaluation", "of", "new", "N", "-", "alkylcarbazole", "derivatives", "as", "STAT3", "inhibitors", ":", "preliminary", "study", "." ]
[ "GENE-N", "CHEMICAL", "GENE-Y" ]
Stoffwechsel is an umlsterm, Pigmentepithel- is an umlsterm, Zellen is an umlsterm
DerOpthalmologe.00970682.ger.abstr_task0
Sentence: Hintergrund . A2-E, ein fluoreszierender Bestandteil von Lipofuszin , beeintraechtigt den lysosomalen Stoffwechsel humaner retinaler Pigmentepithel- ( RPE- ) Zellen . Als weiterer moeglicher Schaedigungsmechanismus wurde hier das phototoxische Potenzial des Retinoidanteils untersucht . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Hintergrund . A2-E, ein fluoreszierender Bestandteil von Lipofuszin , beeintraechtigt den lysosomalen Stoffwechsel humaner retinaler Pigmentepithel- ( RPE- ) Zellen . Als weiterer moeglicher Schaedigungsmechanismus wurde hier das phototoxische Potenzial des Retinoidanteils untersucht .
[ "Hintergrund", ".", "A2-E", ",", "ein", "fluoreszierender", "Bestandteil", "von", "Lipofuszin", ",", "beeintraechtigt", "den", "lysosomalen", "Stoffwechsel", "humaner", "retinaler", "Pigmentepithel-", "(", "RPE-", ")", "Zellen", ".", "Als", "weiterer", "moeglicher", "Schaedigungsmechanismus", "wurde", "hier", "das", "phototoxische", "Potenzial", "des", "Retinoidanteils", "untersucht", "." ]
[ "umlsterm" ]
Stoffwechsel is an umlsterm, Pigmentepithel- is an umlsterm, Zellen is an umlsterm
DerOpthalmologe.00970682.ger.abstr_task1
Sentence: Hintergrund . A2-E, ein fluoreszierender Bestandteil von Lipofuszin , beeintraechtigt den lysosomalen Stoffwechsel humaner retinaler Pigmentepithel- ( RPE- ) Zellen . Als weiterer moeglicher Schaedigungsmechanismus wurde hier das phototoxische Potenzial des Retinoidanteils untersucht . Instructions: please typing these entity words according to sentence: Stoffwechsel, Pigmentepithel-, Zellen Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Hintergrund . A2-E, ein fluoreszierender Bestandteil von Lipofuszin , beeintraechtigt den lysosomalen Stoffwechsel humaner retinaler Pigmentepithel- ( RPE- ) Zellen . Als weiterer moeglicher Schaedigungsmechanismus wurde hier das phototoxische Potenzial des Retinoidanteils untersucht .
[ "Hintergrund", ".", "A2-E", ",", "ein", "fluoreszierender", "Bestandteil", "von", "Lipofuszin", ",", "beeintraechtigt", "den", "lysosomalen", "Stoffwechsel", "humaner", "retinaler", "Pigmentepithel-", "(", "RPE-", ")", "Zellen", ".", "Als", "weiterer", "moeglicher", "Schaedigungsmechanismus", "wurde", "hier", "das", "phototoxische", "Potenzial", "des", "Retinoidanteils", "untersucht", "." ]
[ "umlsterm" ]
Stoffwechsel, Pigmentepithel-, Zellen
DerOpthalmologe.00970682.ger.abstr_task2
Sentence: Hintergrund . A2-E, ein fluoreszierender Bestandteil von Lipofuszin , beeintraechtigt den lysosomalen Stoffwechsel humaner retinaler Pigmentepithel- ( RPE- ) Zellen . Als weiterer moeglicher Schaedigungsmechanismus wurde hier das phototoxische Potenzial des Retinoidanteils untersucht . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Hintergrund . A2-E, ein fluoreszierender Bestandteil von Lipofuszin , beeintraechtigt den lysosomalen Stoffwechsel humaner retinaler Pigmentepithel- ( RPE- ) Zellen . Als weiterer moeglicher Schaedigungsmechanismus wurde hier das phototoxische Potenzial des Retinoidanteils untersucht .
[ "Hintergrund", ".", "A2-E", ",", "ein", "fluoreszierender", "Bestandteil", "von", "Lipofuszin", ",", "beeintraechtigt", "den", "lysosomalen", "Stoffwechsel", "humaner", "retinaler", "Pigmentepithel-", "(", "RPE-", ")", "Zellen", ".", "Als", "weiterer", "moeglicher", "Schaedigungsmechanismus", "wurde", "hier", "das", "phototoxische", "Potenzial", "des", "Retinoidanteils", "untersucht", "." ]
[ "umlsterm" ]
Axin is a protein, GSK-3 is a protein, beta - catenin is a protein, GSK-3 is a protein, beta - catenin is a protein, Axin is a protein, dnXgsk-3 is a protein
1.0alpha7.train.174_task0
Sentence: The demonstration that Axin binds GSK-3 and beta-catenin and promotes GSK-3 phosphorylation of beta-catenin suggested that Axin might be the target of the dnXgsk-3. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein
[ "O", "O", "O", "B-protein", "O", "B-protein", "O", "B-protein", "I-protein", "I-protein", "O", "O", "B-protein", "O", "O", "B-protein", "I-protein", "I-protein", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "B-protein", "O" ]
The demonstration that Axin binds GSK-3 and beta-catenin and promotes GSK-3 phosphorylation of beta-catenin suggested that Axin might be the target of the dnXgsk-3.
[ "The", "demonstration", "that", "Axin", "binds", "GSK-3", "and", "beta", "-", "catenin", "and", "promotes", "GSK-3", "phosphorylation", "of", "beta", "-", "catenin", "suggested", "that", "Axin", "might", "be", "the", "target", "of", "the", "dnXgsk-3", "." ]
[ "protein" ]
Axin is a protein, GSK-3 is a protein, beta - catenin is a protein, GSK-3 is a protein, beta - catenin is a protein, Axin is a protein, dnXgsk-3 is a protein
1.0alpha7.train.174_task1
Sentence: The demonstration that Axin binds GSK-3 and beta-catenin and promotes GSK-3 phosphorylation of beta-catenin suggested that Axin might be the target of the dnXgsk-3. Instructions: please typing these entity words according to sentence: Axin, GSK-3, beta - catenin, GSK-3, beta - catenin, Axin, dnXgsk-3 Options: protein
[ "O", "O", "O", "B-protein", "O", "B-protein", "O", "B-protein", "I-protein", "I-protein", "O", "O", "B-protein", "O", "O", "B-protein", "I-protein", "I-protein", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "B-protein", "O" ]
The demonstration that Axin binds GSK-3 and beta-catenin and promotes GSK-3 phosphorylation of beta-catenin suggested that Axin might be the target of the dnXgsk-3.
[ "The", "demonstration", "that", "Axin", "binds", "GSK-3", "and", "beta", "-", "catenin", "and", "promotes", "GSK-3", "phosphorylation", "of", "beta", "-", "catenin", "suggested", "that", "Axin", "might", "be", "the", "target", "of", "the", "dnXgsk-3", "." ]
[ "protein" ]
Axin, GSK-3, beta - catenin, GSK-3, beta - catenin, Axin, dnXgsk-3
1.0alpha7.train.174_task2
Sentence: The demonstration that Axin binds GSK-3 and beta-catenin and promotes GSK-3 phosphorylation of beta-catenin suggested that Axin might be the target of the dnXgsk-3. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "B-protein", "O", "B-protein", "O", "B-protein", "I-protein", "I-protein", "O", "O", "B-protein", "O", "O", "B-protein", "I-protein", "I-protein", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "B-protein", "O" ]
The demonstration that Axin binds GSK-3 and beta-catenin and promotes GSK-3 phosphorylation of beta-catenin suggested that Axin might be the target of the dnXgsk-3.
[ "The", "demonstration", "that", "Axin", "binds", "GSK-3", "and", "beta", "-", "catenin", "and", "promotes", "GSK-3", "phosphorylation", "of", "beta", "-", "catenin", "suggested", "that", "Axin", "might", "be", "the", "target", "of", "the", "dnXgsk-3", "." ]
[ "protein" ]
Anti - tumor necrosis factor alpha is a Intervention_Physical, Crohn ' s disease is a Participant_Condition
91805_task0
Sentence: Anti-tumor necrosis factor alpha : Crohn 's disease guided missile . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Physical, Participant_Condition
[ "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O" ]
Anti-tumor necrosis factor alpha : Crohn 's disease guided missile .
[ "Anti", "-", "tumor", "necrosis", "factor", "alpha", ":", "Crohn", "'", "s", "disease", "guided", "missile", "." ]
[ "Intervention_Physical", "Participant_Condition" ]
Anti - tumor necrosis factor alpha is a Intervention_Physical, Crohn ' s disease is a Participant_Condition
91805_task1
Sentence: Anti-tumor necrosis factor alpha : Crohn 's disease guided missile . Instructions: please typing these entity words according to sentence: Anti - tumor necrosis factor alpha, Crohn ' s disease Options: Intervention_Physical, Participant_Condition
[ "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O" ]
Anti-tumor necrosis factor alpha : Crohn 's disease guided missile .
[ "Anti", "-", "tumor", "necrosis", "factor", "alpha", ":", "Crohn", "'", "s", "disease", "guided", "missile", "." ]
[ "Intervention_Physical", "Participant_Condition" ]
Anti - tumor necrosis factor alpha, Crohn ' s disease
91805_task2
Sentence: Anti-tumor necrosis factor alpha : Crohn 's disease guided missile . Instructions: please extract entity words from the input sentence
[ "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O" ]
Anti-tumor necrosis factor alpha : Crohn 's disease guided missile .
[ "Anti", "-", "tumor", "necrosis", "factor", "alpha", ":", "Crohn", "'", "s", "disease", "guided", "missile", "." ]
[ "Intervention_Physical", "Participant_Condition" ]
growth hormone - releasing hormone receptor messenger ribonucleic acid is a Genes & Molecular Sequences, growth hormone - secreting pituitary adenoma is a Diseases & Disorders, Gsalpha protein mutation is a SNP & Sequence variations
13463_task0
Sentence: Elevation of growth hormone-releasing hormone receptor messenger ribonucleic acid expression in growth hormone-secreting pituitary adenoma with Gsalpha protein mutation. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: SNP & Sequence variations, Diseases & Disorders, Genes & Molecular Sequences
[ "O", "O", "B-Genes & Molecular Sequences", "I-Genes & Molecular Sequences", "I-Genes & Molecular Sequences", "I-Genes & Molecular Sequences", "I-Genes & Molecular Sequences", "I-Genes & Molecular Sequences", "I-Genes & Molecular Sequences", "I-Genes & Molecular Sequences", "I-Genes & Molecular Sequences", "O", "O", "B-Diseases & Disorders", "I-Diseases & Disorders", "I-Diseases & Disorders", "I-Diseases & Disorders", "I-Diseases & Disorders", "I-Diseases & Disorders", "O", "B-SNP & Sequence variations", "I-SNP & Sequence variations", "I-SNP & Sequence variations", "O" ]
Elevation of growth hormone-releasing hormone receptor messenger ribonucleic acid expression in growth hormone-secreting pituitary adenoma with Gsalpha protein mutation.
[ "Elevation", "of", "growth", "hormone", "-", "releasing", "hormone", "receptor", "messenger", "ribonucleic", "acid", "expression", "in", "growth", "hormone", "-", "secreting", "pituitary", "adenoma", "with", "Gsalpha", "protein", "mutation", "." ]
[ "Genes & Molecular Sequences", "", "SNP & Sequence variations", "Diseases & Disorders" ]
growth hormone - releasing hormone receptor messenger ribonucleic acid is a Genes & Molecular Sequences, growth hormone - secreting pituitary adenoma is a Diseases & Disorders, Gsalpha protein mutation is a SNP & Sequence variations
13463_task1
Sentence: Elevation of growth hormone-releasing hormone receptor messenger ribonucleic acid expression in growth hormone-secreting pituitary adenoma with Gsalpha protein mutation. Instructions: please typing these entity words according to sentence: growth hormone - releasing hormone receptor messenger ribonucleic acid, growth hormone - secreting pituitary adenoma, Gsalpha protein mutation Options: SNP & Sequence variations, Diseases & Disorders, Genes & Molecular Sequences
[ "O", "O", "B-Genes & Molecular Sequences", "I-Genes & Molecular Sequences", "I-Genes & Molecular Sequences", "I-Genes & Molecular Sequences", "I-Genes & Molecular Sequences", "I-Genes & Molecular Sequences", "I-Genes & Molecular Sequences", "I-Genes & Molecular Sequences", "I-Genes & Molecular Sequences", "O", "O", "B-Diseases & Disorders", "I-Diseases & Disorders", "I-Diseases & Disorders", "I-Diseases & Disorders", "I-Diseases & Disorders", "I-Diseases & Disorders", "O", "B-SNP & Sequence variations", "I-SNP & Sequence variations", "I-SNP & Sequence variations", "O" ]
Elevation of growth hormone-releasing hormone receptor messenger ribonucleic acid expression in growth hormone-secreting pituitary adenoma with Gsalpha protein mutation.
[ "Elevation", "of", "growth", "hormone", "-", "releasing", "hormone", "receptor", "messenger", "ribonucleic", "acid", "expression", "in", "growth", "hormone", "-", "secreting", "pituitary", "adenoma", "with", "Gsalpha", "protein", "mutation", "." ]
[ "Genes & Molecular Sequences", "", "SNP & Sequence variations", "Diseases & Disorders" ]
growth hormone - releasing hormone receptor messenger ribonucleic acid, growth hormone - secreting pituitary adenoma, Gsalpha protein mutation
13463_task2
Sentence: Elevation of growth hormone-releasing hormone receptor messenger ribonucleic acid expression in growth hormone-secreting pituitary adenoma with Gsalpha protein mutation. Instructions: please extract entity words from the input sentence
[ "O", "O", "B-Genes & Molecular Sequences", "I-Genes & Molecular Sequences", "I-Genes & Molecular Sequences", "I-Genes & Molecular Sequences", "I-Genes & Molecular Sequences", "I-Genes & Molecular Sequences", "I-Genes & Molecular Sequences", "I-Genes & Molecular Sequences", "I-Genes & Molecular Sequences", "O", "O", "B-Diseases & Disorders", "I-Diseases & Disorders", "I-Diseases & Disorders", "I-Diseases & Disorders", "I-Diseases & Disorders", "I-Diseases & Disorders", "O", "B-SNP & Sequence variations", "I-SNP & Sequence variations", "I-SNP & Sequence variations", "O" ]
Elevation of growth hormone-releasing hormone receptor messenger ribonucleic acid expression in growth hormone-secreting pituitary adenoma with Gsalpha protein mutation.
[ "Elevation", "of", "growth", "hormone", "-", "releasing", "hormone", "receptor", "messenger", "ribonucleic", "acid", "expression", "in", "growth", "hormone", "-", "secreting", "pituitary", "adenoma", "with", "Gsalpha", "protein", "mutation", "." ]
[ "Genes & Molecular Sequences", "", "SNP & Sequence variations", "Diseases & Disorders" ]
myozenin is a protein-family, alpha - actinin is a protein-family
1.0alpha7.train.853_task0
Sentence: Here we have shown that myozenin also binds alpha-actinin in this region, likely somewhere within residues 606-757. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein-family
[ "O", "O", "O", "O", "O", "O", "B-protein-family", "O", "O", "O", "B-protein-family", "I-protein-family", "I-protein-family", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Here we have shown that myozenin also binds alpha-actinin in this region, likely somewhere within residues 606-757.
[ "Here", "we", "have", "shown", "that", " ", "myozenin", "also", "binds", " ", "alpha", "-", "actinin", "in", "this", "region", ",", "likely", "somewhere", "within", "residues", "606", "-", "757", "." ]
[ "protein-family" ]
myozenin is a protein-family, alpha - actinin is a protein-family
1.0alpha7.train.853_task1
Sentence: Here we have shown that myozenin also binds alpha-actinin in this region, likely somewhere within residues 606-757. Instructions: please typing these entity words according to sentence: myozenin, alpha - actinin Options: protein-family
[ "O", "O", "O", "O", "O", "O", "B-protein-family", "O", "O", "O", "B-protein-family", "I-protein-family", "I-protein-family", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Here we have shown that myozenin also binds alpha-actinin in this region, likely somewhere within residues 606-757.
[ "Here", "we", "have", "shown", "that", " ", "myozenin", "also", "binds", " ", "alpha", "-", "actinin", "in", "this", "region", ",", "likely", "somewhere", "within", "residues", "606", "-", "757", "." ]
[ "protein-family" ]
myozenin, alpha - actinin
1.0alpha7.train.853_task2
Sentence: Here we have shown that myozenin also binds alpha-actinin in this region, likely somewhere within residues 606-757. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "B-protein-family", "O", "O", "O", "B-protein-family", "I-protein-family", "I-protein-family", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Here we have shown that myozenin also binds alpha-actinin in this region, likely somewhere within residues 606-757.
[ "Here", "we", "have", "shown", "that", " ", "myozenin", "also", "binds", " ", "alpha", "-", "actinin", "in", "this", "region", ",", "likely", "somewhere", "within", "residues", "606", "-", "757", "." ]
[ "protein-family" ]
arginine is a CHEMICAL, lysine is a CHEMICAL, glucosyltransferase is a GENE-N, Beta-1,4-galactosyltransferase I is a GENE-Y, beta4Gal - T1 is a GENE-Y, Gal is a CHEMICAL, UDP - Gal is a CHEMICAL, GlcNAc is a CHEMICAL, Mn(2 + ) is a CHEMICAL, Gal - T is a GENE-N, Glc is a CHEMICAL, UDP - Glc is a CHEMICAL, GlcNAc is a CHEMICAL, Glc - T is a GENE-N, alpha - lactalbumin is a GENE-Y, LA is a GENE-Y, Glc - T is a GENE-N, UDP - Glc is a CHEMICAL, beta4Gal - T1 is a GENE-Y, O4 hydroxyl is a CHEMICAL, Gal is a CHEMICAL, Glc is a CHEMICAL, hydrogen is a CHEMICAL, carboxylate is a CHEMICAL, O4 hydroxyl of glucose is a CHEMICAL, carboxylate is a CHEMICAL, Glc - T is a GENE-N, lysine is a CHEMICAL, R228K is a GENE-N, Gal - T1 is a GENE-N, Glc - T is a GENE-N, Gal - T is a GENE-N, lysine is a CHEMICAL, Glc - T is a GENE-N, Gal - T is a GENE-N, R228K is a GENE-N, Gal - T1 is a GENE-N, UDP - Gal is a CHEMICAL, Mn(2 + ) is a CHEMICAL, O4 hydroxyl is a CHEMICAL, Gal is a CHEMICAL, UDP - Gal is a CHEMICAL, UDP - Gal is a CHEMICAL, Gal - T is a GENE-N
521_task0
Sentence: Mutation of arginine 228 to lysine enhances the glucosyltransferase activity of bovine beta-1,4-galactosyltransferase I. Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency. In addition, alpha-lactalbumin (LA) enhances this Glc-T activity more than 25 times. Comparison of the crystal structures of UDP-Gal- and UDP-Glc-bound beta4Gal-T1 reveals that the O4 hydroxyl group in both Gal and Glc moieties forms a hydrogen bond with the side chain carboxylate group of Glu317. The orientation of the O4 hydroxyl of glucose causes a steric hindrance to the side chain carboxylate group of Glu317, accounting for the enzyme's low Glc-T activity. In this study, we show that mutation of Arg228, a residue in the vicinity of Glu317, to lysine (R228K-Gal-T1) results in a 15-fold higher Glc-T activity, which is further enhanced by LA to nearly 25% of the Gal-T activity of the wild type. The kinetic parameters indicate that the main effect of the mutation of Arg228 to lysine is on the k(cat) of Glc-T, which increases 3-4-fold, both in the absence and in the presence of LA; simultaneously, the k(cat) for the Gal-T reaction is reduced 30-fold. The crystal structure of R228K-Gal-T1 complexed with LA, UDP-Gal, and Mn(2+) determined at 1.9 A resolution shows that the Asp318 side chain exhibits a minor alternate conformation, compared to that in the wild type. This alternate conformation now causes a steric hindrance to the O4 hydroxyl group of the Gal moiety of UDP-Gal, probably causing the dissociation of UDP-Gal and the reduced k(cat) of the Gal-T reaction. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, GENE-N, CHEMICAL
[ "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-GENE-N", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O" ]
Mutation of arginine 228 to lysine enhances the glucosyltransferase activity of bovine beta-1,4-galactosyltransferase I. Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency. In addition, alpha-lactalbumin (LA) enhances this Glc-T activity more than 25 times. Comparison of the crystal structures of UDP-Gal- and UDP-Glc-bound beta4Gal-T1 reveals that the O4 hydroxyl group in both Gal and Glc moieties forms a hydrogen bond with the side chain carboxylate group of Glu317. The orientation of the O4 hydroxyl of glucose causes a steric hindrance to the side chain carboxylate group of Glu317, accounting for the enzyme's low Glc-T activity. In this study, we show that mutation of Arg228, a residue in the vicinity of Glu317, to lysine (R228K-Gal-T1) results in a 15-fold higher Glc-T activity, which is further enhanced by LA to nearly 25% of the Gal-T activity of the wild type. The kinetic parameters indicate that the main effect of the mutation of Arg228 to lysine is on the k(cat) of Glc-T, which increases 3-4-fold, both in the absence and in the presence of LA; simultaneously, the k(cat) for the Gal-T reaction is reduced 30-fold. The crystal structure of R228K-Gal-T1 complexed with LA, UDP-Gal, and Mn(2+) determined at 1.9 A resolution shows that the Asp318 side chain exhibits a minor alternate conformation, compared to that in the wild type. This alternate conformation now causes a steric hindrance to the O4 hydroxyl group of the Gal moiety of UDP-Gal, probably causing the dissociation of UDP-Gal and the reduced k(cat) of the Gal-T reaction.
[ "Mutation", "of", "arginine", "228", "to", "lysine", "enhances", "the", "glucosyltransferase", "activity", "of", "bovine", "beta-1,4-galactosyltransferase", "I.", "\n", "Beta-1,4-galactosyltransferase", "I", "(", "beta4Gal", "-", "T1", ")", "normally", "transfers", "Gal", "from", "UDP", "-", "Gal", "to", "GlcNAc", "in", "the", "presence", "of", "Mn(2", "+", ")", "ion", "(", "Gal", "-", "T", "activity", ")", "and", "also", "transfers", "Glc", "from", "UDP", "-", "Glc", "to", "GlcNAc", "(", "Glc", "-", "T", "activity", ")", ",", "albeit", "at", "only", "0.3", "%", "efficiency", ".", "In", "addition", ",", "alpha", "-", "lactalbumin", "(", "LA", ")", "enhances", "this", "Glc", "-", "T", "activity", "more", "than", "25", "times", ".", "Comparison", "of", "the", "crystal", "structures", "of", "UDP", "-", "Gal-", "and", "UDP", "-", "Glc", "-", "bound", "beta4Gal", "-", "T1", "reveals", "that", "the", "O4", "hydroxyl", "group", "in", "both", "Gal", "and", "Glc", "moieties", "forms", "a", "hydrogen", "bond", "with", "the", "side", "chain", "carboxylate", "group", "of", "Glu317", ".", "The", "orientation", "of", "the", "O4", "hydroxyl", "of", "glucose", "causes", "a", "steric", "hindrance", "to", "the", "side", "chain", "carboxylate", "group", "of", "Glu317", ",", "accounting", "for", "the", "enzyme", "'s", "low", "Glc", "-", "T", "activity", ".", "In", "this", "study", ",", "we", "show", "that", "mutation", "of", "Arg228", ",", "a", "residue", "in", "the", "vicinity", "of", "Glu317", ",", "to", "lysine", "(", "R228K", "-", "Gal", "-", "T1", ")", "results", "in", "a", "15-fold", "higher", "Glc", "-", "T", "activity", ",", "which", "is", "further", "enhanced", "by", "LA", "to", "nearly", "25", "%", "of", "the", "Gal", "-", "T", "activity", "of", "the", "wild", "type", ".", "The", "kinetic", "parameters", "indicate", "that", "the", "main", "effect", "of", "the", "mutation", "of", "Arg228", "to", "lysine", "is", "on", "the", "k(cat", ")", "of", "Glc", "-", "T", ",", "which", "increases", "3", "-", "4-fold", ",", "both", "in", "the", "absence", "and", "in", "the", "presence", "of", "LA", ";", "simultaneously", ",", "the", "k(cat", ")", "for", "the", "Gal", "-", "T", "reaction", "is", "reduced", "30-fold", ".", "The", "crystal", "structure", "of", "R228K", "-", "Gal", "-", "T1", "complexed", "with", "LA", ",", "UDP", "-", "Gal", ",", "and", "Mn(2", "+", ")", "determined", "at", "1.9", "A", "resolution", "shows", "that", "the", "Asp318", "side", "chain", "exhibits", "a", "minor", "alternate", "conformation", ",", "compared", "to", "that", "in", "the", "wild", "type", ".", "This", "alternate", "conformation", "now", "causes", "a", "steric", "hindrance", "to", "the", "O4", "hydroxyl", "group", "of", "the", "Gal", "moiety", "of", "UDP", "-", "Gal", ",", "probably", "causing", "the", "dissociation", "of", "UDP", "-", "Gal", "and", "the", "reduced", "k(cat", ")", "of", "the", "Gal", "-", "T", "reaction", "." ]
[ "GENE-Y", "CHEMICAL", "GENE-N" ]
arginine is a CHEMICAL, lysine is a CHEMICAL, glucosyltransferase is a GENE-N, Beta-1,4-galactosyltransferase I is a GENE-Y, beta4Gal - T1 is a GENE-Y, Gal is a CHEMICAL, UDP - Gal is a CHEMICAL, GlcNAc is a CHEMICAL, Mn(2 + ) is a CHEMICAL, Gal - T is a GENE-N, Glc is a CHEMICAL, UDP - Glc is a CHEMICAL, GlcNAc is a CHEMICAL, Glc - T is a GENE-N, alpha - lactalbumin is a GENE-Y, LA is a GENE-Y, Glc - T is a GENE-N, UDP - Glc is a CHEMICAL, beta4Gal - T1 is a GENE-Y, O4 hydroxyl is a CHEMICAL, Gal is a CHEMICAL, Glc is a CHEMICAL, hydrogen is a CHEMICAL, carboxylate is a CHEMICAL, O4 hydroxyl of glucose is a CHEMICAL, carboxylate is a CHEMICAL, Glc - T is a GENE-N, lysine is a CHEMICAL, R228K is a GENE-N, Gal - T1 is a GENE-N, Glc - T is a GENE-N, Gal - T is a GENE-N, lysine is a CHEMICAL, Glc - T is a GENE-N, Gal - T is a GENE-N, R228K is a GENE-N, Gal - T1 is a GENE-N, UDP - Gal is a CHEMICAL, Mn(2 + ) is a CHEMICAL, O4 hydroxyl is a CHEMICAL, Gal is a CHEMICAL, UDP - Gal is a CHEMICAL, UDP - Gal is a CHEMICAL, Gal - T is a GENE-N
521_task1
Sentence: Mutation of arginine 228 to lysine enhances the glucosyltransferase activity of bovine beta-1,4-galactosyltransferase I. Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency. In addition, alpha-lactalbumin (LA) enhances this Glc-T activity more than 25 times. Comparison of the crystal structures of UDP-Gal- and UDP-Glc-bound beta4Gal-T1 reveals that the O4 hydroxyl group in both Gal and Glc moieties forms a hydrogen bond with the side chain carboxylate group of Glu317. The orientation of the O4 hydroxyl of glucose causes a steric hindrance to the side chain carboxylate group of Glu317, accounting for the enzyme's low Glc-T activity. In this study, we show that mutation of Arg228, a residue in the vicinity of Glu317, to lysine (R228K-Gal-T1) results in a 15-fold higher Glc-T activity, which is further enhanced by LA to nearly 25% of the Gal-T activity of the wild type. The kinetic parameters indicate that the main effect of the mutation of Arg228 to lysine is on the k(cat) of Glc-T, which increases 3-4-fold, both in the absence and in the presence of LA; simultaneously, the k(cat) for the Gal-T reaction is reduced 30-fold. The crystal structure of R228K-Gal-T1 complexed with LA, UDP-Gal, and Mn(2+) determined at 1.9 A resolution shows that the Asp318 side chain exhibits a minor alternate conformation, compared to that in the wild type. This alternate conformation now causes a steric hindrance to the O4 hydroxyl group of the Gal moiety of UDP-Gal, probably causing the dissociation of UDP-Gal and the reduced k(cat) of the Gal-T reaction. Instructions: please typing these entity words according to sentence: arginine, lysine, glucosyltransferase, Beta-1,4-galactosyltransferase I, beta4Gal - T1, Gal, UDP - Gal, GlcNAc, Mn(2 + ), Gal - T, Glc, UDP - Glc, GlcNAc, Glc - T, alpha - lactalbumin, LA, Glc - T, UDP - Glc, beta4Gal - T1, O4 hydroxyl, Gal, Glc, hydrogen, carboxylate, O4 hydroxyl of glucose, carboxylate, Glc - T, lysine, R228K, Gal - T1, Glc - T, Gal - T, lysine, Glc - T, Gal - T, R228K, Gal - T1, UDP - Gal, Mn(2 + ), O4 hydroxyl, Gal, UDP - Gal, UDP - Gal, Gal - T Options: GENE-Y, GENE-N, CHEMICAL
[ "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-GENE-N", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O" ]
Mutation of arginine 228 to lysine enhances the glucosyltransferase activity of bovine beta-1,4-galactosyltransferase I. Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency. In addition, alpha-lactalbumin (LA) enhances this Glc-T activity more than 25 times. Comparison of the crystal structures of UDP-Gal- and UDP-Glc-bound beta4Gal-T1 reveals that the O4 hydroxyl group in both Gal and Glc moieties forms a hydrogen bond with the side chain carboxylate group of Glu317. The orientation of the O4 hydroxyl of glucose causes a steric hindrance to the side chain carboxylate group of Glu317, accounting for the enzyme's low Glc-T activity. In this study, we show that mutation of Arg228, a residue in the vicinity of Glu317, to lysine (R228K-Gal-T1) results in a 15-fold higher Glc-T activity, which is further enhanced by LA to nearly 25% of the Gal-T activity of the wild type. The kinetic parameters indicate that the main effect of the mutation of Arg228 to lysine is on the k(cat) of Glc-T, which increases 3-4-fold, both in the absence and in the presence of LA; simultaneously, the k(cat) for the Gal-T reaction is reduced 30-fold. The crystal structure of R228K-Gal-T1 complexed with LA, UDP-Gal, and Mn(2+) determined at 1.9 A resolution shows that the Asp318 side chain exhibits a minor alternate conformation, compared to that in the wild type. This alternate conformation now causes a steric hindrance to the O4 hydroxyl group of the Gal moiety of UDP-Gal, probably causing the dissociation of UDP-Gal and the reduced k(cat) of the Gal-T reaction.
[ "Mutation", "of", "arginine", "228", "to", "lysine", "enhances", "the", "glucosyltransferase", "activity", "of", "bovine", "beta-1,4-galactosyltransferase", "I.", "\n", "Beta-1,4-galactosyltransferase", "I", "(", "beta4Gal", "-", "T1", ")", "normally", "transfers", "Gal", "from", "UDP", "-", "Gal", "to", "GlcNAc", "in", "the", "presence", "of", "Mn(2", "+", ")", "ion", "(", "Gal", "-", "T", "activity", ")", "and", "also", "transfers", "Glc", "from", "UDP", "-", "Glc", "to", "GlcNAc", "(", "Glc", "-", "T", "activity", ")", ",", "albeit", "at", "only", "0.3", "%", "efficiency", ".", "In", "addition", ",", "alpha", "-", "lactalbumin", "(", "LA", ")", "enhances", "this", "Glc", "-", "T", "activity", "more", "than", "25", "times", ".", "Comparison", "of", "the", "crystal", "structures", "of", "UDP", "-", "Gal-", "and", "UDP", "-", "Glc", "-", "bound", "beta4Gal", "-", "T1", "reveals", "that", "the", "O4", "hydroxyl", "group", "in", "both", "Gal", "and", "Glc", "moieties", "forms", "a", "hydrogen", "bond", "with", "the", "side", "chain", "carboxylate", "group", "of", "Glu317", ".", "The", "orientation", "of", "the", "O4", "hydroxyl", "of", "glucose", "causes", "a", "steric", "hindrance", "to", "the", "side", "chain", "carboxylate", "group", "of", "Glu317", ",", "accounting", "for", "the", "enzyme", "'s", "low", "Glc", "-", "T", "activity", ".", "In", "this", "study", ",", "we", "show", "that", "mutation", "of", "Arg228", ",", "a", "residue", "in", "the", "vicinity", "of", "Glu317", ",", "to", "lysine", "(", "R228K", "-", "Gal", "-", "T1", ")", "results", "in", "a", "15-fold", "higher", "Glc", "-", "T", "activity", ",", "which", "is", "further", "enhanced", "by", "LA", "to", "nearly", "25", "%", "of", "the", "Gal", "-", "T", "activity", "of", "the", "wild", "type", ".", "The", "kinetic", "parameters", "indicate", "that", "the", "main", "effect", "of", "the", "mutation", "of", "Arg228", "to", "lysine", "is", "on", "the", "k(cat", ")", "of", "Glc", "-", "T", ",", "which", "increases", "3", "-", "4-fold", ",", "both", "in", "the", "absence", "and", "in", "the", "presence", "of", "LA", ";", "simultaneously", ",", "the", "k(cat", ")", "for", "the", "Gal", "-", "T", "reaction", "is", "reduced", "30-fold", ".", "The", "crystal", "structure", "of", "R228K", "-", "Gal", "-", "T1", "complexed", "with", "LA", ",", "UDP", "-", "Gal", ",", "and", "Mn(2", "+", ")", "determined", "at", "1.9", "A", "resolution", "shows", "that", "the", "Asp318", "side", "chain", "exhibits", "a", "minor", "alternate", "conformation", ",", "compared", "to", "that", "in", "the", "wild", "type", ".", "This", "alternate", "conformation", "now", "causes", "a", "steric", "hindrance", "to", "the", "O4", "hydroxyl", "group", "of", "the", "Gal", "moiety", "of", "UDP", "-", "Gal", ",", "probably", "causing", "the", "dissociation", "of", "UDP", "-", "Gal", "and", "the", "reduced", "k(cat", ")", "of", "the", "Gal", "-", "T", "reaction", "." ]
[ "GENE-Y", "CHEMICAL", "GENE-N" ]
arginine, lysine, glucosyltransferase, Beta-1,4-galactosyltransferase I, beta4Gal - T1, Gal, UDP - Gal, GlcNAc, Mn(2 + ), Gal - T, Glc, UDP - Glc, GlcNAc, Glc - T, alpha - lactalbumin, LA, Glc - T, UDP - Glc, beta4Gal - T1, O4 hydroxyl, Gal, Glc, hydrogen, carboxylate, O4 hydroxyl of glucose, carboxylate, Glc - T, lysine, R228K, Gal - T1, Glc - T, Gal - T, lysine, Glc - T, Gal - T, R228K, Gal - T1, UDP - Gal, Mn(2 + ), O4 hydroxyl, Gal, UDP - Gal, UDP - Gal, Gal - T
521_task2
Sentence: Mutation of arginine 228 to lysine enhances the glucosyltransferase activity of bovine beta-1,4-galactosyltransferase I. Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency. In addition, alpha-lactalbumin (LA) enhances this Glc-T activity more than 25 times. Comparison of the crystal structures of UDP-Gal- and UDP-Glc-bound beta4Gal-T1 reveals that the O4 hydroxyl group in both Gal and Glc moieties forms a hydrogen bond with the side chain carboxylate group of Glu317. The orientation of the O4 hydroxyl of glucose causes a steric hindrance to the side chain carboxylate group of Glu317, accounting for the enzyme's low Glc-T activity. In this study, we show that mutation of Arg228, a residue in the vicinity of Glu317, to lysine (R228K-Gal-T1) results in a 15-fold higher Glc-T activity, which is further enhanced by LA to nearly 25% of the Gal-T activity of the wild type. The kinetic parameters indicate that the main effect of the mutation of Arg228 to lysine is on the k(cat) of Glc-T, which increases 3-4-fold, both in the absence and in the presence of LA; simultaneously, the k(cat) for the Gal-T reaction is reduced 30-fold. The crystal structure of R228K-Gal-T1 complexed with LA, UDP-Gal, and Mn(2+) determined at 1.9 A resolution shows that the Asp318 side chain exhibits a minor alternate conformation, compared to that in the wild type. This alternate conformation now causes a steric hindrance to the O4 hydroxyl group of the Gal moiety of UDP-Gal, probably causing the dissociation of UDP-Gal and the reduced k(cat) of the Gal-T reaction. Instructions: please extract entity words from the input sentence
[ "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-GENE-N", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O" ]
Mutation of arginine 228 to lysine enhances the glucosyltransferase activity of bovine beta-1,4-galactosyltransferase I. Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency. In addition, alpha-lactalbumin (LA) enhances this Glc-T activity more than 25 times. Comparison of the crystal structures of UDP-Gal- and UDP-Glc-bound beta4Gal-T1 reveals that the O4 hydroxyl group in both Gal and Glc moieties forms a hydrogen bond with the side chain carboxylate group of Glu317. The orientation of the O4 hydroxyl of glucose causes a steric hindrance to the side chain carboxylate group of Glu317, accounting for the enzyme's low Glc-T activity. In this study, we show that mutation of Arg228, a residue in the vicinity of Glu317, to lysine (R228K-Gal-T1) results in a 15-fold higher Glc-T activity, which is further enhanced by LA to nearly 25% of the Gal-T activity of the wild type. The kinetic parameters indicate that the main effect of the mutation of Arg228 to lysine is on the k(cat) of Glc-T, which increases 3-4-fold, both in the absence and in the presence of LA; simultaneously, the k(cat) for the Gal-T reaction is reduced 30-fold. The crystal structure of R228K-Gal-T1 complexed with LA, UDP-Gal, and Mn(2+) determined at 1.9 A resolution shows that the Asp318 side chain exhibits a minor alternate conformation, compared to that in the wild type. This alternate conformation now causes a steric hindrance to the O4 hydroxyl group of the Gal moiety of UDP-Gal, probably causing the dissociation of UDP-Gal and the reduced k(cat) of the Gal-T reaction.
[ "Mutation", "of", "arginine", "228", "to", "lysine", "enhances", "the", "glucosyltransferase", "activity", "of", "bovine", "beta-1,4-galactosyltransferase", "I.", "\n", "Beta-1,4-galactosyltransferase", "I", "(", "beta4Gal", "-", "T1", ")", "normally", "transfers", "Gal", "from", "UDP", "-", "Gal", "to", "GlcNAc", "in", "the", "presence", "of", "Mn(2", "+", ")", "ion", "(", "Gal", "-", "T", "activity", ")", "and", "also", "transfers", "Glc", "from", "UDP", "-", "Glc", "to", "GlcNAc", "(", "Glc", "-", "T", "activity", ")", ",", "albeit", "at", "only", "0.3", "%", "efficiency", ".", "In", "addition", ",", "alpha", "-", "lactalbumin", "(", "LA", ")", "enhances", "this", "Glc", "-", "T", "activity", "more", "than", "25", "times", ".", "Comparison", "of", "the", "crystal", "structures", "of", "UDP", "-", "Gal-", "and", "UDP", "-", "Glc", "-", "bound", "beta4Gal", "-", "T1", "reveals", "that", "the", "O4", "hydroxyl", "group", "in", "both", "Gal", "and", "Glc", "moieties", "forms", "a", "hydrogen", "bond", "with", "the", "side", "chain", "carboxylate", "group", "of", "Glu317", ".", "The", "orientation", "of", "the", "O4", "hydroxyl", "of", "glucose", "causes", "a", "steric", "hindrance", "to", "the", "side", "chain", "carboxylate", "group", "of", "Glu317", ",", "accounting", "for", "the", "enzyme", "'s", "low", "Glc", "-", "T", "activity", ".", "In", "this", "study", ",", "we", "show", "that", "mutation", "of", "Arg228", ",", "a", "residue", "in", "the", "vicinity", "of", "Glu317", ",", "to", "lysine", "(", "R228K", "-", "Gal", "-", "T1", ")", "results", "in", "a", "15-fold", "higher", "Glc", "-", "T", "activity", ",", "which", "is", "further", "enhanced", "by", "LA", "to", "nearly", "25", "%", "of", "the", "Gal", "-", "T", "activity", "of", "the", "wild", "type", ".", "The", "kinetic", "parameters", "indicate", "that", "the", "main", "effect", "of", "the", "mutation", "of", "Arg228", "to", "lysine", "is", "on", "the", "k(cat", ")", "of", "Glc", "-", "T", ",", "which", "increases", "3", "-", "4-fold", ",", "both", "in", "the", "absence", "and", "in", "the", "presence", "of", "LA", ";", "simultaneously", ",", "the", "k(cat", ")", "for", "the", "Gal", "-", "T", "reaction", "is", "reduced", "30-fold", ".", "The", "crystal", "structure", "of", "R228K", "-", "Gal", "-", "T1", "complexed", "with", "LA", ",", "UDP", "-", "Gal", ",", "and", "Mn(2", "+", ")", "determined", "at", "1.9", "A", "resolution", "shows", "that", "the", "Asp318", "side", "chain", "exhibits", "a", "minor", "alternate", "conformation", ",", "compared", "to", "that", "in", "the", "wild", "type", ".", "This", "alternate", "conformation", "now", "causes", "a", "steric", "hindrance", "to", "the", "O4", "hydroxyl", "group", "of", "the", "Gal", "moiety", "of", "UDP", "-", "Gal", ",", "probably", "causing", "the", "dissociation", "of", "UDP", "-", "Gal", "and", "the", "reduced", "k(cat", ")", "of", "the", "Gal", "-", "T", "reaction", "." ]
[ "GENE-Y", "CHEMICAL", "GENE-N" ]
Pregnane X Receptor is a GENE-Y, HIV Protease is a GENE-N, Amprenavir is a CHEMICAL
23519392_task0
Sentence: Pregnane X Receptor Mediates Dyslipidemia Induced by the HIV Protease Inhibitor Amprenavir in Mice. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL, GENE-Y, GENE-N
[ "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "B-CHEMICAL", "O", "O", "O" ]
Pregnane X Receptor Mediates Dyslipidemia Induced by the HIV Protease Inhibitor Amprenavir in Mice.
[ "Pregnane", "X", "Receptor", "Mediates", "Dyslipidemia", "Induced", "by", "the", "HIV", "Protease", "Inhibitor", "Amprenavir", "in", "Mice", "." ]
[ "GENE-Y", "GENE-N", "CHEMICAL" ]
Pregnane X Receptor is a GENE-Y, HIV Protease is a GENE-N, Amprenavir is a CHEMICAL
23519392_task1
Sentence: Pregnane X Receptor Mediates Dyslipidemia Induced by the HIV Protease Inhibitor Amprenavir in Mice. Instructions: please typing these entity words according to sentence: Pregnane X Receptor, HIV Protease, Amprenavir Options: CHEMICAL, GENE-Y, GENE-N
[ "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "B-CHEMICAL", "O", "O", "O" ]
Pregnane X Receptor Mediates Dyslipidemia Induced by the HIV Protease Inhibitor Amprenavir in Mice.
[ "Pregnane", "X", "Receptor", "Mediates", "Dyslipidemia", "Induced", "by", "the", "HIV", "Protease", "Inhibitor", "Amprenavir", "in", "Mice", "." ]
[ "GENE-Y", "GENE-N", "CHEMICAL" ]
Pregnane X Receptor, HIV Protease, Amprenavir
23519392_task2
Sentence: Pregnane X Receptor Mediates Dyslipidemia Induced by the HIV Protease Inhibitor Amprenavir in Mice. Instructions: please extract entity words from the input sentence
[ "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "B-CHEMICAL", "O", "O", "O" ]
Pregnane X Receptor Mediates Dyslipidemia Induced by the HIV Protease Inhibitor Amprenavir in Mice.
[ "Pregnane", "X", "Receptor", "Mediates", "Dyslipidemia", "Induced", "by", "the", "HIV", "Protease", "Inhibitor", "Amprenavir", "in", "Mice", "." ]
[ "GENE-Y", "GENE-N", "CHEMICAL" ]
Industrielaendern is an umlsterm, Bevoelkerung is an umlsterm, Langzeitpflegeheimen is an umlsterm, Personen is an umlsterm, Charakter is an umlsterm, Methode is an umlsterm, Bewusstsein is an umlsterm, Arztes is an umlsterm, Risikobeurteilung is an umlsterm, Differentialdiagnose is an umlsterm
ZfuerGerontologie+Geriatrie.9032s038.ger.abstr_task0
Sentence: In Industrielaendern sind es eher medizinische Zustaende als Nahrungsmangel , die zur Entstehung von Unterernaehrung beitragen . Unterernaehrung ist in der aelteren Bevoelkerung besonders haeufig und kommt bei 5-12 % der unabhaengig lebenden , bei 30-61 % der hospitalisierten und bei 40-85 % der in Langzeitpflegeheimen untergebrachten aelteren Personen vor . Der multifaktorielle Charakter der Unterernaehrung im Alter erfordert eine strukturierte differentialdiagnostische Methode zur Klaerung ihrer Ursachen . Ein geschaerftes Bewusstsein des Arztes fuer Ernaehrungsprobleme und eine prompte Risikobeurteilung sind unerlaessliche Voraussetzungen , um die Folgeerscheinungen der Unterernaehrung zu verhindern . Dieses strukturierte Vorgehen bei der Differentialdiagnose ist wichtig im Hinblick auf die Evaluation potentiell reversibler Ursachen der Unterernaehrung . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
In Industrielaendern sind es eher medizinische Zustaende als Nahrungsmangel , die zur Entstehung von Unterernaehrung beitragen . Unterernaehrung ist in der aelteren Bevoelkerung besonders haeufig und kommt bei 5-12 % der unabhaengig lebenden , bei 30-61 % der hospitalisierten und bei 40-85 % der in Langzeitpflegeheimen untergebrachten aelteren Personen vor . Der multifaktorielle Charakter der Unterernaehrung im Alter erfordert eine strukturierte differentialdiagnostische Methode zur Klaerung ihrer Ursachen . Ein geschaerftes Bewusstsein des Arztes fuer Ernaehrungsprobleme und eine prompte Risikobeurteilung sind unerlaessliche Voraussetzungen , um die Folgeerscheinungen der Unterernaehrung zu verhindern . Dieses strukturierte Vorgehen bei der Differentialdiagnose ist wichtig im Hinblick auf die Evaluation potentiell reversibler Ursachen der Unterernaehrung .
[ "In", "Industrielaendern", "sind", "es", "eher", "medizinische", "Zustaende", "als", "Nahrungsmangel", ",", "die", "zur", "Entstehung", "von", "Unterernaehrung", "beitragen", ".", "Unterernaehrung", "ist", "in", "der", "aelteren", "Bevoelkerung", "besonders", "haeufig", "und", "kommt", "bei", "5", "-", "12", "%", "der", "unabhaengig", "lebenden", ",", "bei", "30", "-", "61", "%", "der", "hospitalisierten", "und", "bei", "40", "-", "85", "%", "der", "in", "Langzeitpflegeheimen", "untergebrachten", "aelteren", "Personen", "vor", ".", "Der", "multifaktorielle", "Charakter", "der", "Unterernaehrung", "im", "Alter", "erfordert", "eine", "strukturierte", "differentialdiagnostische", "Methode", "zur", "Klaerung", "ihrer", "Ursachen", ".", "Ein", "geschaerftes", "Bewusstsein", "des", "Arztes", "fuer", "Ernaehrungsprobleme", "und", "eine", "prompte", "Risikobeurteilung", "sind", "unerlaessliche", "Voraussetzungen", ",", "um", "die", "Folgeerscheinungen", "der", "Unterernaehrung", "zu", "verhindern", ".", "Dieses", "strukturierte", "Vorgehen", "bei", "der", "Differentialdiagnose", "ist", "wichtig", "im", "Hinblick", "auf", "die", "Evaluation", "potentiell", "reversibler", "Ursachen", "der", "Unterernaehrung", "." ]
[ "umlsterm" ]
Industrielaendern is an umlsterm, Bevoelkerung is an umlsterm, Langzeitpflegeheimen is an umlsterm, Personen is an umlsterm, Charakter is an umlsterm, Methode is an umlsterm, Bewusstsein is an umlsterm, Arztes is an umlsterm, Risikobeurteilung is an umlsterm, Differentialdiagnose is an umlsterm
ZfuerGerontologie+Geriatrie.9032s038.ger.abstr_task1
Sentence: In Industrielaendern sind es eher medizinische Zustaende als Nahrungsmangel , die zur Entstehung von Unterernaehrung beitragen . Unterernaehrung ist in der aelteren Bevoelkerung besonders haeufig und kommt bei 5-12 % der unabhaengig lebenden , bei 30-61 % der hospitalisierten und bei 40-85 % der in Langzeitpflegeheimen untergebrachten aelteren Personen vor . Der multifaktorielle Charakter der Unterernaehrung im Alter erfordert eine strukturierte differentialdiagnostische Methode zur Klaerung ihrer Ursachen . Ein geschaerftes Bewusstsein des Arztes fuer Ernaehrungsprobleme und eine prompte Risikobeurteilung sind unerlaessliche Voraussetzungen , um die Folgeerscheinungen der Unterernaehrung zu verhindern . Dieses strukturierte Vorgehen bei der Differentialdiagnose ist wichtig im Hinblick auf die Evaluation potentiell reversibler Ursachen der Unterernaehrung . Instructions: please typing these entity words according to sentence: Industrielaendern, Bevoelkerung, Langzeitpflegeheimen, Personen, Charakter, Methode, Bewusstsein, Arztes, Risikobeurteilung, Differentialdiagnose Options: umlsterm
[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
In Industrielaendern sind es eher medizinische Zustaende als Nahrungsmangel , die zur Entstehung von Unterernaehrung beitragen . Unterernaehrung ist in der aelteren Bevoelkerung besonders haeufig und kommt bei 5-12 % der unabhaengig lebenden , bei 30-61 % der hospitalisierten und bei 40-85 % der in Langzeitpflegeheimen untergebrachten aelteren Personen vor . Der multifaktorielle Charakter der Unterernaehrung im Alter erfordert eine strukturierte differentialdiagnostische Methode zur Klaerung ihrer Ursachen . Ein geschaerftes Bewusstsein des Arztes fuer Ernaehrungsprobleme und eine prompte Risikobeurteilung sind unerlaessliche Voraussetzungen , um die Folgeerscheinungen der Unterernaehrung zu verhindern . Dieses strukturierte Vorgehen bei der Differentialdiagnose ist wichtig im Hinblick auf die Evaluation potentiell reversibler Ursachen der Unterernaehrung .
[ "In", "Industrielaendern", "sind", "es", "eher", "medizinische", "Zustaende", "als", "Nahrungsmangel", ",", "die", "zur", "Entstehung", "von", "Unterernaehrung", "beitragen", ".", "Unterernaehrung", "ist", "in", "der", "aelteren", "Bevoelkerung", "besonders", "haeufig", "und", "kommt", "bei", "5", "-", "12", "%", "der", "unabhaengig", "lebenden", ",", "bei", "30", "-", "61", "%", "der", "hospitalisierten", "und", "bei", "40", "-", "85", "%", "der", "in", "Langzeitpflegeheimen", "untergebrachten", "aelteren", "Personen", "vor", ".", "Der", "multifaktorielle", "Charakter", "der", "Unterernaehrung", "im", "Alter", "erfordert", "eine", "strukturierte", "differentialdiagnostische", "Methode", "zur", "Klaerung", "ihrer", "Ursachen", ".", "Ein", "geschaerftes", "Bewusstsein", "des", "Arztes", "fuer", "Ernaehrungsprobleme", "und", "eine", "prompte", "Risikobeurteilung", "sind", "unerlaessliche", "Voraussetzungen", ",", "um", "die", "Folgeerscheinungen", "der", "Unterernaehrung", "zu", "verhindern", ".", "Dieses", "strukturierte", "Vorgehen", "bei", "der", "Differentialdiagnose", "ist", "wichtig", "im", "Hinblick", "auf", "die", "Evaluation", "potentiell", "reversibler", "Ursachen", "der", "Unterernaehrung", "." ]
[ "umlsterm" ]
Industrielaendern, Bevoelkerung, Langzeitpflegeheimen, Personen, Charakter, Methode, Bewusstsein, Arztes, Risikobeurteilung, Differentialdiagnose
ZfuerGerontologie+Geriatrie.9032s038.ger.abstr_task2
Sentence: In Industrielaendern sind es eher medizinische Zustaende als Nahrungsmangel , die zur Entstehung von Unterernaehrung beitragen . Unterernaehrung ist in der aelteren Bevoelkerung besonders haeufig und kommt bei 5-12 % der unabhaengig lebenden , bei 30-61 % der hospitalisierten und bei 40-85 % der in Langzeitpflegeheimen untergebrachten aelteren Personen vor . Der multifaktorielle Charakter der Unterernaehrung im Alter erfordert eine strukturierte differentialdiagnostische Methode zur Klaerung ihrer Ursachen . Ein geschaerftes Bewusstsein des Arztes fuer Ernaehrungsprobleme und eine prompte Risikobeurteilung sind unerlaessliche Voraussetzungen , um die Folgeerscheinungen der Unterernaehrung zu verhindern . Dieses strukturierte Vorgehen bei der Differentialdiagnose ist wichtig im Hinblick auf die Evaluation potentiell reversibler Ursachen der Unterernaehrung . Instructions: please extract entity words from the input sentence
[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
In Industrielaendern sind es eher medizinische Zustaende als Nahrungsmangel , die zur Entstehung von Unterernaehrung beitragen . Unterernaehrung ist in der aelteren Bevoelkerung besonders haeufig und kommt bei 5-12 % der unabhaengig lebenden , bei 30-61 % der hospitalisierten und bei 40-85 % der in Langzeitpflegeheimen untergebrachten aelteren Personen vor . Der multifaktorielle Charakter der Unterernaehrung im Alter erfordert eine strukturierte differentialdiagnostische Methode zur Klaerung ihrer Ursachen . Ein geschaerftes Bewusstsein des Arztes fuer Ernaehrungsprobleme und eine prompte Risikobeurteilung sind unerlaessliche Voraussetzungen , um die Folgeerscheinungen der Unterernaehrung zu verhindern . Dieses strukturierte Vorgehen bei der Differentialdiagnose ist wichtig im Hinblick auf die Evaluation potentiell reversibler Ursachen der Unterernaehrung .
[ "In", "Industrielaendern", "sind", "es", "eher", "medizinische", "Zustaende", "als", "Nahrungsmangel", ",", "die", "zur", "Entstehung", "von", "Unterernaehrung", "beitragen", ".", "Unterernaehrung", "ist", "in", "der", "aelteren", "Bevoelkerung", "besonders", "haeufig", "und", "kommt", "bei", "5", "-", "12", "%", "der", "unabhaengig", "lebenden", ",", "bei", "30", "-", "61", "%", "der", "hospitalisierten", "und", "bei", "40", "-", "85", "%", "der", "in", "Langzeitpflegeheimen", "untergebrachten", "aelteren", "Personen", "vor", ".", "Der", "multifaktorielle", "Charakter", "der", "Unterernaehrung", "im", "Alter", "erfordert", "eine", "strukturierte", "differentialdiagnostische", "Methode", "zur", "Klaerung", "ihrer", "Ursachen", ".", "Ein", "geschaerftes", "Bewusstsein", "des", "Arztes", "fuer", "Ernaehrungsprobleme", "und", "eine", "prompte", "Risikobeurteilung", "sind", "unerlaessliche", "Voraussetzungen", ",", "um", "die", "Folgeerscheinungen", "der", "Unterernaehrung", "zu", "verhindern", ".", "Dieses", "strukturierte", "Vorgehen", "bei", "der", "Differentialdiagnose", "ist", "wichtig", "im", "Hinblick", "auf", "die", "Evaluation", "potentiell", "reversibler", "Ursachen", "der", "Unterernaehrung", "." ]
[ "umlsterm" ]
LMP1 is a Protein, LMP1 is a Protein, CD19 is a Protein, CD5 is a Protein, LMP1 is a Protein, LMP1 is a Protein, LMP1 is a Protein, LMP1 is a Protein, CD19 is a Protein, LMP1 is a Protein
59_task0
Sentence: LMP1 Promotes B-1a Lymphomas That Can Escape Allelic Exclusion (A) Flow cytometry analysis of splenocytes from a WT or LMP1 transgenic lymphoma for the pan-B cell (CD19), B-1a cell (CD5), and Ig heavy chain (IgM and IgD) and light chain (kappa and lambda) markers. Shown are the results from WT lymphoma 1 and LMP1 transgenic lymphoma 4. This analysis was repeated on four other LMP1 transgenic lymphomas (1, 2, 3, and 6) showing a similar B-1a phenotype, of which lymphomas 2 and 4 were also doubly positive for kappa and lambda light chains. (B) Flow cytometry analysis of WT or LMP1 transgenic splenocytes for B-1a (CD19+CD5+) and B-1b or B2 subsets (CD19+CD5-). Percentages of B-1a and B-1b or B2 subsets are shown in each quadrant. This analysis was repeated on three other WT and two other LMP1 transgenic mice with similar results. (C) Immunoblot analysis for kappa and lambda light chains of B cells (CD19+) purified from WT and LMP1 transgenic mice. Actin was used as a loading control. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein
[ "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
LMP1 Promotes B-1a Lymphomas That Can Escape Allelic Exclusion (A) Flow cytometry analysis of splenocytes from a WT or LMP1 transgenic lymphoma for the pan-B cell (CD19), B-1a cell (CD5), and Ig heavy chain (IgM and IgD) and light chain (kappa and lambda) markers. Shown are the results from WT lymphoma 1 and LMP1 transgenic lymphoma 4. This analysis was repeated on four other LMP1 transgenic lymphomas (1, 2, 3, and 6) showing a similar B-1a phenotype, of which lymphomas 2 and 4 were also doubly positive for kappa and lambda light chains. (B) Flow cytometry analysis of WT or LMP1 transgenic splenocytes for B-1a (CD19+CD5+) and B-1b or B2 subsets (CD19+CD5-). Percentages of B-1a and B-1b or B2 subsets are shown in each quadrant. This analysis was repeated on three other WT and two other LMP1 transgenic mice with similar results. (C) Immunoblot analysis for kappa and lambda light chains of B cells (CD19+) purified from WT and LMP1 transgenic mice. Actin was used as a loading control.
[ "LMP1", "Promotes", "B-1a", "Lymphomas", "That", "Can", "Escape", "Allelic", "Exclusion", "\n", "(", "A", ")", "Flow", "cytometry", "analysis", "of", "splenocytes", "from", "a", "WT", "or", "LMP1", "transgenic", "lymphoma", "for", "the", "pan", "-", "B", "cell", "(", "CD19", ")", ",", "B-1a", "cell", "(", "CD5", ")", ",", "and", "Ig", "heavy", "chain", "(", "IgM", "and", "IgD", ")", "and", "light", "chain", "(", "kappa", "and", "lambda", ")", "markers", ".", "Shown", "are", "the", "results", "from", "WT", "lymphoma", "1", "and", "LMP1", "transgenic", "lymphoma", "4", ".", "This", "analysis", "was", "repeated", "on", "four", "other", "LMP1", "transgenic", "lymphomas", "(", "1", ",", "2", ",", "3", ",", "and", "6", ")", "showing", "a", "similar", "B-1a", "phenotype", ",", "of", "which", "lymphomas", "2", "and", "4", "were", "also", "doubly", "positive", "for", "kappa", "and", "lambda", "light", "chains", ".", "\n", "(", "B", ")", "Flow", "cytometry", "analysis", "of", "WT", "or", "LMP1", "transgenic", "splenocytes", "for", "B-1a", "(", "CD19+CD5", "+", ")", "and", "B-1b", "or", "B2", "subsets", "(", "CD19+CD5-", ")", ".", "Percentages", "of", "B-1a", "and", "B-1b", "or", "B2", "subsets", "are", "shown", "in", "each", "quadrant", ".", "This", "analysis", "was", "repeated", "on", "three", "other", "WT", "and", "two", "other", "LMP1", "transgenic", "mice", "with", "similar", "results", ".", "\n", "(", "C", ")", "Immunoblot", "analysis", "for", "kappa", "and", "lambda", "light", "chains", "of", "B", "cells", "(", "CD19", "+", ")", "purified", "from", "WT", "and", "LMP1", "transgenic", "mice", ".", "Actin", "was", "used", "as", "a", "loading", "control", ".", "\n" ]
[ "Protein" ]
LMP1 is a Protein, LMP1 is a Protein, CD19 is a Protein, CD5 is a Protein, LMP1 is a Protein, LMP1 is a Protein, LMP1 is a Protein, LMP1 is a Protein, CD19 is a Protein, LMP1 is a Protein
59_task1
Sentence: LMP1 Promotes B-1a Lymphomas That Can Escape Allelic Exclusion (A) Flow cytometry analysis of splenocytes from a WT or LMP1 transgenic lymphoma for the pan-B cell (CD19), B-1a cell (CD5), and Ig heavy chain (IgM and IgD) and light chain (kappa and lambda) markers. Shown are the results from WT lymphoma 1 and LMP1 transgenic lymphoma 4. This analysis was repeated on four other LMP1 transgenic lymphomas (1, 2, 3, and 6) showing a similar B-1a phenotype, of which lymphomas 2 and 4 were also doubly positive for kappa and lambda light chains. (B) Flow cytometry analysis of WT or LMP1 transgenic splenocytes for B-1a (CD19+CD5+) and B-1b or B2 subsets (CD19+CD5-). Percentages of B-1a and B-1b or B2 subsets are shown in each quadrant. This analysis was repeated on three other WT and two other LMP1 transgenic mice with similar results. (C) Immunoblot analysis for kappa and lambda light chains of B cells (CD19+) purified from WT and LMP1 transgenic mice. Actin was used as a loading control. Instructions: please typing these entity words according to sentence: LMP1, LMP1, CD19, CD5, LMP1, LMP1, LMP1, LMP1, CD19, LMP1 Options: Protein
[ "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
LMP1 Promotes B-1a Lymphomas That Can Escape Allelic Exclusion (A) Flow cytometry analysis of splenocytes from a WT or LMP1 transgenic lymphoma for the pan-B cell (CD19), B-1a cell (CD5), and Ig heavy chain (IgM and IgD) and light chain (kappa and lambda) markers. Shown are the results from WT lymphoma 1 and LMP1 transgenic lymphoma 4. This analysis was repeated on four other LMP1 transgenic lymphomas (1, 2, 3, and 6) showing a similar B-1a phenotype, of which lymphomas 2 and 4 were also doubly positive for kappa and lambda light chains. (B) Flow cytometry analysis of WT or LMP1 transgenic splenocytes for B-1a (CD19+CD5+) and B-1b or B2 subsets (CD19+CD5-). Percentages of B-1a and B-1b or B2 subsets are shown in each quadrant. This analysis was repeated on three other WT and two other LMP1 transgenic mice with similar results. (C) Immunoblot analysis for kappa and lambda light chains of B cells (CD19+) purified from WT and LMP1 transgenic mice. Actin was used as a loading control.
[ "LMP1", "Promotes", "B-1a", "Lymphomas", "That", "Can", "Escape", "Allelic", "Exclusion", "\n", "(", "A", ")", "Flow", "cytometry", "analysis", "of", "splenocytes", "from", "a", "WT", "or", "LMP1", "transgenic", "lymphoma", "for", "the", "pan", "-", "B", "cell", "(", "CD19", ")", ",", "B-1a", "cell", "(", "CD5", ")", ",", "and", "Ig", "heavy", "chain", "(", "IgM", "and", "IgD", ")", "and", "light", "chain", "(", "kappa", "and", "lambda", ")", "markers", ".", "Shown", "are", "the", "results", "from", "WT", "lymphoma", "1", "and", "LMP1", "transgenic", "lymphoma", "4", ".", "This", "analysis", "was", "repeated", "on", "four", "other", "LMP1", "transgenic", "lymphomas", "(", "1", ",", "2", ",", "3", ",", "and", "6", ")", "showing", "a", "similar", "B-1a", "phenotype", ",", "of", "which", "lymphomas", "2", "and", "4", "were", "also", "doubly", "positive", "for", "kappa", "and", "lambda", "light", "chains", ".", "\n", "(", "B", ")", "Flow", "cytometry", "analysis", "of", "WT", "or", "LMP1", "transgenic", "splenocytes", "for", "B-1a", "(", "CD19+CD5", "+", ")", "and", "B-1b", "or", "B2", "subsets", "(", "CD19+CD5-", ")", ".", "Percentages", "of", "B-1a", "and", "B-1b", "or", "B2", "subsets", "are", "shown", "in", "each", "quadrant", ".", "This", "analysis", "was", "repeated", "on", "three", "other", "WT", "and", "two", "other", "LMP1", "transgenic", "mice", "with", "similar", "results", ".", "\n", "(", "C", ")", "Immunoblot", "analysis", "for", "kappa", "and", "lambda", "light", "chains", "of", "B", "cells", "(", "CD19", "+", ")", "purified", "from", "WT", "and", "LMP1", "transgenic", "mice", ".", "Actin", "was", "used", "as", "a", "loading", "control", ".", "\n" ]
[ "Protein" ]
LMP1, LMP1, CD19, CD5, LMP1, LMP1, LMP1, LMP1, CD19, LMP1
59_task2
Sentence: LMP1 Promotes B-1a Lymphomas That Can Escape Allelic Exclusion (A) Flow cytometry analysis of splenocytes from a WT or LMP1 transgenic lymphoma for the pan-B cell (CD19), B-1a cell (CD5), and Ig heavy chain (IgM and IgD) and light chain (kappa and lambda) markers. Shown are the results from WT lymphoma 1 and LMP1 transgenic lymphoma 4. This analysis was repeated on four other LMP1 transgenic lymphomas (1, 2, 3, and 6) showing a similar B-1a phenotype, of which lymphomas 2 and 4 were also doubly positive for kappa and lambda light chains. (B) Flow cytometry analysis of WT or LMP1 transgenic splenocytes for B-1a (CD19+CD5+) and B-1b or B2 subsets (CD19+CD5-). Percentages of B-1a and B-1b or B2 subsets are shown in each quadrant. This analysis was repeated on three other WT and two other LMP1 transgenic mice with similar results. (C) Immunoblot analysis for kappa and lambda light chains of B cells (CD19+) purified from WT and LMP1 transgenic mice. Actin was used as a loading control. Instructions: please extract entity words from the input sentence
[ "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
LMP1 Promotes B-1a Lymphomas That Can Escape Allelic Exclusion (A) Flow cytometry analysis of splenocytes from a WT or LMP1 transgenic lymphoma for the pan-B cell (CD19), B-1a cell (CD5), and Ig heavy chain (IgM and IgD) and light chain (kappa and lambda) markers. Shown are the results from WT lymphoma 1 and LMP1 transgenic lymphoma 4. This analysis was repeated on four other LMP1 transgenic lymphomas (1, 2, 3, and 6) showing a similar B-1a phenotype, of which lymphomas 2 and 4 were also doubly positive for kappa and lambda light chains. (B) Flow cytometry analysis of WT or LMP1 transgenic splenocytes for B-1a (CD19+CD5+) and B-1b or B2 subsets (CD19+CD5-). Percentages of B-1a and B-1b or B2 subsets are shown in each quadrant. This analysis was repeated on three other WT and two other LMP1 transgenic mice with similar results. (C) Immunoblot analysis for kappa and lambda light chains of B cells (CD19+) purified from WT and LMP1 transgenic mice. Actin was used as a loading control.
[ "LMP1", "Promotes", "B-1a", "Lymphomas", "That", "Can", "Escape", "Allelic", "Exclusion", "\n", "(", "A", ")", "Flow", "cytometry", "analysis", "of", "splenocytes", "from", "a", "WT", "or", "LMP1", "transgenic", "lymphoma", "for", "the", "pan", "-", "B", "cell", "(", "CD19", ")", ",", "B-1a", "cell", "(", "CD5", ")", ",", "and", "Ig", "heavy", "chain", "(", "IgM", "and", "IgD", ")", "and", "light", "chain", "(", "kappa", "and", "lambda", ")", "markers", ".", "Shown", "are", "the", "results", "from", "WT", "lymphoma", "1", "and", "LMP1", "transgenic", "lymphoma", "4", ".", "This", "analysis", "was", "repeated", "on", "four", "other", "LMP1", "transgenic", "lymphomas", "(", "1", ",", "2", ",", "3", ",", "and", "6", ")", "showing", "a", "similar", "B-1a", "phenotype", ",", "of", "which", "lymphomas", "2", "and", "4", "were", "also", "doubly", "positive", "for", "kappa", "and", "lambda", "light", "chains", ".", "\n", "(", "B", ")", "Flow", "cytometry", "analysis", "of", "WT", "or", "LMP1", "transgenic", "splenocytes", "for", "B-1a", "(", "CD19+CD5", "+", ")", "and", "B-1b", "or", "B2", "subsets", "(", "CD19+CD5-", ")", ".", "Percentages", "of", "B-1a", "and", "B-1b", "or", "B2", "subsets", "are", "shown", "in", "each", "quadrant", ".", "This", "analysis", "was", "repeated", "on", "three", "other", "WT", "and", "two", "other", "LMP1", "transgenic", "mice", "with", "similar", "results", ".", "\n", "(", "C", ")", "Immunoblot", "analysis", "for", "kappa", "and", "lambda", "light", "chains", "of", "B", "cells", "(", "CD19", "+", ")", "purified", "from", "WT", "and", "LMP1", "transgenic", "mice", ".", "Actin", "was", "used", "as", "a", "loading", "control", ".", "\n" ]
[ "Protein" ]
outpatients is a Visit, aged is a Person, 18 - 70 years is a Value, H. pylori infection is a Condition, 13C - urea breath test , histology , rapid urease test or bacterial culture is a Scope
NCT02833623_inc_task0
Sentence: outpatients aged 18-70 years confirmed diagnosis of H. pylori infection by at least one of the following methods: 13C-urea breath test, histology, rapid urease test or bacterial culture an intention of H. pylori eradication treatment and have written inform consent ability to read short messages on the mobile phone Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Condition, Value, Person, Scope, Visit
[ "B-Visit", "B-Person", "B-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
outpatients aged 18-70 years confirmed diagnosis of H. pylori infection by at least one of the following methods: 13C-urea breath test, histology, rapid urease test or bacterial culture an intention of H. pylori eradication treatment and have written inform consent ability to read short messages on the mobile phone
[ "outpatients", "aged", "18", "-", "70", "years", "\n", "confirmed", "diagnosis", "of", "H.", "pylori", "infection", "by", "at", "least", "one", "of", "the", "following", "methods", ":", "13C", "-", "urea", "breath", "test", ",", "histology", ",", "rapid", "urease", "test", "or", "bacterial", "culture", "\n", "an", "intention", "of", "H.", "pylori", "eradication", "treatment", "and", "have", "written", "inform", "consent", "\n", "ability", "to", "read", "short", "messages", "on", "the", "mobile", "phone", "\n" ]
[ "Scope", "Measurement", "Condition", "Visit", "Value", "Person" ]
outpatients is a Visit, aged is a Person, 18 - 70 years is a Value, H. pylori infection is a Condition, 13C - urea breath test , histology , rapid urease test or bacterial culture is a Scope
NCT02833623_inc_task1
Sentence: outpatients aged 18-70 years confirmed diagnosis of H. pylori infection by at least one of the following methods: 13C-urea breath test, histology, rapid urease test or bacterial culture an intention of H. pylori eradication treatment and have written inform consent ability to read short messages on the mobile phone Instructions: please typing these entity words according to sentence: outpatients, aged, 18 - 70 years, H. pylori infection, 13C - urea breath test , histology , rapid urease test or bacterial culture Options: Condition, Value, Person, Scope, Visit
[ "B-Visit", "B-Person", "B-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
outpatients aged 18-70 years confirmed diagnosis of H. pylori infection by at least one of the following methods: 13C-urea breath test, histology, rapid urease test or bacterial culture an intention of H. pylori eradication treatment and have written inform consent ability to read short messages on the mobile phone
[ "outpatients", "aged", "18", "-", "70", "years", "\n", "confirmed", "diagnosis", "of", "H.", "pylori", "infection", "by", "at", "least", "one", "of", "the", "following", "methods", ":", "13C", "-", "urea", "breath", "test", ",", "histology", ",", "rapid", "urease", "test", "or", "bacterial", "culture", "\n", "an", "intention", "of", "H.", "pylori", "eradication", "treatment", "and", "have", "written", "inform", "consent", "\n", "ability", "to", "read", "short", "messages", "on", "the", "mobile", "phone", "\n" ]
[ "Scope", "Measurement", "Condition", "Visit", "Value", "Person" ]
outpatients, aged, 18 - 70 years, H. pylori infection, 13C - urea breath test , histology , rapid urease test or bacterial culture
NCT02833623_inc_task2
Sentence: outpatients aged 18-70 years confirmed diagnosis of H. pylori infection by at least one of the following methods: 13C-urea breath test, histology, rapid urease test or bacterial culture an intention of H. pylori eradication treatment and have written inform consent ability to read short messages on the mobile phone Instructions: please extract entity words from the input sentence
[ "B-Visit", "B-Person", "B-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
outpatients aged 18-70 years confirmed diagnosis of H. pylori infection by at least one of the following methods: 13C-urea breath test, histology, rapid urease test or bacterial culture an intention of H. pylori eradication treatment and have written inform consent ability to read short messages on the mobile phone
[ "outpatients", "aged", "18", "-", "70", "years", "\n", "confirmed", "diagnosis", "of", "H.", "pylori", "infection", "by", "at", "least", "one", "of", "the", "following", "methods", ":", "13C", "-", "urea", "breath", "test", ",", "histology", ",", "rapid", "urease", "test", "or", "bacterial", "culture", "\n", "an", "intention", "of", "H.", "pylori", "eradication", "treatment", "and", "have", "written", "inform", "consent", "\n", "ability", "to", "read", "short", "messages", "on", "the", "mobile", "phone", "\n" ]
[ "Scope", "Measurement", "Condition", "Visit", "Value", "Person" ]
Cefizox is a BRAND, cephalosporins is a GROUP, aminoglycosides is a GROUP
Ceftizoxime_ddi_task0
Sentence: Although the occurrence has not been reported with Cefizox, nephrotoxicity has been reported following concomitant administration of other cephalosporins and aminoglycosides. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GROUP, BRAND
[ "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "O" ]
Although the occurrence has not been reported with Cefizox, nephrotoxicity has been reported following concomitant administration of other cephalosporins and aminoglycosides.
[ "Although", "the", "occurrence", "has", "not", "been", "reported", "with", "Cefizox", ",", "nephrotoxicity", "has", "been", "reported", "following", "concomitant", "administration", "of", "other", "cephalosporins", "and", "aminoglycosides", "." ]
[ "GROUP", "BRAND" ]
Cefizox is a BRAND, cephalosporins is a GROUP, aminoglycosides is a GROUP
Ceftizoxime_ddi_task1
Sentence: Although the occurrence has not been reported with Cefizox, nephrotoxicity has been reported following concomitant administration of other cephalosporins and aminoglycosides. Instructions: please typing these entity words according to sentence: Cefizox, cephalosporins, aminoglycosides Options: GROUP, BRAND
[ "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "O" ]
Although the occurrence has not been reported with Cefizox, nephrotoxicity has been reported following concomitant administration of other cephalosporins and aminoglycosides.
[ "Although", "the", "occurrence", "has", "not", "been", "reported", "with", "Cefizox", ",", "nephrotoxicity", "has", "been", "reported", "following", "concomitant", "administration", "of", "other", "cephalosporins", "and", "aminoglycosides", "." ]
[ "GROUP", "BRAND" ]
Cefizox, cephalosporins, aminoglycosides
Ceftizoxime_ddi_task2
Sentence: Although the occurrence has not been reported with Cefizox, nephrotoxicity has been reported following concomitant administration of other cephalosporins and aminoglycosides. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "B-BRAND", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "B-GROUP", "O" ]
Although the occurrence has not been reported with Cefizox, nephrotoxicity has been reported following concomitant administration of other cephalosporins and aminoglycosides.
[ "Although", "the", "occurrence", "has", "not", "been", "reported", "with", "Cefizox", ",", "nephrotoxicity", "has", "been", "reported", "following", "concomitant", "administration", "of", "other", "cephalosporins", "and", "aminoglycosides", "." ]
[ "GROUP", "BRAND" ]
IL-17R is a Complex, IL-23 is a Complex, p19 is a Gene_or_gene_product, NF - kappaB is a Complex, JNK is a Gene_or_gene_product, AP-1 is a Complex, Interleukin ( IL)-23 is a Complex, IL-17 is a Complex, IL-23 is a Complex, p19 is a Gene_or_gene_product, IL-23 is a Complex, IL-17 receptor is a Complex, IL-17R is a Complex, IL-17 is a Complex, IL-23 is a Complex, p19 is a Gene_or_gene_product, IL-17 is a Complex, IL-17R is a Complex, IL-23 is a Complex, p19 is a Gene_or_gene_product, IL-17 is a Complex, Akt is a Gene_or_gene_product, p38 is a Gene_or_gene_product, mitogen - activated protein kinase is a Gene_or_gene_product, MAPK is a Gene_or_gene_product, extracellular signal - regulated kinase ( ERK ) 1/2 is a Gene_or_gene_product, c - Jun - N - terminal kinase is a Gene_or_gene_product, JNK is a Gene_or_gene_product, nuclear factor - kappaB is a Complex, NF - kappaB is a Complex, activator protein-1 is a Complex, AP-1 is a Complex, Akt is a Gene_or_gene_product, p38 MAPK is a Gene_or_gene_product, ERK 1/2 is a Gene_or_gene_product, NF - kappaB is a Complex, JNK is a Gene_or_gene_product, AP-1 is a Complex, IL-23 is a Complex, p19 is a Gene_or_gene_product, NF - kappaB is a Complex, Akt is a Gene_or_gene_product, p38 MAPK is a Gene_or_gene_product, ERK 1/2 is a Gene_or_gene_product, AP-1 is a Complex, JNK is a Gene_or_gene_product, IL-17 is a Complex, IL-23 is a Complex, p19 is a Gene_or_gene_product, NF - kappaB is a Complex, JNK is a Gene_or_gene_product, AP-1 is a Complex, IL-17 is a Complex, IL-23 is a Complex
211_task0
Sentence: IL-17R activation of human periodontal ligament fibroblasts induces IL-23 p19 production: Differential involvement of NF-kappaB versus JNK/AP-1 pathways. Interleukin (IL)-23 is an essential cytokine involved in the expansion of a novel CD4(+) T helper subset known as Th17, which has been implicated in the pathogenesis of periodontitis recently. This study hypothesised that Th17 signature cytokine IL-17 may target specialised human periodontal ligament fibroblasts (hPDLFs) for production of IL-23 p19, a key subunit of IL-23. Primary hPDLFs had steady expression of IL-17 receptor (IL-17R) mRNA and surface-bound protein. IL-17 was capable of stimulating the expression of IL-23 p19 mRNA and protein in cultured hPDLFs, which was attenuated by IL-17 or IL-17R neutralising antibodies. In accordance with the enhanced expression of IL-23 p19, IL-17 stimulation resulted in rapid activation of Akt, p38 mitogen-activated protein kinase (MAPK), extracellular signal-regulated kinase (ERK) 1/2, c-Jun-N-terminal kinase (JNK), nuclear factor-kappaB (NF-kappaB), and activator protein-1 (AP-1) in hPDLFs. Inhibitors of Akt, p38 MAPK, ERK 1/2, or NF-kappaB significantly suppressed, whereas blocking JNK and AP-1 substantially augmented IL-23 p19 production from IL-17-stimulated hPDLFs. Moreover, IL-17-initiated NF-kappaB activation was blocked by Akt, p38 MAPK, or ERK 1/2 inhibition, while AP-1 activity was specifically abrogated by JNK inhibition. Thus, these results provide evidence that hPDLFs are a target of Th17, and that IL-17 appears to up-regulate the expression of IL-23 p19 via a homeostatic mechanism involving Akt-, p38 MAPK-, and ERK 1/2-dependent NF-kappaB signalling versus the JNK/AP-1 pathway. Taken together, our findings suggest that disruption of the interaction between IL-17 and IL-23 may be a potential therapeutic approach in the treatment of periodontitis. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Complex, Gene_or_gene_product
[ "B-Complex", "O", "O", "O", "O", "O", "O", "O", "B-Complex", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Complex", "I-Complex", "I-Complex", "O", "B-Gene_or_gene_product", "O", "B-Complex", "O", "O", "O", "B-Complex", "I-Complex", "I-Complex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Complex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Complex", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Complex", "O", "O", "O", "O", "O", "O", "O", "B-Complex", "I-Complex", "O", "B-Complex", "O", "O", "O", "O", "O", "O", "O", "O", "B-Complex", "O", "O", "O", "O", "O", "O", "O", "B-Complex", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Complex", "O", "B-Complex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Complex", "B-Gene_or_gene_product", "O", "B-Complex", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Complex", "I-Complex", "I-Complex", "I-Complex", "O", "B-Complex", "I-Complex", "I-Complex", "O", "O", "O", "B-Complex", "I-Complex", "O", "B-Complex", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Complex", "I-Complex", "I-Complex", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Complex", "O", "O", "B-Complex", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Complex", "I-Complex", "I-Complex", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "B-Complex", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Complex", "O", "O", "O", "O", "O", "O", "O", "O", "B-Complex", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Complex", "I-Complex", "I-Complex", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Complex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Complex", "O", "B-Complex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
IL-17R activation of human periodontal ligament fibroblasts induces IL-23 p19 production: Differential involvement of NF-kappaB versus JNK/AP-1 pathways. Interleukin (IL)-23 is an essential cytokine involved in the expansion of a novel CD4(+) T helper subset known as Th17, which has been implicated in the pathogenesis of periodontitis recently. This study hypothesised that Th17 signature cytokine IL-17 may target specialised human periodontal ligament fibroblasts (hPDLFs) for production of IL-23 p19, a key subunit of IL-23. Primary hPDLFs had steady expression of IL-17 receptor (IL-17R) mRNA and surface-bound protein. IL-17 was capable of stimulating the expression of IL-23 p19 mRNA and protein in cultured hPDLFs, which was attenuated by IL-17 or IL-17R neutralising antibodies. In accordance with the enhanced expression of IL-23 p19, IL-17 stimulation resulted in rapid activation of Akt, p38 mitogen-activated protein kinase (MAPK), extracellular signal-regulated kinase (ERK) 1/2, c-Jun-N-terminal kinase (JNK), nuclear factor-kappaB (NF-kappaB), and activator protein-1 (AP-1) in hPDLFs. Inhibitors of Akt, p38 MAPK, ERK 1/2, or NF-kappaB significantly suppressed, whereas blocking JNK and AP-1 substantially augmented IL-23 p19 production from IL-17-stimulated hPDLFs. Moreover, IL-17-initiated NF-kappaB activation was blocked by Akt, p38 MAPK, or ERK 1/2 inhibition, while AP-1 activity was specifically abrogated by JNK inhibition. Thus, these results provide evidence that hPDLFs are a target of Th17, and that IL-17 appears to up-regulate the expression of IL-23 p19 via a homeostatic mechanism involving Akt-, p38 MAPK-, and ERK 1/2-dependent NF-kappaB signalling versus the JNK/AP-1 pathway. Taken together, our findings suggest that disruption of the interaction between IL-17 and IL-23 may be a potential therapeutic approach in the treatment of periodontitis.
[ "IL-17R", "activation", "of", "human", "periodontal", "ligament", "fibroblasts", "induces", "IL-23", "p19", "production", ":", "Differential", "involvement", "of", "NF", "-", "kappaB", "versus", "JNK", "/", "AP-1", "pathways", ".", "\n", "Interleukin", "(", "IL)-23", "is", "an", "essential", "cytokine", "involved", "in", "the", "expansion", "of", "a", "novel", "CD4(+", ")", "T", "helper", "subset", "known", "as", "Th17", ",", "which", "has", "been", "implicated", "in", "the", "pathogenesis", "of", "periodontitis", "recently", ".", "This", "study", "hypothesised", "that", "Th17", "signature", "cytokine", "IL-17", "may", "target", "specialised", "human", "periodontal", "ligament", "fibroblasts", "(", "hPDLFs", ")", "for", "production", "of", "IL-23", "p19", ",", "a", "key", "subunit", "of", "IL-23", ".", "Primary", "hPDLFs", "had", "steady", "expression", "of", "IL-17", "receptor", "(", "IL-17R", ")", "mRNA", "and", "surface", "-", "bound", "protein", ".", "IL-17", "was", "capable", "of", "stimulating", "the", "expression", "of", "IL-23", "p19", "mRNA", "and", "protein", "in", "cultured", "hPDLFs", ",", "which", "was", "attenuated", "by", "IL-17", "or", "IL-17R", "neutralising", "antibodies", ".", "In", "accordance", "with", "the", "enhanced", "expression", "of", "IL-23", "p19", ",", "IL-17", "stimulation", "resulted", "in", "rapid", "activation", "of", "Akt", ",", "p38", "mitogen", "-", "activated", "protein", "kinase", "(", "MAPK", ")", ",", "extracellular", "signal", "-", "regulated", "kinase", "(", "ERK", ")", "1/2", ",", "c", "-", "Jun", "-", "N", "-", "terminal", "kinase", "(", "JNK", ")", ",", "nuclear", "factor", "-", "kappaB", "(", "NF", "-", "kappaB", ")", ",", "and", "activator", "protein-1", "(", "AP-1", ")", "in", "hPDLFs", ".", "Inhibitors", "of", "Akt", ",", "p38", "MAPK", ",", "ERK", "1/2", ",", "or", "NF", "-", "kappaB", "significantly", "suppressed", ",", "whereas", "blocking", "JNK", "and", "AP-1", "substantially", "augmented", "IL-23", "p19", "production", "from", "IL-17-stimulated", "hPDLFs", ".", "Moreover", ",", "IL-17-initiated", "NF", "-", "kappaB", "activation", "was", "blocked", "by", "Akt", ",", "p38", "MAPK", ",", "or", "ERK", "1/2", "inhibition", ",", "while", "AP-1", "activity", "was", "specifically", "abrogated", "by", "JNK", "inhibition", ".", "Thus", ",", "these", "results", "provide", "evidence", "that", "hPDLFs", "are", "a", "target", "of", "Th17", ",", "and", "that", "IL-17", "appears", "to", "up", "-", "regulate", "the", "expression", "of", "IL-23", "p19", "via", "a", "homeostatic", "mechanism", "involving", "Akt-", ",", "p38", "MAPK-", ",", "and", "ERK", "1/2-dependent", "NF", "-", "kappaB", "signalling", "versus", "the", "JNK", "/", "AP-1", "pathway", ".", "Taken", "together", ",", "our", "findings", "suggest", "that", "disruption", "of", "the", "interaction", "between", "IL-17", "and", "IL-23", "may", "be", "a", "potential", "therapeutic", "approach", "in", "the", "treatment", "of", "periodontitis", ".", "\n" ]
[ "Gene_or_gene_product", "Complex" ]
IL-17R is a Complex, IL-23 is a Complex, p19 is a Gene_or_gene_product, NF - kappaB is a Complex, JNK is a Gene_or_gene_product, AP-1 is a Complex, Interleukin ( IL)-23 is a Complex, IL-17 is a Complex, IL-23 is a Complex, p19 is a Gene_or_gene_product, IL-23 is a Complex, IL-17 receptor is a Complex, IL-17R is a Complex, IL-17 is a Complex, IL-23 is a Complex, p19 is a Gene_or_gene_product, IL-17 is a Complex, IL-17R is a Complex, IL-23 is a Complex, p19 is a Gene_or_gene_product, IL-17 is a Complex, Akt is a Gene_or_gene_product, p38 is a Gene_or_gene_product, mitogen - activated protein kinase is a Gene_or_gene_product, MAPK is a Gene_or_gene_product, extracellular signal - regulated kinase ( ERK ) 1/2 is a Gene_or_gene_product, c - Jun - N - terminal kinase is a Gene_or_gene_product, JNK is a Gene_or_gene_product, nuclear factor - kappaB is a Complex, NF - kappaB is a Complex, activator protein-1 is a Complex, AP-1 is a Complex, Akt is a Gene_or_gene_product, p38 MAPK is a Gene_or_gene_product, ERK 1/2 is a Gene_or_gene_product, NF - kappaB is a Complex, JNK is a Gene_or_gene_product, AP-1 is a Complex, IL-23 is a Complex, p19 is a Gene_or_gene_product, NF - kappaB is a Complex, Akt is a Gene_or_gene_product, p38 MAPK is a Gene_or_gene_product, ERK 1/2 is a Gene_or_gene_product, AP-1 is a Complex, JNK is a Gene_or_gene_product, IL-17 is a Complex, IL-23 is a Complex, p19 is a Gene_or_gene_product, NF - kappaB is a Complex, JNK is a Gene_or_gene_product, AP-1 is a Complex, IL-17 is a Complex, IL-23 is a Complex
211_task1
Sentence: IL-17R activation of human periodontal ligament fibroblasts induces IL-23 p19 production: Differential involvement of NF-kappaB versus JNK/AP-1 pathways. Interleukin (IL)-23 is an essential cytokine involved in the expansion of a novel CD4(+) T helper subset known as Th17, which has been implicated in the pathogenesis of periodontitis recently. This study hypothesised that Th17 signature cytokine IL-17 may target specialised human periodontal ligament fibroblasts (hPDLFs) for production of IL-23 p19, a key subunit of IL-23. Primary hPDLFs had steady expression of IL-17 receptor (IL-17R) mRNA and surface-bound protein. IL-17 was capable of stimulating the expression of IL-23 p19 mRNA and protein in cultured hPDLFs, which was attenuated by IL-17 or IL-17R neutralising antibodies. In accordance with the enhanced expression of IL-23 p19, IL-17 stimulation resulted in rapid activation of Akt, p38 mitogen-activated protein kinase (MAPK), extracellular signal-regulated kinase (ERK) 1/2, c-Jun-N-terminal kinase (JNK), nuclear factor-kappaB (NF-kappaB), and activator protein-1 (AP-1) in hPDLFs. Inhibitors of Akt, p38 MAPK, ERK 1/2, or NF-kappaB significantly suppressed, whereas blocking JNK and AP-1 substantially augmented IL-23 p19 production from IL-17-stimulated hPDLFs. Moreover, IL-17-initiated NF-kappaB activation was blocked by Akt, p38 MAPK, or ERK 1/2 inhibition, while AP-1 activity was specifically abrogated by JNK inhibition. Thus, these results provide evidence that hPDLFs are a target of Th17, and that IL-17 appears to up-regulate the expression of IL-23 p19 via a homeostatic mechanism involving Akt-, p38 MAPK-, and ERK 1/2-dependent NF-kappaB signalling versus the JNK/AP-1 pathway. Taken together, our findings suggest that disruption of the interaction between IL-17 and IL-23 may be a potential therapeutic approach in the treatment of periodontitis. Instructions: please typing these entity words according to sentence: IL-17R, IL-23, p19, NF - kappaB, JNK, AP-1, Interleukin ( IL)-23, IL-17, IL-23, p19, IL-23, IL-17 receptor, IL-17R, IL-17, IL-23, p19, IL-17, IL-17R, IL-23, p19, IL-17, Akt, p38, mitogen - activated protein kinase, MAPK, extracellular signal - regulated kinase ( ERK ) 1/2, c - Jun - N - terminal kinase, JNK, nuclear factor - kappaB, NF - kappaB, activator protein-1, AP-1, Akt, p38 MAPK, ERK 1/2, NF - kappaB, JNK, AP-1, IL-23, p19, NF - kappaB, Akt, p38 MAPK, ERK 1/2, AP-1, JNK, IL-17, IL-23, p19, NF - kappaB, JNK, AP-1, IL-17, IL-23 Options: Complex, Gene_or_gene_product
[ "B-Complex", "O", "O", "O", "O", "O", "O", "O", "B-Complex", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Complex", "I-Complex", "I-Complex", "O", "B-Gene_or_gene_product", "O", "B-Complex", "O", "O", "O", "B-Complex", "I-Complex", "I-Complex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Complex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Complex", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Complex", "O", "O", "O", "O", "O", "O", "O", "B-Complex", "I-Complex", "O", "B-Complex", "O", "O", "O", "O", "O", "O", "O", "O", "B-Complex", "O", "O", "O", "O", "O", "O", "O", "B-Complex", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Complex", "O", "B-Complex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Complex", "B-Gene_or_gene_product", "O", "B-Complex", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Complex", "I-Complex", "I-Complex", "I-Complex", "O", "B-Complex", "I-Complex", "I-Complex", "O", "O", "O", "B-Complex", "I-Complex", "O", "B-Complex", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Complex", "I-Complex", "I-Complex", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Complex", "O", "O", "B-Complex", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Complex", "I-Complex", "I-Complex", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "B-Complex", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Complex", "O", "O", "O", "O", "O", "O", "O", "O", "B-Complex", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Complex", "I-Complex", "I-Complex", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Complex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Complex", "O", "B-Complex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
IL-17R activation of human periodontal ligament fibroblasts induces IL-23 p19 production: Differential involvement of NF-kappaB versus JNK/AP-1 pathways. Interleukin (IL)-23 is an essential cytokine involved in the expansion of a novel CD4(+) T helper subset known as Th17, which has been implicated in the pathogenesis of periodontitis recently. This study hypothesised that Th17 signature cytokine IL-17 may target specialised human periodontal ligament fibroblasts (hPDLFs) for production of IL-23 p19, a key subunit of IL-23. Primary hPDLFs had steady expression of IL-17 receptor (IL-17R) mRNA and surface-bound protein. IL-17 was capable of stimulating the expression of IL-23 p19 mRNA and protein in cultured hPDLFs, which was attenuated by IL-17 or IL-17R neutralising antibodies. In accordance with the enhanced expression of IL-23 p19, IL-17 stimulation resulted in rapid activation of Akt, p38 mitogen-activated protein kinase (MAPK), extracellular signal-regulated kinase (ERK) 1/2, c-Jun-N-terminal kinase (JNK), nuclear factor-kappaB (NF-kappaB), and activator protein-1 (AP-1) in hPDLFs. Inhibitors of Akt, p38 MAPK, ERK 1/2, or NF-kappaB significantly suppressed, whereas blocking JNK and AP-1 substantially augmented IL-23 p19 production from IL-17-stimulated hPDLFs. Moreover, IL-17-initiated NF-kappaB activation was blocked by Akt, p38 MAPK, or ERK 1/2 inhibition, while AP-1 activity was specifically abrogated by JNK inhibition. Thus, these results provide evidence that hPDLFs are a target of Th17, and that IL-17 appears to up-regulate the expression of IL-23 p19 via a homeostatic mechanism involving Akt-, p38 MAPK-, and ERK 1/2-dependent NF-kappaB signalling versus the JNK/AP-1 pathway. Taken together, our findings suggest that disruption of the interaction between IL-17 and IL-23 may be a potential therapeutic approach in the treatment of periodontitis.
[ "IL-17R", "activation", "of", "human", "periodontal", "ligament", "fibroblasts", "induces", "IL-23", "p19", "production", ":", "Differential", "involvement", "of", "NF", "-", "kappaB", "versus", "JNK", "/", "AP-1", "pathways", ".", "\n", "Interleukin", "(", "IL)-23", "is", "an", "essential", "cytokine", "involved", "in", "the", "expansion", "of", "a", "novel", "CD4(+", ")", "T", "helper", "subset", "known", "as", "Th17", ",", "which", "has", "been", "implicated", "in", "the", "pathogenesis", "of", "periodontitis", "recently", ".", "This", "study", "hypothesised", "that", "Th17", "signature", "cytokine", "IL-17", "may", "target", "specialised", "human", "periodontal", "ligament", "fibroblasts", "(", "hPDLFs", ")", "for", "production", "of", "IL-23", "p19", ",", "a", "key", "subunit", "of", "IL-23", ".", "Primary", "hPDLFs", "had", "steady", "expression", "of", "IL-17", "receptor", "(", "IL-17R", ")", "mRNA", "and", "surface", "-", "bound", "protein", ".", "IL-17", "was", "capable", "of", "stimulating", "the", "expression", "of", "IL-23", "p19", "mRNA", "and", "protein", "in", "cultured", "hPDLFs", ",", "which", "was", "attenuated", "by", "IL-17", "or", "IL-17R", "neutralising", "antibodies", ".", "In", "accordance", "with", "the", "enhanced", "expression", "of", "IL-23", "p19", ",", "IL-17", "stimulation", "resulted", "in", "rapid", "activation", "of", "Akt", ",", "p38", "mitogen", "-", "activated", "protein", "kinase", "(", "MAPK", ")", ",", "extracellular", "signal", "-", "regulated", "kinase", "(", "ERK", ")", "1/2", ",", "c", "-", "Jun", "-", "N", "-", "terminal", "kinase", "(", "JNK", ")", ",", "nuclear", "factor", "-", "kappaB", "(", "NF", "-", "kappaB", ")", ",", "and", "activator", "protein-1", "(", "AP-1", ")", "in", "hPDLFs", ".", "Inhibitors", "of", "Akt", ",", "p38", "MAPK", ",", "ERK", "1/2", ",", "or", "NF", "-", "kappaB", "significantly", "suppressed", ",", "whereas", "blocking", "JNK", "and", "AP-1", "substantially", "augmented", "IL-23", "p19", "production", "from", "IL-17-stimulated", "hPDLFs", ".", "Moreover", ",", "IL-17-initiated", "NF", "-", "kappaB", "activation", "was", "blocked", "by", "Akt", ",", "p38", "MAPK", ",", "or", "ERK", "1/2", "inhibition", ",", "while", "AP-1", "activity", "was", "specifically", "abrogated", "by", "JNK", "inhibition", ".", "Thus", ",", "these", "results", "provide", "evidence", "that", "hPDLFs", "are", "a", "target", "of", "Th17", ",", "and", "that", "IL-17", "appears", "to", "up", "-", "regulate", "the", "expression", "of", "IL-23", "p19", "via", "a", "homeostatic", "mechanism", "involving", "Akt-", ",", "p38", "MAPK-", ",", "and", "ERK", "1/2-dependent", "NF", "-", "kappaB", "signalling", "versus", "the", "JNK", "/", "AP-1", "pathway", ".", "Taken", "together", ",", "our", "findings", "suggest", "that", "disruption", "of", "the", "interaction", "between", "IL-17", "and", "IL-23", "may", "be", "a", "potential", "therapeutic", "approach", "in", "the", "treatment", "of", "periodontitis", ".", "\n" ]
[ "Gene_or_gene_product", "Complex" ]
IL-17R, IL-23, p19, NF - kappaB, JNK, AP-1, Interleukin ( IL)-23, IL-17, IL-23, p19, IL-23, IL-17 receptor, IL-17R, IL-17, IL-23, p19, IL-17, IL-17R, IL-23, p19, IL-17, Akt, p38, mitogen - activated protein kinase, MAPK, extracellular signal - regulated kinase ( ERK ) 1/2, c - Jun - N - terminal kinase, JNK, nuclear factor - kappaB, NF - kappaB, activator protein-1, AP-1, Akt, p38 MAPK, ERK 1/2, NF - kappaB, JNK, AP-1, IL-23, p19, NF - kappaB, Akt, p38 MAPK, ERK 1/2, AP-1, JNK, IL-17, IL-23, p19, NF - kappaB, JNK, AP-1, IL-17, IL-23
211_task2
Sentence: IL-17R activation of human periodontal ligament fibroblasts induces IL-23 p19 production: Differential involvement of NF-kappaB versus JNK/AP-1 pathways. Interleukin (IL)-23 is an essential cytokine involved in the expansion of a novel CD4(+) T helper subset known as Th17, which has been implicated in the pathogenesis of periodontitis recently. This study hypothesised that Th17 signature cytokine IL-17 may target specialised human periodontal ligament fibroblasts (hPDLFs) for production of IL-23 p19, a key subunit of IL-23. Primary hPDLFs had steady expression of IL-17 receptor (IL-17R) mRNA and surface-bound protein. IL-17 was capable of stimulating the expression of IL-23 p19 mRNA and protein in cultured hPDLFs, which was attenuated by IL-17 or IL-17R neutralising antibodies. In accordance with the enhanced expression of IL-23 p19, IL-17 stimulation resulted in rapid activation of Akt, p38 mitogen-activated protein kinase (MAPK), extracellular signal-regulated kinase (ERK) 1/2, c-Jun-N-terminal kinase (JNK), nuclear factor-kappaB (NF-kappaB), and activator protein-1 (AP-1) in hPDLFs. Inhibitors of Akt, p38 MAPK, ERK 1/2, or NF-kappaB significantly suppressed, whereas blocking JNK and AP-1 substantially augmented IL-23 p19 production from IL-17-stimulated hPDLFs. Moreover, IL-17-initiated NF-kappaB activation was blocked by Akt, p38 MAPK, or ERK 1/2 inhibition, while AP-1 activity was specifically abrogated by JNK inhibition. Thus, these results provide evidence that hPDLFs are a target of Th17, and that IL-17 appears to up-regulate the expression of IL-23 p19 via a homeostatic mechanism involving Akt-, p38 MAPK-, and ERK 1/2-dependent NF-kappaB signalling versus the JNK/AP-1 pathway. Taken together, our findings suggest that disruption of the interaction between IL-17 and IL-23 may be a potential therapeutic approach in the treatment of periodontitis. Instructions: please extract entity words from the input sentence
[ "B-Complex", "O", "O", "O", "O", "O", "O", "O", "B-Complex", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Complex", "I-Complex", "I-Complex", "O", "B-Gene_or_gene_product", "O", "B-Complex", "O", "O", "O", "B-Complex", "I-Complex", "I-Complex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Complex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Complex", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Complex", "O", "O", "O", "O", "O", "O", "O", "B-Complex", "I-Complex", "O", "B-Complex", "O", "O", "O", "O", "O", "O", "O", "O", "B-Complex", "O", "O", "O", "O", "O", "O", "O", "B-Complex", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Complex", "O", "B-Complex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Complex", "B-Gene_or_gene_product", "O", "B-Complex", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Complex", "I-Complex", "I-Complex", "I-Complex", "O", "B-Complex", "I-Complex", "I-Complex", "O", "O", "O", "B-Complex", "I-Complex", "O", "B-Complex", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Complex", "I-Complex", "I-Complex", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Complex", "O", "O", "B-Complex", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Complex", "I-Complex", "I-Complex", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "B-Complex", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Complex", "O", "O", "O", "O", "O", "O", "O", "O", "B-Complex", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Complex", "I-Complex", "I-Complex", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Complex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Complex", "O", "B-Complex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
IL-17R activation of human periodontal ligament fibroblasts induces IL-23 p19 production: Differential involvement of NF-kappaB versus JNK/AP-1 pathways. Interleukin (IL)-23 is an essential cytokine involved in the expansion of a novel CD4(+) T helper subset known as Th17, which has been implicated in the pathogenesis of periodontitis recently. This study hypothesised that Th17 signature cytokine IL-17 may target specialised human periodontal ligament fibroblasts (hPDLFs) for production of IL-23 p19, a key subunit of IL-23. Primary hPDLFs had steady expression of IL-17 receptor (IL-17R) mRNA and surface-bound protein. IL-17 was capable of stimulating the expression of IL-23 p19 mRNA and protein in cultured hPDLFs, which was attenuated by IL-17 or IL-17R neutralising antibodies. In accordance with the enhanced expression of IL-23 p19, IL-17 stimulation resulted in rapid activation of Akt, p38 mitogen-activated protein kinase (MAPK), extracellular signal-regulated kinase (ERK) 1/2, c-Jun-N-terminal kinase (JNK), nuclear factor-kappaB (NF-kappaB), and activator protein-1 (AP-1) in hPDLFs. Inhibitors of Akt, p38 MAPK, ERK 1/2, or NF-kappaB significantly suppressed, whereas blocking JNK and AP-1 substantially augmented IL-23 p19 production from IL-17-stimulated hPDLFs. Moreover, IL-17-initiated NF-kappaB activation was blocked by Akt, p38 MAPK, or ERK 1/2 inhibition, while AP-1 activity was specifically abrogated by JNK inhibition. Thus, these results provide evidence that hPDLFs are a target of Th17, and that IL-17 appears to up-regulate the expression of IL-23 p19 via a homeostatic mechanism involving Akt-, p38 MAPK-, and ERK 1/2-dependent NF-kappaB signalling versus the JNK/AP-1 pathway. Taken together, our findings suggest that disruption of the interaction between IL-17 and IL-23 may be a potential therapeutic approach in the treatment of periodontitis.
[ "IL-17R", "activation", "of", "human", "periodontal", "ligament", "fibroblasts", "induces", "IL-23", "p19", "production", ":", "Differential", "involvement", "of", "NF", "-", "kappaB", "versus", "JNK", "/", "AP-1", "pathways", ".", "\n", "Interleukin", "(", "IL)-23", "is", "an", "essential", "cytokine", "involved", "in", "the", "expansion", "of", "a", "novel", "CD4(+", ")", "T", "helper", "subset", "known", "as", "Th17", ",", "which", "has", "been", "implicated", "in", "the", "pathogenesis", "of", "periodontitis", "recently", ".", "This", "study", "hypothesised", "that", "Th17", "signature", "cytokine", "IL-17", "may", "target", "specialised", "human", "periodontal", "ligament", "fibroblasts", "(", "hPDLFs", ")", "for", "production", "of", "IL-23", "p19", ",", "a", "key", "subunit", "of", "IL-23", ".", "Primary", "hPDLFs", "had", "steady", "expression", "of", "IL-17", "receptor", "(", "IL-17R", ")", "mRNA", "and", "surface", "-", "bound", "protein", ".", "IL-17", "was", "capable", "of", "stimulating", "the", "expression", "of", "IL-23", "p19", "mRNA", "and", "protein", "in", "cultured", "hPDLFs", ",", "which", "was", "attenuated", "by", "IL-17", "or", "IL-17R", "neutralising", "antibodies", ".", "In", "accordance", "with", "the", "enhanced", "expression", "of", "IL-23", "p19", ",", "IL-17", "stimulation", "resulted", "in", "rapid", "activation", "of", "Akt", ",", "p38", "mitogen", "-", "activated", "protein", "kinase", "(", "MAPK", ")", ",", "extracellular", "signal", "-", "regulated", "kinase", "(", "ERK", ")", "1/2", ",", "c", "-", "Jun", "-", "N", "-", "terminal", "kinase", "(", "JNK", ")", ",", "nuclear", "factor", "-", "kappaB", "(", "NF", "-", "kappaB", ")", ",", "and", "activator", "protein-1", "(", "AP-1", ")", "in", "hPDLFs", ".", "Inhibitors", "of", "Akt", ",", "p38", "MAPK", ",", "ERK", "1/2", ",", "or", "NF", "-", "kappaB", "significantly", "suppressed", ",", "whereas", "blocking", "JNK", "and", "AP-1", "substantially", "augmented", "IL-23", "p19", "production", "from", "IL-17-stimulated", "hPDLFs", ".", "Moreover", ",", "IL-17-initiated", "NF", "-", "kappaB", "activation", "was", "blocked", "by", "Akt", ",", "p38", "MAPK", ",", "or", "ERK", "1/2", "inhibition", ",", "while", "AP-1", "activity", "was", "specifically", "abrogated", "by", "JNK", "inhibition", ".", "Thus", ",", "these", "results", "provide", "evidence", "that", "hPDLFs", "are", "a", "target", "of", "Th17", ",", "and", "that", "IL-17", "appears", "to", "up", "-", "regulate", "the", "expression", "of", "IL-23", "p19", "via", "a", "homeostatic", "mechanism", "involving", "Akt-", ",", "p38", "MAPK-", ",", "and", "ERK", "1/2-dependent", "NF", "-", "kappaB", "signalling", "versus", "the", "JNK", "/", "AP-1", "pathway", ".", "Taken", "together", ",", "our", "findings", "suggest", "that", "disruption", "of", "the", "interaction", "between", "IL-17", "and", "IL-23", "may", "be", "a", "potential", "therapeutic", "approach", "in", "the", "treatment", "of", "periodontitis", ".", "\n" ]
[ "Gene_or_gene_product", "Complex" ]
LMNA is a Gene, LMNA , is a Gene, LMNA is a Gene
12_task0
Sentence: Different mutations in the LMNA gene cause autosomal dominant and autosomal recessive Emery-Dreifuss muscular dystrophy. Emery-Dreifuss muscular dystrophy (EMD) is a condition characterized by the clinical triad of early-onset contractures, progressive weakness in humeroperoneal muscles, and cardiomyopathy with conduction block. The disease was described for the first time as an X-linked muscular dystrophy, but autosomal dominant and autosomal recessive forms were reported. The genes for X-linked EMD and autosomal dominant EMD (AD-EMD) were identified. We report here that heterozygote mutations in LMNA, the gene for AD-EMD, may cause diverse phenotypes ranging from typical EMD to no phenotypic effect. Our results show that LMNA mutations are also responsible for the recessive form of the disease. Our results give further support to the notion that different genetic forms of EMD have a common pathophysiological background. The distribution of the mutations in AD-EMD patients (in the tail and in the 2A rod domain) suggests that unique interactions between lamin A/C and other nuclear components exist that have an important role in cardiac and skeletal muscle function. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Gene
[ "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Different mutations in the LMNA gene cause autosomal dominant and autosomal recessive Emery-Dreifuss muscular dystrophy. Emery-Dreifuss muscular dystrophy (EMD) is a condition characterized by the clinical triad of early-onset contractures, progressive weakness in humeroperoneal muscles, and cardiomyopathy with conduction block. The disease was described for the first time as an X-linked muscular dystrophy, but autosomal dominant and autosomal recessive forms were reported. The genes for X-linked EMD and autosomal dominant EMD (AD-EMD) were identified. We report here that heterozygote mutations in LMNA, the gene for AD-EMD, may cause diverse phenotypes ranging from typical EMD to no phenotypic effect. Our results show that LMNA mutations are also responsible for the recessive form of the disease. Our results give further support to the notion that different genetic forms of EMD have a common pathophysiological background. The distribution of the mutations in AD-EMD patients (in the tail and in the 2A rod domain) suggests that unique interactions between lamin A/C and other nuclear components exist that have an important role in cardiac and skeletal muscle function.
[ "Different", "mutations", "in", "the", "LMNA", "gene", "cause", "autosomal", "dominant", "and", "autosomal", "recessive", "Emery", "-", "Dreifuss", "muscular", "dystrophy", ".", "Emery", "-", "Dreifuss", "muscular", "dystrophy", "(", "EMD", ")", "is", "a", "condition", "characterized", "by", "the", "clinical", "triad", "of", "early", "-", "onset", "contractures", ",", "progressive", "weakness", "in", "humeroperoneal", "muscles", ",", "and", "cardiomyopathy", "with", "conduction", "block", ".", "The", "disease", "was", "described", "for", "the", "first", "time", "as", "an", "X", "-", "linked", "muscular", "dystrophy", ",", "but", "autosomal", "dominant", "and", "autosomal", "recessive", "forms", "were", "reported", ".", "The", "genes", "for", "X", "-", "linked", "EMD", "and", "autosomal", "dominant", "EMD", "(", "AD", "-", "EMD", ")", "were", "identified", ".", "We", "report", "here", "that", "heterozygote", "mutations", "in", "LMNA", ",", "the", "gene", "for", "AD", "-", "EMD", ",", "may", "cause", "diverse", "phenotypes", "ranging", "from", "typical", "EMD", "to", "no", "phenotypic", "effect", ".", "Our", "results", "show", "that", "LMNA", "mutations", "are", "also", "responsible", "for", "the", "recessive", "form", "of", "the", "disease", ".", "Our", "results", "give", "further", "support", "to", "the", "notion", "that", "different", "genetic", "forms", "of", "EMD", "have", "a", "common", "pathophysiological", "background", ".", "The", "distribution", "of", "the", "mutations", "in", "AD", "-", "EMD", "patients", "(", "in", "the", "tail", "and", "in", "the", "2A", "rod", "domain", ")", "suggests", "that", "unique", "interactions", "between", "lamin", "A", "/", "C", "and", "other", "nuclear", "components", "exist", "that", "have", "an", "important", "role", "in", "cardiac", "and", "skeletal", "muscle", "function", ".", "\n" ]
[ "Gene" ]
LMNA is a Gene, LMNA , is a Gene, LMNA is a Gene
12_task1
Sentence: Different mutations in the LMNA gene cause autosomal dominant and autosomal recessive Emery-Dreifuss muscular dystrophy. Emery-Dreifuss muscular dystrophy (EMD) is a condition characterized by the clinical triad of early-onset contractures, progressive weakness in humeroperoneal muscles, and cardiomyopathy with conduction block. The disease was described for the first time as an X-linked muscular dystrophy, but autosomal dominant and autosomal recessive forms were reported. The genes for X-linked EMD and autosomal dominant EMD (AD-EMD) were identified. We report here that heterozygote mutations in LMNA, the gene for AD-EMD, may cause diverse phenotypes ranging from typical EMD to no phenotypic effect. Our results show that LMNA mutations are also responsible for the recessive form of the disease. Our results give further support to the notion that different genetic forms of EMD have a common pathophysiological background. The distribution of the mutations in AD-EMD patients (in the tail and in the 2A rod domain) suggests that unique interactions between lamin A/C and other nuclear components exist that have an important role in cardiac and skeletal muscle function. Instructions: please typing these entity words according to sentence: LMNA, LMNA ,, LMNA Options: Gene
[ "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Different mutations in the LMNA gene cause autosomal dominant and autosomal recessive Emery-Dreifuss muscular dystrophy. Emery-Dreifuss muscular dystrophy (EMD) is a condition characterized by the clinical triad of early-onset contractures, progressive weakness in humeroperoneal muscles, and cardiomyopathy with conduction block. The disease was described for the first time as an X-linked muscular dystrophy, but autosomal dominant and autosomal recessive forms were reported. The genes for X-linked EMD and autosomal dominant EMD (AD-EMD) were identified. We report here that heterozygote mutations in LMNA, the gene for AD-EMD, may cause diverse phenotypes ranging from typical EMD to no phenotypic effect. Our results show that LMNA mutations are also responsible for the recessive form of the disease. Our results give further support to the notion that different genetic forms of EMD have a common pathophysiological background. The distribution of the mutations in AD-EMD patients (in the tail and in the 2A rod domain) suggests that unique interactions between lamin A/C and other nuclear components exist that have an important role in cardiac and skeletal muscle function.
[ "Different", "mutations", "in", "the", "LMNA", "gene", "cause", "autosomal", "dominant", "and", "autosomal", "recessive", "Emery", "-", "Dreifuss", "muscular", "dystrophy", ".", "Emery", "-", "Dreifuss", "muscular", "dystrophy", "(", "EMD", ")", "is", "a", "condition", "characterized", "by", "the", "clinical", "triad", "of", "early", "-", "onset", "contractures", ",", "progressive", "weakness", "in", "humeroperoneal", "muscles", ",", "and", "cardiomyopathy", "with", "conduction", "block", ".", "The", "disease", "was", "described", "for", "the", "first", "time", "as", "an", "X", "-", "linked", "muscular", "dystrophy", ",", "but", "autosomal", "dominant", "and", "autosomal", "recessive", "forms", "were", "reported", ".", "The", "genes", "for", "X", "-", "linked", "EMD", "and", "autosomal", "dominant", "EMD", "(", "AD", "-", "EMD", ")", "were", "identified", ".", "We", "report", "here", "that", "heterozygote", "mutations", "in", "LMNA", ",", "the", "gene", "for", "AD", "-", "EMD", ",", "may", "cause", "diverse", "phenotypes", "ranging", "from", "typical", "EMD", "to", "no", "phenotypic", "effect", ".", "Our", "results", "show", "that", "LMNA", "mutations", "are", "also", "responsible", "for", "the", "recessive", "form", "of", "the", "disease", ".", "Our", "results", "give", "further", "support", "to", "the", "notion", "that", "different", "genetic", "forms", "of", "EMD", "have", "a", "common", "pathophysiological", "background", ".", "The", "distribution", "of", "the", "mutations", "in", "AD", "-", "EMD", "patients", "(", "in", "the", "tail", "and", "in", "the", "2A", "rod", "domain", ")", "suggests", "that", "unique", "interactions", "between", "lamin", "A", "/", "C", "and", "other", "nuclear", "components", "exist", "that", "have", "an", "important", "role", "in", "cardiac", "and", "skeletal", "muscle", "function", ".", "\n" ]
[ "Gene" ]
LMNA, LMNA ,, LMNA
12_task2
Sentence: Different mutations in the LMNA gene cause autosomal dominant and autosomal recessive Emery-Dreifuss muscular dystrophy. Emery-Dreifuss muscular dystrophy (EMD) is a condition characterized by the clinical triad of early-onset contractures, progressive weakness in humeroperoneal muscles, and cardiomyopathy with conduction block. The disease was described for the first time as an X-linked muscular dystrophy, but autosomal dominant and autosomal recessive forms were reported. The genes for X-linked EMD and autosomal dominant EMD (AD-EMD) were identified. We report here that heterozygote mutations in LMNA, the gene for AD-EMD, may cause diverse phenotypes ranging from typical EMD to no phenotypic effect. Our results show that LMNA mutations are also responsible for the recessive form of the disease. Our results give further support to the notion that different genetic forms of EMD have a common pathophysiological background. The distribution of the mutations in AD-EMD patients (in the tail and in the 2A rod domain) suggests that unique interactions between lamin A/C and other nuclear components exist that have an important role in cardiac and skeletal muscle function. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "I-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Different mutations in the LMNA gene cause autosomal dominant and autosomal recessive Emery-Dreifuss muscular dystrophy. Emery-Dreifuss muscular dystrophy (EMD) is a condition characterized by the clinical triad of early-onset contractures, progressive weakness in humeroperoneal muscles, and cardiomyopathy with conduction block. The disease was described for the first time as an X-linked muscular dystrophy, but autosomal dominant and autosomal recessive forms were reported. The genes for X-linked EMD and autosomal dominant EMD (AD-EMD) were identified. We report here that heterozygote mutations in LMNA, the gene for AD-EMD, may cause diverse phenotypes ranging from typical EMD to no phenotypic effect. Our results show that LMNA mutations are also responsible for the recessive form of the disease. Our results give further support to the notion that different genetic forms of EMD have a common pathophysiological background. The distribution of the mutations in AD-EMD patients (in the tail and in the 2A rod domain) suggests that unique interactions between lamin A/C and other nuclear components exist that have an important role in cardiac and skeletal muscle function.
[ "Different", "mutations", "in", "the", "LMNA", "gene", "cause", "autosomal", "dominant", "and", "autosomal", "recessive", "Emery", "-", "Dreifuss", "muscular", "dystrophy", ".", "Emery", "-", "Dreifuss", "muscular", "dystrophy", "(", "EMD", ")", "is", "a", "condition", "characterized", "by", "the", "clinical", "triad", "of", "early", "-", "onset", "contractures", ",", "progressive", "weakness", "in", "humeroperoneal", "muscles", ",", "and", "cardiomyopathy", "with", "conduction", "block", ".", "The", "disease", "was", "described", "for", "the", "first", "time", "as", "an", "X", "-", "linked", "muscular", "dystrophy", ",", "but", "autosomal", "dominant", "and", "autosomal", "recessive", "forms", "were", "reported", ".", "The", "genes", "for", "X", "-", "linked", "EMD", "and", "autosomal", "dominant", "EMD", "(", "AD", "-", "EMD", ")", "were", "identified", ".", "We", "report", "here", "that", "heterozygote", "mutations", "in", "LMNA", ",", "the", "gene", "for", "AD", "-", "EMD", ",", "may", "cause", "diverse", "phenotypes", "ranging", "from", "typical", "EMD", "to", "no", "phenotypic", "effect", ".", "Our", "results", "show", "that", "LMNA", "mutations", "are", "also", "responsible", "for", "the", "recessive", "form", "of", "the", "disease", ".", "Our", "results", "give", "further", "support", "to", "the", "notion", "that", "different", "genetic", "forms", "of", "EMD", "have", "a", "common", "pathophysiological", "background", ".", "The", "distribution", "of", "the", "mutations", "in", "AD", "-", "EMD", "patients", "(", "in", "the", "tail", "and", "in", "the", "2A", "rod", "domain", ")", "suggests", "that", "unique", "interactions", "between", "lamin", "A", "/", "C", "and", "other", "nuclear", "components", "exist", "that", "have", "an", "important", "role", "in", "cardiac", "and", "skeletal", "muscle", "function", ".", "\n" ]
[ "Gene" ]
Tumoren is an umlsterm, Orbita is an umlsterm, Radio- is an umlsterm, Chemotherapie is an umlsterm, Analyse is an umlsterm, Patientenkollektivs is an umlsterm, Therapie is an umlsterm, Prognose is an umlsterm
DerOpthalmologe.70940914.ger.abstr_task0
Sentence: Fragestellung : Rhabdomyosarkome sind die haeufigsten malignen Tumoren der Orbita im Kindesalter . Die Behandlungskonzepte ( Individualtherapie Studienprotokolle ) , der Erkrankung haben sich deutlich veraendert . Operative Verfahren wurden um Radio- und Chemotherapie erweitert . Ziel der retrospektiven Analyse war es , anhand eines selektionsfreien Patientenkollektivs Auswirkungen der veraenderten Therapie auf die Prognose darzustellen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O" ]
Fragestellung : Rhabdomyosarkome sind die haeufigsten malignen Tumoren der Orbita im Kindesalter . Die Behandlungskonzepte ( Individualtherapie Studienprotokolle ) , der Erkrankung haben sich deutlich veraendert . Operative Verfahren wurden um Radio- und Chemotherapie erweitert . Ziel der retrospektiven Analyse war es , anhand eines selektionsfreien Patientenkollektivs Auswirkungen der veraenderten Therapie auf die Prognose darzustellen .
[ "Fragestellung", ":", "Rhabdomyosarkome", "sind", "die", "haeufigsten", "malignen", "Tumoren", "der", "Orbita", "im", "Kindesalter", ".", "Die", "Behandlungskonzepte", "(", "Individualtherapie", "Studienprotokolle", ")", ",", "der", "Erkrankung", "haben", "sich", "deutlich", "veraendert", ".", "Operative", "Verfahren", "wurden", "um", "Radio-", "und", "Chemotherapie", "erweitert", ".", "Ziel", "der", "retrospektiven", "Analyse", "war", "es", ",", "anhand", "eines", "selektionsfreien", "Patientenkollektivs", "Auswirkungen", "der", "veraenderten", "Therapie", "auf", "die", "Prognose", "darzustellen", "." ]
[ "umlsterm" ]
Tumoren is an umlsterm, Orbita is an umlsterm, Radio- is an umlsterm, Chemotherapie is an umlsterm, Analyse is an umlsterm, Patientenkollektivs is an umlsterm, Therapie is an umlsterm, Prognose is an umlsterm
DerOpthalmologe.70940914.ger.abstr_task1
Sentence: Fragestellung : Rhabdomyosarkome sind die haeufigsten malignen Tumoren der Orbita im Kindesalter . Die Behandlungskonzepte ( Individualtherapie Studienprotokolle ) , der Erkrankung haben sich deutlich veraendert . Operative Verfahren wurden um Radio- und Chemotherapie erweitert . Ziel der retrospektiven Analyse war es , anhand eines selektionsfreien Patientenkollektivs Auswirkungen der veraenderten Therapie auf die Prognose darzustellen . Instructions: please typing these entity words according to sentence: Tumoren, Orbita, Radio-, Chemotherapie, Analyse, Patientenkollektivs, Therapie, Prognose Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O" ]
Fragestellung : Rhabdomyosarkome sind die haeufigsten malignen Tumoren der Orbita im Kindesalter . Die Behandlungskonzepte ( Individualtherapie Studienprotokolle ) , der Erkrankung haben sich deutlich veraendert . Operative Verfahren wurden um Radio- und Chemotherapie erweitert . Ziel der retrospektiven Analyse war es , anhand eines selektionsfreien Patientenkollektivs Auswirkungen der veraenderten Therapie auf die Prognose darzustellen .
[ "Fragestellung", ":", "Rhabdomyosarkome", "sind", "die", "haeufigsten", "malignen", "Tumoren", "der", "Orbita", "im", "Kindesalter", ".", "Die", "Behandlungskonzepte", "(", "Individualtherapie", "Studienprotokolle", ")", ",", "der", "Erkrankung", "haben", "sich", "deutlich", "veraendert", ".", "Operative", "Verfahren", "wurden", "um", "Radio-", "und", "Chemotherapie", "erweitert", ".", "Ziel", "der", "retrospektiven", "Analyse", "war", "es", ",", "anhand", "eines", "selektionsfreien", "Patientenkollektivs", "Auswirkungen", "der", "veraenderten", "Therapie", "auf", "die", "Prognose", "darzustellen", "." ]
[ "umlsterm" ]
Tumoren, Orbita, Radio-, Chemotherapie, Analyse, Patientenkollektivs, Therapie, Prognose
DerOpthalmologe.70940914.ger.abstr_task2
Sentence: Fragestellung : Rhabdomyosarkome sind die haeufigsten malignen Tumoren der Orbita im Kindesalter . Die Behandlungskonzepte ( Individualtherapie Studienprotokolle ) , der Erkrankung haben sich deutlich veraendert . Operative Verfahren wurden um Radio- und Chemotherapie erweitert . Ziel der retrospektiven Analyse war es , anhand eines selektionsfreien Patientenkollektivs Auswirkungen der veraenderten Therapie auf die Prognose darzustellen . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O" ]
Fragestellung : Rhabdomyosarkome sind die haeufigsten malignen Tumoren der Orbita im Kindesalter . Die Behandlungskonzepte ( Individualtherapie Studienprotokolle ) , der Erkrankung haben sich deutlich veraendert . Operative Verfahren wurden um Radio- und Chemotherapie erweitert . Ziel der retrospektiven Analyse war es , anhand eines selektionsfreien Patientenkollektivs Auswirkungen der veraenderten Therapie auf die Prognose darzustellen .
[ "Fragestellung", ":", "Rhabdomyosarkome", "sind", "die", "haeufigsten", "malignen", "Tumoren", "der", "Orbita", "im", "Kindesalter", ".", "Die", "Behandlungskonzepte", "(", "Individualtherapie", "Studienprotokolle", ")", ",", "der", "Erkrankung", "haben", "sich", "deutlich", "veraendert", ".", "Operative", "Verfahren", "wurden", "um", "Radio-", "und", "Chemotherapie", "erweitert", ".", "Ziel", "der", "retrospektiven", "Analyse", "war", "es", ",", "anhand", "eines", "selektionsfreien", "Patientenkollektivs", "Auswirkungen", "der", "veraenderten", "Therapie", "auf", "die", "Prognose", "darzustellen", "." ]
[ "umlsterm" ]
Kleinkindforschung is an umlsterm, Belastbarkeit is an umlsterm, Leben is an umlsterm, Kind is an umlsterm, Lebensmonaten is an umlsterm, Kindes is an umlsterm, Mutter - Kind - Paares is an umlsterm, Faehigkeiten is an umlsterm, Behandlung is an umlsterm
Psychotherapeut.00450018.ger.abstr_task0
Sentence: Zusammenfassung Die Saeuglings- und Kleinkindforschung lieferte in den letzten beiden Dekaden empirisch begruendete Ergebnisse , die eine mangelnde psychophysische Belastbarkeit im spaeteren Leben und eine Anfaelligkeit fuer psychosomatische Symptome erklaeren koennen . Interaktionsprozesse und der affektive Austausch zwischen Bezugsperson und Kind ermoeglichen in den ersten Lebensmonaten die Grundregulation und fuehren zu Repraesentanzen von Interaktionen , die die Basis fuer die spaetere Bindungsqualitaet des Kindes bilden . Diese mutuelle Regulation des Mutter-Kind-Paares bildet die Grundlage fuer die selbstregulativen Faehigkeiten des spaeteren Erwachsenen , der in unterschiedlichem Ausmass auf verschiedenen Ebenen sprachlich-symbolisch oder koerperlich-psychosomatisch auf Disstress reagiert . Erste Erfahrungen mit der Umsetzung dieser Vorstellungen auf die Behandlung psychosomatisch Erkrankter werden vorgestellt . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]
Zusammenfassung Die Saeuglings- und Kleinkindforschung lieferte in den letzten beiden Dekaden empirisch begruendete Ergebnisse , die eine mangelnde psychophysische Belastbarkeit im spaeteren Leben und eine Anfaelligkeit fuer psychosomatische Symptome erklaeren koennen . Interaktionsprozesse und der affektive Austausch zwischen Bezugsperson und Kind ermoeglichen in den ersten Lebensmonaten die Grundregulation und fuehren zu Repraesentanzen von Interaktionen , die die Basis fuer die spaetere Bindungsqualitaet des Kindes bilden . Diese mutuelle Regulation des Mutter-Kind-Paares bildet die Grundlage fuer die selbstregulativen Faehigkeiten des spaeteren Erwachsenen , der in unterschiedlichem Ausmass auf verschiedenen Ebenen sprachlich-symbolisch oder koerperlich-psychosomatisch auf Disstress reagiert . Erste Erfahrungen mit der Umsetzung dieser Vorstellungen auf die Behandlung psychosomatisch Erkrankter werden vorgestellt .
[ "Zusammenfassung", "Die", "Saeuglings-", "und", "Kleinkindforschung", "lieferte", "in", "den", "letzten", "beiden", "Dekaden", "empirisch", "begruendete", "Ergebnisse", ",", "die", "eine", "mangelnde", "psychophysische", "Belastbarkeit", "im", "spaeteren", "Leben", "und", "eine", "Anfaelligkeit", "fuer", "psychosomatische", "Symptome", "erklaeren", "koennen", ".", "Interaktionsprozesse", "und", "der", "affektive", "Austausch", "zwischen", "Bezugsperson", "und", "Kind", "ermoeglichen", "in", "den", "ersten", "Lebensmonaten", "die", "Grundregulation", "und", "fuehren", "zu", "Repraesentanzen", "von", "Interaktionen", ",", "die", "die", "Basis", "fuer", "die", "spaetere", "Bindungsqualitaet", "des", "Kindes", "bilden", ".", "Diese", "mutuelle", "Regulation", "des", "Mutter", "-", "Kind", "-", "Paares", "bildet", "die", "Grundlage", "fuer", "die", "selbstregulativen", "Faehigkeiten", "des", "spaeteren", "Erwachsenen", ",", "der", "in", "unterschiedlichem", "Ausmass", "auf", "verschiedenen", "Ebenen", "sprachlich", "-", "symbolisch", "oder", "koerperlich", "-", "psychosomatisch", "auf", "Disstress", "reagiert", ".", "Erste", "Erfahrungen", "mit", "der", "Umsetzung", "dieser", "Vorstellungen", "auf", "die", "Behandlung", "psychosomatisch", "Erkrankter", "werden", "vorgestellt", "." ]
[ "umlsterm" ]
Kleinkindforschung is an umlsterm, Belastbarkeit is an umlsterm, Leben is an umlsterm, Kind is an umlsterm, Lebensmonaten is an umlsterm, Kindes is an umlsterm, Mutter - Kind - Paares is an umlsterm, Faehigkeiten is an umlsterm, Behandlung is an umlsterm
Psychotherapeut.00450018.ger.abstr_task1
Sentence: Zusammenfassung Die Saeuglings- und Kleinkindforschung lieferte in den letzten beiden Dekaden empirisch begruendete Ergebnisse , die eine mangelnde psychophysische Belastbarkeit im spaeteren Leben und eine Anfaelligkeit fuer psychosomatische Symptome erklaeren koennen . Interaktionsprozesse und der affektive Austausch zwischen Bezugsperson und Kind ermoeglichen in den ersten Lebensmonaten die Grundregulation und fuehren zu Repraesentanzen von Interaktionen , die die Basis fuer die spaetere Bindungsqualitaet des Kindes bilden . Diese mutuelle Regulation des Mutter-Kind-Paares bildet die Grundlage fuer die selbstregulativen Faehigkeiten des spaeteren Erwachsenen , der in unterschiedlichem Ausmass auf verschiedenen Ebenen sprachlich-symbolisch oder koerperlich-psychosomatisch auf Disstress reagiert . Erste Erfahrungen mit der Umsetzung dieser Vorstellungen auf die Behandlung psychosomatisch Erkrankter werden vorgestellt . Instructions: please typing these entity words according to sentence: Kleinkindforschung, Belastbarkeit, Leben, Kind, Lebensmonaten, Kindes, Mutter - Kind - Paares, Faehigkeiten, Behandlung Options: umlsterm
[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]
Zusammenfassung Die Saeuglings- und Kleinkindforschung lieferte in den letzten beiden Dekaden empirisch begruendete Ergebnisse , die eine mangelnde psychophysische Belastbarkeit im spaeteren Leben und eine Anfaelligkeit fuer psychosomatische Symptome erklaeren koennen . Interaktionsprozesse und der affektive Austausch zwischen Bezugsperson und Kind ermoeglichen in den ersten Lebensmonaten die Grundregulation und fuehren zu Repraesentanzen von Interaktionen , die die Basis fuer die spaetere Bindungsqualitaet des Kindes bilden . Diese mutuelle Regulation des Mutter-Kind-Paares bildet die Grundlage fuer die selbstregulativen Faehigkeiten des spaeteren Erwachsenen , der in unterschiedlichem Ausmass auf verschiedenen Ebenen sprachlich-symbolisch oder koerperlich-psychosomatisch auf Disstress reagiert . Erste Erfahrungen mit der Umsetzung dieser Vorstellungen auf die Behandlung psychosomatisch Erkrankter werden vorgestellt .
[ "Zusammenfassung", "Die", "Saeuglings-", "und", "Kleinkindforschung", "lieferte", "in", "den", "letzten", "beiden", "Dekaden", "empirisch", "begruendete", "Ergebnisse", ",", "die", "eine", "mangelnde", "psychophysische", "Belastbarkeit", "im", "spaeteren", "Leben", "und", "eine", "Anfaelligkeit", "fuer", "psychosomatische", "Symptome", "erklaeren", "koennen", ".", "Interaktionsprozesse", "und", "der", "affektive", "Austausch", "zwischen", "Bezugsperson", "und", "Kind", "ermoeglichen", "in", "den", "ersten", "Lebensmonaten", "die", "Grundregulation", "und", "fuehren", "zu", "Repraesentanzen", "von", "Interaktionen", ",", "die", "die", "Basis", "fuer", "die", "spaetere", "Bindungsqualitaet", "des", "Kindes", "bilden", ".", "Diese", "mutuelle", "Regulation", "des", "Mutter", "-", "Kind", "-", "Paares", "bildet", "die", "Grundlage", "fuer", "die", "selbstregulativen", "Faehigkeiten", "des", "spaeteren", "Erwachsenen", ",", "der", "in", "unterschiedlichem", "Ausmass", "auf", "verschiedenen", "Ebenen", "sprachlich", "-", "symbolisch", "oder", "koerperlich", "-", "psychosomatisch", "auf", "Disstress", "reagiert", ".", "Erste", "Erfahrungen", "mit", "der", "Umsetzung", "dieser", "Vorstellungen", "auf", "die", "Behandlung", "psychosomatisch", "Erkrankter", "werden", "vorgestellt", "." ]
[ "umlsterm" ]
Kleinkindforschung, Belastbarkeit, Leben, Kind, Lebensmonaten, Kindes, Mutter - Kind - Paares, Faehigkeiten, Behandlung
Psychotherapeut.00450018.ger.abstr_task2
Sentence: Zusammenfassung Die Saeuglings- und Kleinkindforschung lieferte in den letzten beiden Dekaden empirisch begruendete Ergebnisse , die eine mangelnde psychophysische Belastbarkeit im spaeteren Leben und eine Anfaelligkeit fuer psychosomatische Symptome erklaeren koennen . Interaktionsprozesse und der affektive Austausch zwischen Bezugsperson und Kind ermoeglichen in den ersten Lebensmonaten die Grundregulation und fuehren zu Repraesentanzen von Interaktionen , die die Basis fuer die spaetere Bindungsqualitaet des Kindes bilden . Diese mutuelle Regulation des Mutter-Kind-Paares bildet die Grundlage fuer die selbstregulativen Faehigkeiten des spaeteren Erwachsenen , der in unterschiedlichem Ausmass auf verschiedenen Ebenen sprachlich-symbolisch oder koerperlich-psychosomatisch auf Disstress reagiert . Erste Erfahrungen mit der Umsetzung dieser Vorstellungen auf die Behandlung psychosomatisch Erkrankter werden vorgestellt . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O" ]
Zusammenfassung Die Saeuglings- und Kleinkindforschung lieferte in den letzten beiden Dekaden empirisch begruendete Ergebnisse , die eine mangelnde psychophysische Belastbarkeit im spaeteren Leben und eine Anfaelligkeit fuer psychosomatische Symptome erklaeren koennen . Interaktionsprozesse und der affektive Austausch zwischen Bezugsperson und Kind ermoeglichen in den ersten Lebensmonaten die Grundregulation und fuehren zu Repraesentanzen von Interaktionen , die die Basis fuer die spaetere Bindungsqualitaet des Kindes bilden . Diese mutuelle Regulation des Mutter-Kind-Paares bildet die Grundlage fuer die selbstregulativen Faehigkeiten des spaeteren Erwachsenen , der in unterschiedlichem Ausmass auf verschiedenen Ebenen sprachlich-symbolisch oder koerperlich-psychosomatisch auf Disstress reagiert . Erste Erfahrungen mit der Umsetzung dieser Vorstellungen auf die Behandlung psychosomatisch Erkrankter werden vorgestellt .
[ "Zusammenfassung", "Die", "Saeuglings-", "und", "Kleinkindforschung", "lieferte", "in", "den", "letzten", "beiden", "Dekaden", "empirisch", "begruendete", "Ergebnisse", ",", "die", "eine", "mangelnde", "psychophysische", "Belastbarkeit", "im", "spaeteren", "Leben", "und", "eine", "Anfaelligkeit", "fuer", "psychosomatische", "Symptome", "erklaeren", "koennen", ".", "Interaktionsprozesse", "und", "der", "affektive", "Austausch", "zwischen", "Bezugsperson", "und", "Kind", "ermoeglichen", "in", "den", "ersten", "Lebensmonaten", "die", "Grundregulation", "und", "fuehren", "zu", "Repraesentanzen", "von", "Interaktionen", ",", "die", "die", "Basis", "fuer", "die", "spaetere", "Bindungsqualitaet", "des", "Kindes", "bilden", ".", "Diese", "mutuelle", "Regulation", "des", "Mutter", "-", "Kind", "-", "Paares", "bildet", "die", "Grundlage", "fuer", "die", "selbstregulativen", "Faehigkeiten", "des", "spaeteren", "Erwachsenen", ",", "der", "in", "unterschiedlichem", "Ausmass", "auf", "verschiedenen", "Ebenen", "sprachlich", "-", "symbolisch", "oder", "koerperlich", "-", "psychosomatisch", "auf", "Disstress", "reagiert", ".", "Erste", "Erfahrungen", "mit", "der", "Umsetzung", "dieser", "Vorstellungen", "auf", "die", "Behandlung", "psychosomatisch", "Erkrankter", "werden", "vorgestellt", "." ]
[ "umlsterm" ]
radioimmunoassay is a Intervention_Physical, evaluation of radioimmunoassay is a Intervention_Physical, single tubes is a Intervention_Physical
80560_task0
Sentence: An evaluation method providing confidence intervals applied to radioimmunoassay . A method for evaluation of radioimmunoassay results is described . The order of the single tubes in each assay run is randomized . A polynomial is fitted to untransformed data ( y = counts per minute ; x = concentration of curve.A confidence interval is calculated for each sample , taking into account the variance of the standard curve and that of the actual duplicate assay jointly . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Physical
[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
An evaluation method providing confidence intervals applied to radioimmunoassay . A method for evaluation of radioimmunoassay results is described . The order of the single tubes in each assay run is randomized . A polynomial is fitted to untransformed data ( y = counts per minute ; x = concentration of curve.A confidence interval is calculated for each sample , taking into account the variance of the standard curve and that of the actual duplicate assay jointly .
[ "An", "evaluation", "method", "providing", "confidence", "intervals", "applied", "to", "radioimmunoassay", ".", "A", "method", "for", "evaluation", "of", "radioimmunoassay", "results", "is", "described", ".", "The", "order", "of", "the", "single", "tubes", "in", "each", "assay", "run", "is", "randomized", ".", "A", "polynomial", "is", "fitted", "to", "untransformed", "data", "(", "y", "=", "counts", "per", "minute", ";", "x", "=", "concentration", "of", "curve", ".", "A", "confidence", "interval", "is", "calculated", "for", "each", "sample", ",", "taking", "into", "account", "the", "variance", "of", "the", "standard", "curve", "and", "that", "of", "the", "actual", "duplicate", "assay", "jointly", "." ]
[ "Intervention_Physical" ]
radioimmunoassay is a Intervention_Physical, evaluation of radioimmunoassay is a Intervention_Physical, single tubes is a Intervention_Physical
80560_task1
Sentence: An evaluation method providing confidence intervals applied to radioimmunoassay . A method for evaluation of radioimmunoassay results is described . The order of the single tubes in each assay run is randomized . A polynomial is fitted to untransformed data ( y = counts per minute ; x = concentration of curve.A confidence interval is calculated for each sample , taking into account the variance of the standard curve and that of the actual duplicate assay jointly . Instructions: please typing these entity words according to sentence: radioimmunoassay, evaluation of radioimmunoassay, single tubes Options: Intervention_Physical
[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
An evaluation method providing confidence intervals applied to radioimmunoassay . A method for evaluation of radioimmunoassay results is described . The order of the single tubes in each assay run is randomized . A polynomial is fitted to untransformed data ( y = counts per minute ; x = concentration of curve.A confidence interval is calculated for each sample , taking into account the variance of the standard curve and that of the actual duplicate assay jointly .
[ "An", "evaluation", "method", "providing", "confidence", "intervals", "applied", "to", "radioimmunoassay", ".", "A", "method", "for", "evaluation", "of", "radioimmunoassay", "results", "is", "described", ".", "The", "order", "of", "the", "single", "tubes", "in", "each", "assay", "run", "is", "randomized", ".", "A", "polynomial", "is", "fitted", "to", "untransformed", "data", "(", "y", "=", "counts", "per", "minute", ";", "x", "=", "concentration", "of", "curve", ".", "A", "confidence", "interval", "is", "calculated", "for", "each", "sample", ",", "taking", "into", "account", "the", "variance", "of", "the", "standard", "curve", "and", "that", "of", "the", "actual", "duplicate", "assay", "jointly", "." ]
[ "Intervention_Physical" ]
radioimmunoassay, evaluation of radioimmunoassay, single tubes
80560_task2
Sentence: An evaluation method providing confidence intervals applied to radioimmunoassay . A method for evaluation of radioimmunoassay results is described . The order of the single tubes in each assay run is randomized . A polynomial is fitted to untransformed data ( y = counts per minute ; x = concentration of curve.A confidence interval is calculated for each sample , taking into account the variance of the standard curve and that of the actual duplicate assay jointly . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
An evaluation method providing confidence intervals applied to radioimmunoassay . A method for evaluation of radioimmunoassay results is described . The order of the single tubes in each assay run is randomized . A polynomial is fitted to untransformed data ( y = counts per minute ; x = concentration of curve.A confidence interval is calculated for each sample , taking into account the variance of the standard curve and that of the actual duplicate assay jointly .
[ "An", "evaluation", "method", "providing", "confidence", "intervals", "applied", "to", "radioimmunoassay", ".", "A", "method", "for", "evaluation", "of", "radioimmunoassay", "results", "is", "described", ".", "The", "order", "of", "the", "single", "tubes", "in", "each", "assay", "run", "is", "randomized", ".", "A", "polynomial", "is", "fitted", "to", "untransformed", "data", "(", "y", "=", "counts", "per", "minute", ";", "x", "=", "concentration", "of", "curve", ".", "A", "confidence", "interval", "is", "calculated", "for", "each", "sample", ",", "taking", "into", "account", "the", "variance", "of", "the", "standard", "curve", "and", "that", "of", "the", "actual", "duplicate", "assay", "jointly", "." ]
[ "Intervention_Physical" ]
glutathione peroxidase is a Protein, GPX is a Protein, GPX is a Protein
8852698_task0
Sentence: Selenium-mediated inhibition of transcription factor NF-kappa B and HIV-1 LTR promoter activity. The eukaryotic transcription factor NF-kappa B is involved in the inducible expression of various inflammatory genes as well as in HIV-1 replication. Activation of NF-kappa B is induced by prooxidants and several stimuli eliciting oxidative stress, such as cytokines, lipopolysaccharide, UV irradiation and other mediators. Various antioxidants inhibit NF-kappa B activation in response to these stimuli. In this study, we have investigated the effects of selenium, an integral component of glutathione peroxidase (GPX), on NF-kappa B activation. In selenium-deprived Jurkat and ESb-L T lymphocytes, supplementation of selenium led to a substantial increase of GPX activity. Analysis of DNA binding revealed that NF-kappa B activation in response to TNF was significantly inhibited under these conditions. Likewise, reporter gene assays using luciferase constructs driven by the HIV-1 long terminal repeat showed a dose-dependent inhibition of NF-kappa B controlled gene expression by selenium. The effects of selenium were specific for NF-kappa B, since the activity of the transcription factor AP-1 was not suppressed. These data suggest that selenium supplementation may be used to modulate the expression of NF-kappa B target genes and HIV-1. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Selenium-mediated inhibition of transcription factor NF-kappa B and HIV-1 LTR promoter activity. The eukaryotic transcription factor NF-kappa B is involved in the inducible expression of various inflammatory genes as well as in HIV-1 replication. Activation of NF-kappa B is induced by prooxidants and several stimuli eliciting oxidative stress, such as cytokines, lipopolysaccharide, UV irradiation and other mediators. Various antioxidants inhibit NF-kappa B activation in response to these stimuli. In this study, we have investigated the effects of selenium, an integral component of glutathione peroxidase (GPX), on NF-kappa B activation. In selenium-deprived Jurkat and ESb-L T lymphocytes, supplementation of selenium led to a substantial increase of GPX activity. Analysis of DNA binding revealed that NF-kappa B activation in response to TNF was significantly inhibited under these conditions. Likewise, reporter gene assays using luciferase constructs driven by the HIV-1 long terminal repeat showed a dose-dependent inhibition of NF-kappa B controlled gene expression by selenium. The effects of selenium were specific for NF-kappa B, since the activity of the transcription factor AP-1 was not suppressed. These data suggest that selenium supplementation may be used to modulate the expression of NF-kappa B target genes and HIV-1.
[ "Selenium", "-", "mediated", "inhibition", "of", "transcription", "factor", "NF", "-", "kappa", "B", "and", "HIV-1", "LTR", "promoter", "activity", ".", "\n", "The", "eukaryotic", "transcription", "factor", "NF", "-", "kappa", "B", "is", "involved", "in", "the", "inducible", "expression", "of", "various", "inflammatory", "genes", "as", "well", "as", "in", "HIV-1", "replication", ".", "Activation", "of", "NF", "-", "kappa", "B", "is", "induced", "by", "prooxidants", "and", "several", "stimuli", "eliciting", "oxidative", "stress", ",", "such", "as", "cytokines", ",", "lipopolysaccharide", ",", "UV", "irradiation", "and", "other", "mediators", ".", "Various", "antioxidants", "inhibit", "NF", "-", "kappa", "B", "activation", "in", "response", "to", "these", "stimuli", ".", "In", "this", "study", ",", "we", "have", "investigated", "the", "effects", "of", "selenium", ",", "an", "integral", "component", "of", "glutathione", "peroxidase", "(", "GPX", ")", ",", "on", "NF", "-", "kappa", "B", "activation", ".", "In", "selenium", "-", "deprived", "Jurkat", "and", "ESb", "-", "L", "T", "lymphocytes", ",", "supplementation", "of", "selenium", "led", "to", "a", "substantial", "increase", "of", "GPX", "activity", ".", "Analysis", "of", "DNA", "binding", "revealed", "that", "NF", "-", "kappa", "B", "activation", "in", "response", "to", "TNF", "was", "significantly", "inhibited", "under", "these", "conditions", ".", "Likewise", ",", "reporter", "gene", "assays", "using", "luciferase", "constructs", "driven", "by", "the", "HIV-1", "long", "terminal", "repeat", "showed", "a", "dose", "-", "dependent", "inhibition", "of", "NF", "-", "kappa", "B", "controlled", "gene", "expression", "by", "selenium", ".", "The", "effects", "of", "selenium", "were", "specific", "for", "NF", "-", "kappa", "B", ",", "since", "the", "activity", "of", "the", "transcription", "factor", "AP-1", "was", "not", "suppressed", ".", "These", "data", "suggest", "that", "selenium", "supplementation", "may", "be", "used", "to", "modulate", "the", "expression", "of", "NF", "-", "kappa", "B", "target", "genes", "and", "HIV-1", "." ]
[ "Protein" ]
glutathione peroxidase is a Protein, GPX is a Protein, GPX is a Protein
8852698_task1
Sentence: Selenium-mediated inhibition of transcription factor NF-kappa B and HIV-1 LTR promoter activity. The eukaryotic transcription factor NF-kappa B is involved in the inducible expression of various inflammatory genes as well as in HIV-1 replication. Activation of NF-kappa B is induced by prooxidants and several stimuli eliciting oxidative stress, such as cytokines, lipopolysaccharide, UV irradiation and other mediators. Various antioxidants inhibit NF-kappa B activation in response to these stimuli. In this study, we have investigated the effects of selenium, an integral component of glutathione peroxidase (GPX), on NF-kappa B activation. In selenium-deprived Jurkat and ESb-L T lymphocytes, supplementation of selenium led to a substantial increase of GPX activity. Analysis of DNA binding revealed that NF-kappa B activation in response to TNF was significantly inhibited under these conditions. Likewise, reporter gene assays using luciferase constructs driven by the HIV-1 long terminal repeat showed a dose-dependent inhibition of NF-kappa B controlled gene expression by selenium. The effects of selenium were specific for NF-kappa B, since the activity of the transcription factor AP-1 was not suppressed. These data suggest that selenium supplementation may be used to modulate the expression of NF-kappa B target genes and HIV-1. Instructions: please typing these entity words according to sentence: glutathione peroxidase, GPX, GPX Options: Protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Selenium-mediated inhibition of transcription factor NF-kappa B and HIV-1 LTR promoter activity. The eukaryotic transcription factor NF-kappa B is involved in the inducible expression of various inflammatory genes as well as in HIV-1 replication. Activation of NF-kappa B is induced by prooxidants and several stimuli eliciting oxidative stress, such as cytokines, lipopolysaccharide, UV irradiation and other mediators. Various antioxidants inhibit NF-kappa B activation in response to these stimuli. In this study, we have investigated the effects of selenium, an integral component of glutathione peroxidase (GPX), on NF-kappa B activation. In selenium-deprived Jurkat and ESb-L T lymphocytes, supplementation of selenium led to a substantial increase of GPX activity. Analysis of DNA binding revealed that NF-kappa B activation in response to TNF was significantly inhibited under these conditions. Likewise, reporter gene assays using luciferase constructs driven by the HIV-1 long terminal repeat showed a dose-dependent inhibition of NF-kappa B controlled gene expression by selenium. The effects of selenium were specific for NF-kappa B, since the activity of the transcription factor AP-1 was not suppressed. These data suggest that selenium supplementation may be used to modulate the expression of NF-kappa B target genes and HIV-1.
[ "Selenium", "-", "mediated", "inhibition", "of", "transcription", "factor", "NF", "-", "kappa", "B", "and", "HIV-1", "LTR", "promoter", "activity", ".", "\n", "The", "eukaryotic", "transcription", "factor", "NF", "-", "kappa", "B", "is", "involved", "in", "the", "inducible", "expression", "of", "various", "inflammatory", "genes", "as", "well", "as", "in", "HIV-1", "replication", ".", "Activation", "of", "NF", "-", "kappa", "B", "is", "induced", "by", "prooxidants", "and", "several", "stimuli", "eliciting", "oxidative", "stress", ",", "such", "as", "cytokines", ",", "lipopolysaccharide", ",", "UV", "irradiation", "and", "other", "mediators", ".", "Various", "antioxidants", "inhibit", "NF", "-", "kappa", "B", "activation", "in", "response", "to", "these", "stimuli", ".", "In", "this", "study", ",", "we", "have", "investigated", "the", "effects", "of", "selenium", ",", "an", "integral", "component", "of", "glutathione", "peroxidase", "(", "GPX", ")", ",", "on", "NF", "-", "kappa", "B", "activation", ".", "In", "selenium", "-", "deprived", "Jurkat", "and", "ESb", "-", "L", "T", "lymphocytes", ",", "supplementation", "of", "selenium", "led", "to", "a", "substantial", "increase", "of", "GPX", "activity", ".", "Analysis", "of", "DNA", "binding", "revealed", "that", "NF", "-", "kappa", "B", "activation", "in", "response", "to", "TNF", "was", "significantly", "inhibited", "under", "these", "conditions", ".", "Likewise", ",", "reporter", "gene", "assays", "using", "luciferase", "constructs", "driven", "by", "the", "HIV-1", "long", "terminal", "repeat", "showed", "a", "dose", "-", "dependent", "inhibition", "of", "NF", "-", "kappa", "B", "controlled", "gene", "expression", "by", "selenium", ".", "The", "effects", "of", "selenium", "were", "specific", "for", "NF", "-", "kappa", "B", ",", "since", "the", "activity", "of", "the", "transcription", "factor", "AP-1", "was", "not", "suppressed", ".", "These", "data", "suggest", "that", "selenium", "supplementation", "may", "be", "used", "to", "modulate", "the", "expression", "of", "NF", "-", "kappa", "B", "target", "genes", "and", "HIV-1", "." ]
[ "Protein" ]
glutathione peroxidase, GPX, GPX
8852698_task2
Sentence: Selenium-mediated inhibition of transcription factor NF-kappa B and HIV-1 LTR promoter activity. The eukaryotic transcription factor NF-kappa B is involved in the inducible expression of various inflammatory genes as well as in HIV-1 replication. Activation of NF-kappa B is induced by prooxidants and several stimuli eliciting oxidative stress, such as cytokines, lipopolysaccharide, UV irradiation and other mediators. Various antioxidants inhibit NF-kappa B activation in response to these stimuli. In this study, we have investigated the effects of selenium, an integral component of glutathione peroxidase (GPX), on NF-kappa B activation. In selenium-deprived Jurkat and ESb-L T lymphocytes, supplementation of selenium led to a substantial increase of GPX activity. Analysis of DNA binding revealed that NF-kappa B activation in response to TNF was significantly inhibited under these conditions. Likewise, reporter gene assays using luciferase constructs driven by the HIV-1 long terminal repeat showed a dose-dependent inhibition of NF-kappa B controlled gene expression by selenium. The effects of selenium were specific for NF-kappa B, since the activity of the transcription factor AP-1 was not suppressed. These data suggest that selenium supplementation may be used to modulate the expression of NF-kappa B target genes and HIV-1. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Selenium-mediated inhibition of transcription factor NF-kappa B and HIV-1 LTR promoter activity. The eukaryotic transcription factor NF-kappa B is involved in the inducible expression of various inflammatory genes as well as in HIV-1 replication. Activation of NF-kappa B is induced by prooxidants and several stimuli eliciting oxidative stress, such as cytokines, lipopolysaccharide, UV irradiation and other mediators. Various antioxidants inhibit NF-kappa B activation in response to these stimuli. In this study, we have investigated the effects of selenium, an integral component of glutathione peroxidase (GPX), on NF-kappa B activation. In selenium-deprived Jurkat and ESb-L T lymphocytes, supplementation of selenium led to a substantial increase of GPX activity. Analysis of DNA binding revealed that NF-kappa B activation in response to TNF was significantly inhibited under these conditions. Likewise, reporter gene assays using luciferase constructs driven by the HIV-1 long terminal repeat showed a dose-dependent inhibition of NF-kappa B controlled gene expression by selenium. The effects of selenium were specific for NF-kappa B, since the activity of the transcription factor AP-1 was not suppressed. These data suggest that selenium supplementation may be used to modulate the expression of NF-kappa B target genes and HIV-1.
[ "Selenium", "-", "mediated", "inhibition", "of", "transcription", "factor", "NF", "-", "kappa", "B", "and", "HIV-1", "LTR", "promoter", "activity", ".", "\n", "The", "eukaryotic", "transcription", "factor", "NF", "-", "kappa", "B", "is", "involved", "in", "the", "inducible", "expression", "of", "various", "inflammatory", "genes", "as", "well", "as", "in", "HIV-1", "replication", ".", "Activation", "of", "NF", "-", "kappa", "B", "is", "induced", "by", "prooxidants", "and", "several", "stimuli", "eliciting", "oxidative", "stress", ",", "such", "as", "cytokines", ",", "lipopolysaccharide", ",", "UV", "irradiation", "and", "other", "mediators", ".", "Various", "antioxidants", "inhibit", "NF", "-", "kappa", "B", "activation", "in", "response", "to", "these", "stimuli", ".", "In", "this", "study", ",", "we", "have", "investigated", "the", "effects", "of", "selenium", ",", "an", "integral", "component", "of", "glutathione", "peroxidase", "(", "GPX", ")", ",", "on", "NF", "-", "kappa", "B", "activation", ".", "In", "selenium", "-", "deprived", "Jurkat", "and", "ESb", "-", "L", "T", "lymphocytes", ",", "supplementation", "of", "selenium", "led", "to", "a", "substantial", "increase", "of", "GPX", "activity", ".", "Analysis", "of", "DNA", "binding", "revealed", "that", "NF", "-", "kappa", "B", "activation", "in", "response", "to", "TNF", "was", "significantly", "inhibited", "under", "these", "conditions", ".", "Likewise", ",", "reporter", "gene", "assays", "using", "luciferase", "constructs", "driven", "by", "the", "HIV-1", "long", "terminal", "repeat", "showed", "a", "dose", "-", "dependent", "inhibition", "of", "NF", "-", "kappa", "B", "controlled", "gene", "expression", "by", "selenium", ".", "The", "effects", "of", "selenium", "were", "specific", "for", "NF", "-", "kappa", "B", ",", "since", "the", "activity", "of", "the", "transcription", "factor", "AP-1", "was", "not", "suppressed", ".", "These", "data", "suggest", "that", "selenium", "supplementation", "may", "be", "used", "to", "modulate", "the", "expression", "of", "NF", "-", "kappa", "B", "target", "genes", "and", "HIV-1", "." ]
[ "Protein" ]
adenosine is a compound, ecto - apyrase is a protein, CD39 is a protein, ecto-5'-nucleotidase is a protein
DS.d1513_task0
Sentence: The main source of extracellular adenosine stems from a coordinated two-step enzymatic conversion of precursor nucleotides via the ecto-apyrase (CD39) and the ecto-5'-nucleotidase (CD73). Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein
[ "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "O", "B-protein", "O", "O", "O", "B-protein", "O", "O", "O", "O" ]
The main source of extracellular adenosine stems from a coordinated two-step enzymatic conversion of precursor nucleotides via the ecto-apyrase (CD39) and the ecto-5'-nucleotidase (CD73).
[ "The", "main", "source", "of", "extracellular", "adenosine", "stems", "from", "a", "coordinated", "two", "-", "step", "enzymatic", "conversion", "of", "precursor", "nucleotides", "via", "the", "ecto", "-", "apyrase", "(", "CD39", ")", "and", "the", "ecto-5'-nucleotidase", "(", "CD73", ")", "." ]
[ "protein", "compound" ]
adenosine is a compound, ecto - apyrase is a protein, CD39 is a protein, ecto-5'-nucleotidase is a protein
DS.d1513_task1
Sentence: The main source of extracellular adenosine stems from a coordinated two-step enzymatic conversion of precursor nucleotides via the ecto-apyrase (CD39) and the ecto-5'-nucleotidase (CD73). Instructions: please typing these entity words according to sentence: adenosine, ecto - apyrase, CD39, ecto-5'-nucleotidase Options: compound, protein
[ "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "O", "B-protein", "O", "O", "O", "B-protein", "O", "O", "O", "O" ]
The main source of extracellular adenosine stems from a coordinated two-step enzymatic conversion of precursor nucleotides via the ecto-apyrase (CD39) and the ecto-5'-nucleotidase (CD73).
[ "The", "main", "source", "of", "extracellular", "adenosine", "stems", "from", "a", "coordinated", "two", "-", "step", "enzymatic", "conversion", "of", "precursor", "nucleotides", "via", "the", "ecto", "-", "apyrase", "(", "CD39", ")", "and", "the", "ecto-5'-nucleotidase", "(", "CD73", ")", "." ]
[ "protein", "compound" ]
adenosine, ecto - apyrase, CD39, ecto-5'-nucleotidase
DS.d1513_task2
Sentence: The main source of extracellular adenosine stems from a coordinated two-step enzymatic conversion of precursor nucleotides via the ecto-apyrase (CD39) and the ecto-5'-nucleotidase (CD73). Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "O", "B-protein", "O", "O", "O", "B-protein", "O", "O", "O", "O" ]
The main source of extracellular adenosine stems from a coordinated two-step enzymatic conversion of precursor nucleotides via the ecto-apyrase (CD39) and the ecto-5'-nucleotidase (CD73).
[ "The", "main", "source", "of", "extracellular", "adenosine", "stems", "from", "a", "coordinated", "two", "-", "step", "enzymatic", "conversion", "of", "precursor", "nucleotides", "via", "the", "ecto", "-", "apyrase", "(", "CD39", ")", "and", "the", "ecto-5'-nucleotidase", "(", "CD73", ")", "." ]
[ "protein", "compound" ]
operation is an umlsterm, procedure is an umlsterm, open is an umlsterm, tissue repair is an umlsterm, inguinal hernias is an umlsterm, operation is an umlsterm, surgeon 's is an umlsterm, procedure is an umlsterm, time is an umlsterm, repairs is an umlsterm, repair is an umlsterm, set is an umlsterm, standards is an umlsterm, techniques is an umlsterm, technique is an umlsterm, safety is an umlsterm, use is an umlsterm, local anaesthesia is an umlsterm, postoperative complications is an umlsterm, cost is an umlsterm, surgical is an umlsterm, techniques is an umlsterm
DerChirurg.70680965.eng.abstr_task0
Sentence: The Shouldice operation has evolved to become the classic procedure for open pure tissue repair for inguinal hernias . The operation is an important part of a surgeon's repertoire as he may need to perform the procedure at some critical time , especially when faced with strangulation , when tension-free prosthetic repairs and laparoscopic approaches fail . When properly done , the Shouldice repair yields results that have set standards for all other techniques to emulate . Other particular advantages of the technique are : safety , the use of local anaesthesia , benign postoperative complications and the cost , which is the most reasonable of all surgical techniques . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O" ]
The Shouldice operation has evolved to become the classic procedure for open pure tissue repair for inguinal hernias . The operation is an important part of a surgeon's repertoire as he may need to perform the procedure at some critical time , especially when faced with strangulation , when tension-free prosthetic repairs and laparoscopic approaches fail . When properly done , the Shouldice repair yields results that have set standards for all other techniques to emulate . Other particular advantages of the technique are : safety , the use of local anaesthesia , benign postoperative complications and the cost , which is the most reasonable of all surgical techniques .
[ "The", "Shouldice", "operation", "has", "evolved", "to", "become", "the", "classic", "procedure", "for", "open", "pure", "tissue", "repair", "for", "inguinal", "hernias", ".", "The", "operation", "is", "an", "important", "part", "of", "a", "surgeon", "'s", "repertoire", "as", "he", "may", "need", "to", "perform", "the", "procedure", "at", "some", "critical", "time", ",", "especially", "when", "faced", "with", "strangulation", ",", "when", "tension", "-", "free", "prosthetic", "repairs", "and", "laparoscopic", "approaches", "fail", ".", "When", "properly", "done", ",", "the", "Shouldice", "repair", "yields", "results", "that", "have", "set", "standards", "for", "all", "other", "techniques", "to", "emulate", ".", "Other", "particular", "advantages", "of", "the", "technique", "are", ":", "safety", ",", "the", "use", "of", "local", "anaesthesia", ",", "benign", "postoperative", "complications", "and", "the", "cost", ",", "which", "is", "the", "most", "reasonable", "of", "all", "surgical", "techniques", "." ]
[ "umlsterm" ]
operation is an umlsterm, procedure is an umlsterm, open is an umlsterm, tissue repair is an umlsterm, inguinal hernias is an umlsterm, operation is an umlsterm, surgeon 's is an umlsterm, procedure is an umlsterm, time is an umlsterm, repairs is an umlsterm, repair is an umlsterm, set is an umlsterm, standards is an umlsterm, techniques is an umlsterm, technique is an umlsterm, safety is an umlsterm, use is an umlsterm, local anaesthesia is an umlsterm, postoperative complications is an umlsterm, cost is an umlsterm, surgical is an umlsterm, techniques is an umlsterm
DerChirurg.70680965.eng.abstr_task1
Sentence: The Shouldice operation has evolved to become the classic procedure for open pure tissue repair for inguinal hernias . The operation is an important part of a surgeon's repertoire as he may need to perform the procedure at some critical time , especially when faced with strangulation , when tension-free prosthetic repairs and laparoscopic approaches fail . When properly done , the Shouldice repair yields results that have set standards for all other techniques to emulate . Other particular advantages of the technique are : safety , the use of local anaesthesia , benign postoperative complications and the cost , which is the most reasonable of all surgical techniques . Instructions: please typing these entity words according to sentence: operation, procedure, open, tissue repair, inguinal hernias, operation, surgeon 's, procedure, time, repairs, repair, set, standards, techniques, technique, safety, use, local anaesthesia, postoperative complications, cost, surgical, techniques Options: umlsterm
[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O" ]
The Shouldice operation has evolved to become the classic procedure for open pure tissue repair for inguinal hernias . The operation is an important part of a surgeon's repertoire as he may need to perform the procedure at some critical time , especially when faced with strangulation , when tension-free prosthetic repairs and laparoscopic approaches fail . When properly done , the Shouldice repair yields results that have set standards for all other techniques to emulate . Other particular advantages of the technique are : safety , the use of local anaesthesia , benign postoperative complications and the cost , which is the most reasonable of all surgical techniques .
[ "The", "Shouldice", "operation", "has", "evolved", "to", "become", "the", "classic", "procedure", "for", "open", "pure", "tissue", "repair", "for", "inguinal", "hernias", ".", "The", "operation", "is", "an", "important", "part", "of", "a", "surgeon", "'s", "repertoire", "as", "he", "may", "need", "to", "perform", "the", "procedure", "at", "some", "critical", "time", ",", "especially", "when", "faced", "with", "strangulation", ",", "when", "tension", "-", "free", "prosthetic", "repairs", "and", "laparoscopic", "approaches", "fail", ".", "When", "properly", "done", ",", "the", "Shouldice", "repair", "yields", "results", "that", "have", "set", "standards", "for", "all", "other", "techniques", "to", "emulate", ".", "Other", "particular", "advantages", "of", "the", "technique", "are", ":", "safety", ",", "the", "use", "of", "local", "anaesthesia", ",", "benign", "postoperative", "complications", "and", "the", "cost", ",", "which", "is", "the", "most", "reasonable", "of", "all", "surgical", "techniques", "." ]
[ "umlsterm" ]
operation, procedure, open, tissue repair, inguinal hernias, operation, surgeon 's, procedure, time, repairs, repair, set, standards, techniques, technique, safety, use, local anaesthesia, postoperative complications, cost, surgical, techniques
DerChirurg.70680965.eng.abstr_task2
Sentence: The Shouldice operation has evolved to become the classic procedure for open pure tissue repair for inguinal hernias . The operation is an important part of a surgeon's repertoire as he may need to perform the procedure at some critical time , especially when faced with strangulation , when tension-free prosthetic repairs and laparoscopic approaches fail . When properly done , the Shouldice repair yields results that have set standards for all other techniques to emulate . Other particular advantages of the technique are : safety , the use of local anaesthesia , benign postoperative complications and the cost , which is the most reasonable of all surgical techniques . Instructions: please extract entity words from the input sentence
[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O" ]
The Shouldice operation has evolved to become the classic procedure for open pure tissue repair for inguinal hernias . The operation is an important part of a surgeon's repertoire as he may need to perform the procedure at some critical time , especially when faced with strangulation , when tension-free prosthetic repairs and laparoscopic approaches fail . When properly done , the Shouldice repair yields results that have set standards for all other techniques to emulate . Other particular advantages of the technique are : safety , the use of local anaesthesia , benign postoperative complications and the cost , which is the most reasonable of all surgical techniques .
[ "The", "Shouldice", "operation", "has", "evolved", "to", "become", "the", "classic", "procedure", "for", "open", "pure", "tissue", "repair", "for", "inguinal", "hernias", ".", "The", "operation", "is", "an", "important", "part", "of", "a", "surgeon", "'s", "repertoire", "as", "he", "may", "need", "to", "perform", "the", "procedure", "at", "some", "critical", "time", ",", "especially", "when", "faced", "with", "strangulation", ",", "when", "tension", "-", "free", "prosthetic", "repairs", "and", "laparoscopic", "approaches", "fail", ".", "When", "properly", "done", ",", "the", "Shouldice", "repair", "yields", "results", "that", "have", "set", "standards", "for", "all", "other", "techniques", "to", "emulate", ".", "Other", "particular", "advantages", "of", "the", "technique", "are", ":", "safety", ",", "the", "use", "of", "local", "anaesthesia", ",", "benign", "postoperative", "complications", "and", "the", "cost", ",", "which", "is", "the", "most", "reasonable", "of", "all", "surgical", "techniques", "." ]
[ "umlsterm" ]
TCR stimulation is an other_name, Stat3 activation is an other_name, human T cells is a cell_type
33623_task0
Sentence: Cutting edge: TCR stimulation by antibody and bacterial superantigen induces Stat3 activation in human T cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: cell_type, other_name
[ "O", "O", "O", "B-other_name", "I-other_name", "O", "O", "O", "O", "O", "O", "B-other_name", "I-other_name", "O", "B-cell_type", "I-cell_type", "I-cell_type", "O" ]
Cutting edge: TCR stimulation by antibody and bacterial superantigen induces Stat3 activation in human T cells.
[ "Cutting", "edge", ":", "TCR", "stimulation", "by", "antibody", "and", "bacterial", "superantigen", "induces", "Stat3", "activation", "in", "human", "T", "cells", "." ]
[ "other_name", "cell_line", "(AND other_name other_name)", "polynucleotide", "DNA_domain_or_region", "protein_molecule", "cell_type", "", "amino_acid_monomer", "protein_complex", "protein_family_or_group" ]
TCR stimulation is an other_name, Stat3 activation is an other_name, human T cells is a cell_type
33623_task1
Sentence: Cutting edge: TCR stimulation by antibody and bacterial superantigen induces Stat3 activation in human T cells. Instructions: please typing these entity words according to sentence: TCR stimulation, Stat3 activation, human T cells Options: cell_type, other_name
[ "O", "O", "O", "B-other_name", "I-other_name", "O", "O", "O", "O", "O", "O", "B-other_name", "I-other_name", "O", "B-cell_type", "I-cell_type", "I-cell_type", "O" ]
Cutting edge: TCR stimulation by antibody and bacterial superantigen induces Stat3 activation in human T cells.
[ "Cutting", "edge", ":", "TCR", "stimulation", "by", "antibody", "and", "bacterial", "superantigen", "induces", "Stat3", "activation", "in", "human", "T", "cells", "." ]
[ "other_name", "cell_line", "(AND other_name other_name)", "polynucleotide", "DNA_domain_or_region", "protein_molecule", "cell_type", "", "amino_acid_monomer", "protein_complex", "protein_family_or_group" ]
TCR stimulation, Stat3 activation, human T cells
33623_task2
Sentence: Cutting edge: TCR stimulation by antibody and bacterial superantigen induces Stat3 activation in human T cells. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "B-other_name", "I-other_name", "O", "O", "O", "O", "O", "O", "B-other_name", "I-other_name", "O", "B-cell_type", "I-cell_type", "I-cell_type", "O" ]
Cutting edge: TCR stimulation by antibody and bacterial superantigen induces Stat3 activation in human T cells.
[ "Cutting", "edge", ":", "TCR", "stimulation", "by", "antibody", "and", "bacterial", "superantigen", "induces", "Stat3", "activation", "in", "human", "T", "cells", "." ]
[ "other_name", "cell_line", "(AND other_name other_name)", "polynucleotide", "DNA_domain_or_region", "protein_molecule", "cell_type", "", "amino_acid_monomer", "protein_complex", "protein_family_or_group" ]
S is a CHEMICAL, glutathione transferase P1 - 1 is a GENE-Y
23572520_task0
Sentence: S-nitrosation of glutathione transferase P1-1 is controlled by the conformation of a dynamic active-site helix. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL
[ "B-CHEMICAL", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
S-nitrosation of glutathione transferase P1-1 is controlled by the conformation of a dynamic active-site helix.
[ "S", "-", "nitrosation", "of", "glutathione", "transferase", "P1", "-", "1", "is", "controlled", "by", "the", "conformation", "of", "a", "dynamic", "active", "-", "site", "helix", "." ]
[ "GENE-Y", "GENE-N", "CHEMICAL" ]
S is a CHEMICAL, glutathione transferase P1 - 1 is a GENE-Y
23572520_task1
Sentence: S-nitrosation of glutathione transferase P1-1 is controlled by the conformation of a dynamic active-site helix. Instructions: please typing these entity words according to sentence: S, glutathione transferase P1 - 1 Options: GENE-Y, CHEMICAL
[ "B-CHEMICAL", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
S-nitrosation of glutathione transferase P1-1 is controlled by the conformation of a dynamic active-site helix.
[ "S", "-", "nitrosation", "of", "glutathione", "transferase", "P1", "-", "1", "is", "controlled", "by", "the", "conformation", "of", "a", "dynamic", "active", "-", "site", "helix", "." ]
[ "GENE-Y", "GENE-N", "CHEMICAL" ]
S, glutathione transferase P1 - 1
23572520_task2
Sentence: S-nitrosation of glutathione transferase P1-1 is controlled by the conformation of a dynamic active-site helix. Instructions: please extract entity words from the input sentence
[ "B-CHEMICAL", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
S-nitrosation of glutathione transferase P1-1 is controlled by the conformation of a dynamic active-site helix.
[ "S", "-", "nitrosation", "of", "glutathione", "transferase", "P1", "-", "1", "is", "controlled", "by", "the", "conformation", "of", "a", "dynamic", "active", "-", "site", "helix", "." ]
[ "GENE-Y", "GENE-N", "CHEMICAL" ]
Basisfraktur is an umlsterm, Mittelhandknochens is an umlsterm, Arthrose is an umlsterm, Daumensattelgelenks is an umlsterm, Therapie is an umlsterm, anatomiegerechte is an umlsterm, Wiederherstellung is an umlsterm, Gelenkflaeche is an umlsterm, Behandlung is an umlsterm, Kirschner - Draehte is an umlsterm, Basisfrakturen is an umlsterm, Mittelhandknochen is an umlsterm, Gelenkbeteiligung is an umlsterm, anatomiegerechte is an umlsterm, Wiederherstellung is an umlsterm, Gelenkflaeche is an umlsterm, Kirschner - Draehte is an umlsterm, Arthrose is an umlsterm, Arthrodese is an umlsterm, Belastbarkeit is an umlsterm
Trauma+Berufskrankheit.0002s379.ger.abstr_task0
Sentence: Die in Fehlstellung verheilte intraartikulaere Basisfraktur des 1. Mittelhandknochens fuehrt zur Arthrose des Daumensattelgelenks mit erheblicher funktioneller Beeintraechtigung . Fuer die Therapie ist eine anatomiegerechte Wiederherstellung der Gelenkflaeche zu fordern . Im Regelfall ist hierzu die operative Behandlung erforderlich . Zur Stabilisierung werden Kirschner-Draehte oder , unter guenstigen Voraussetzungen , eine Schrauben- oder Plattenosteosynthese verwendet . Die Stabilitaet der Osteosynthese kann durch eine zusaetzliche Drahtfixation des 1. Strahls verbessert werden . Auch an den Langfingerstrahlen erfordern die hier selteneren Basisfrakturen der Mittelhandknochen mit Gelenkbeteiligung die anatomiegerechte Wiederherstellung der Gelenkflaeche . Zur Osteosynthese werden in der Regel Kirschner-Draehte , evtl. in Verbindung mit einer Transfixation , verwendet . Bei posttraumatischer Arthrose ermoeglicht hier die Arthrodese eine schmerzfreie Belastbarkeit ohne wesentlichen Funktionsverlust . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]
Die in Fehlstellung verheilte intraartikulaere Basisfraktur des 1. Mittelhandknochens fuehrt zur Arthrose des Daumensattelgelenks mit erheblicher funktioneller Beeintraechtigung . Fuer die Therapie ist eine anatomiegerechte Wiederherstellung der Gelenkflaeche zu fordern . Im Regelfall ist hierzu die operative Behandlung erforderlich . Zur Stabilisierung werden Kirschner-Draehte oder , unter guenstigen Voraussetzungen , eine Schrauben- oder Plattenosteosynthese verwendet . Die Stabilitaet der Osteosynthese kann durch eine zusaetzliche Drahtfixation des 1. Strahls verbessert werden . Auch an den Langfingerstrahlen erfordern die hier selteneren Basisfrakturen der Mittelhandknochen mit Gelenkbeteiligung die anatomiegerechte Wiederherstellung der Gelenkflaeche . Zur Osteosynthese werden in der Regel Kirschner-Draehte , evtl. in Verbindung mit einer Transfixation , verwendet . Bei posttraumatischer Arthrose ermoeglicht hier die Arthrodese eine schmerzfreie Belastbarkeit ohne wesentlichen Funktionsverlust .
[ "Die", "in", "Fehlstellung", "verheilte", "intraartikulaere", "Basisfraktur", "des", "1", ".", "Mittelhandknochens", "fuehrt", "zur", "Arthrose", "des", "Daumensattelgelenks", "mit", "erheblicher", "funktioneller", "Beeintraechtigung", ".", "Fuer", "die", "Therapie", "ist", "eine", "anatomiegerechte", "Wiederherstellung", "der", "Gelenkflaeche", "zu", "fordern", ".", "Im", "Regelfall", "ist", "hierzu", "die", "operative", "Behandlung", "erforderlich", ".", "Zur", "Stabilisierung", "werden", "Kirschner", "-", "Draehte", "oder", ",", "unter", "guenstigen", "Voraussetzungen", ",", "eine", "Schrauben-", "oder", "Plattenosteosynthese", "verwendet", ".", "Die", "Stabilitaet", "der", "Osteosynthese", "kann", "durch", "eine", "zusaetzliche", "Drahtfixation", "des", "1", ".", "Strahls", "verbessert", "werden", ".", "Auch", "an", "den", "Langfingerstrahlen", "erfordern", "die", "hier", "selteneren", "Basisfrakturen", "der", "Mittelhandknochen", "mit", "Gelenkbeteiligung", "die", "anatomiegerechte", "Wiederherstellung", "der", "Gelenkflaeche", ".", "Zur", "Osteosynthese", "werden", "in", "der", "Regel", "Kirschner", "-", "Draehte", ",", "evtl", ".", "in", "Verbindung", "mit", "einer", "Transfixation", ",", "verwendet", ".", "Bei", "posttraumatischer", "Arthrose", "ermoeglicht", "hier", "die", "Arthrodese", "eine", "schmerzfreie", "Belastbarkeit", "ohne", "wesentlichen", "Funktionsverlust", "." ]
[ "umlsterm" ]
Basisfraktur is an umlsterm, Mittelhandknochens is an umlsterm, Arthrose is an umlsterm, Daumensattelgelenks is an umlsterm, Therapie is an umlsterm, anatomiegerechte is an umlsterm, Wiederherstellung is an umlsterm, Gelenkflaeche is an umlsterm, Behandlung is an umlsterm, Kirschner - Draehte is an umlsterm, Basisfrakturen is an umlsterm, Mittelhandknochen is an umlsterm, Gelenkbeteiligung is an umlsterm, anatomiegerechte is an umlsterm, Wiederherstellung is an umlsterm, Gelenkflaeche is an umlsterm, Kirschner - Draehte is an umlsterm, Arthrose is an umlsterm, Arthrodese is an umlsterm, Belastbarkeit is an umlsterm
Trauma+Berufskrankheit.0002s379.ger.abstr_task1
Sentence: Die in Fehlstellung verheilte intraartikulaere Basisfraktur des 1. Mittelhandknochens fuehrt zur Arthrose des Daumensattelgelenks mit erheblicher funktioneller Beeintraechtigung . Fuer die Therapie ist eine anatomiegerechte Wiederherstellung der Gelenkflaeche zu fordern . Im Regelfall ist hierzu die operative Behandlung erforderlich . Zur Stabilisierung werden Kirschner-Draehte oder , unter guenstigen Voraussetzungen , eine Schrauben- oder Plattenosteosynthese verwendet . Die Stabilitaet der Osteosynthese kann durch eine zusaetzliche Drahtfixation des 1. Strahls verbessert werden . Auch an den Langfingerstrahlen erfordern die hier selteneren Basisfrakturen der Mittelhandknochen mit Gelenkbeteiligung die anatomiegerechte Wiederherstellung der Gelenkflaeche . Zur Osteosynthese werden in der Regel Kirschner-Draehte , evtl. in Verbindung mit einer Transfixation , verwendet . Bei posttraumatischer Arthrose ermoeglicht hier die Arthrodese eine schmerzfreie Belastbarkeit ohne wesentlichen Funktionsverlust . Instructions: please typing these entity words according to sentence: Basisfraktur, Mittelhandknochens, Arthrose, Daumensattelgelenks, Therapie, anatomiegerechte, Wiederherstellung, Gelenkflaeche, Behandlung, Kirschner - Draehte, Basisfrakturen, Mittelhandknochen, Gelenkbeteiligung, anatomiegerechte, Wiederherstellung, Gelenkflaeche, Kirschner - Draehte, Arthrose, Arthrodese, Belastbarkeit Options: umlsterm
[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]
Die in Fehlstellung verheilte intraartikulaere Basisfraktur des 1. Mittelhandknochens fuehrt zur Arthrose des Daumensattelgelenks mit erheblicher funktioneller Beeintraechtigung . Fuer die Therapie ist eine anatomiegerechte Wiederherstellung der Gelenkflaeche zu fordern . Im Regelfall ist hierzu die operative Behandlung erforderlich . Zur Stabilisierung werden Kirschner-Draehte oder , unter guenstigen Voraussetzungen , eine Schrauben- oder Plattenosteosynthese verwendet . Die Stabilitaet der Osteosynthese kann durch eine zusaetzliche Drahtfixation des 1. Strahls verbessert werden . Auch an den Langfingerstrahlen erfordern die hier selteneren Basisfrakturen der Mittelhandknochen mit Gelenkbeteiligung die anatomiegerechte Wiederherstellung der Gelenkflaeche . Zur Osteosynthese werden in der Regel Kirschner-Draehte , evtl. in Verbindung mit einer Transfixation , verwendet . Bei posttraumatischer Arthrose ermoeglicht hier die Arthrodese eine schmerzfreie Belastbarkeit ohne wesentlichen Funktionsverlust .
[ "Die", "in", "Fehlstellung", "verheilte", "intraartikulaere", "Basisfraktur", "des", "1", ".", "Mittelhandknochens", "fuehrt", "zur", "Arthrose", "des", "Daumensattelgelenks", "mit", "erheblicher", "funktioneller", "Beeintraechtigung", ".", "Fuer", "die", "Therapie", "ist", "eine", "anatomiegerechte", "Wiederherstellung", "der", "Gelenkflaeche", "zu", "fordern", ".", "Im", "Regelfall", "ist", "hierzu", "die", "operative", "Behandlung", "erforderlich", ".", "Zur", "Stabilisierung", "werden", "Kirschner", "-", "Draehte", "oder", ",", "unter", "guenstigen", "Voraussetzungen", ",", "eine", "Schrauben-", "oder", "Plattenosteosynthese", "verwendet", ".", "Die", "Stabilitaet", "der", "Osteosynthese", "kann", "durch", "eine", "zusaetzliche", "Drahtfixation", "des", "1", ".", "Strahls", "verbessert", "werden", ".", "Auch", "an", "den", "Langfingerstrahlen", "erfordern", "die", "hier", "selteneren", "Basisfrakturen", "der", "Mittelhandknochen", "mit", "Gelenkbeteiligung", "die", "anatomiegerechte", "Wiederherstellung", "der", "Gelenkflaeche", ".", "Zur", "Osteosynthese", "werden", "in", "der", "Regel", "Kirschner", "-", "Draehte", ",", "evtl", ".", "in", "Verbindung", "mit", "einer", "Transfixation", ",", "verwendet", ".", "Bei", "posttraumatischer", "Arthrose", "ermoeglicht", "hier", "die", "Arthrodese", "eine", "schmerzfreie", "Belastbarkeit", "ohne", "wesentlichen", "Funktionsverlust", "." ]
[ "umlsterm" ]
Basisfraktur, Mittelhandknochens, Arthrose, Daumensattelgelenks, Therapie, anatomiegerechte, Wiederherstellung, Gelenkflaeche, Behandlung, Kirschner - Draehte, Basisfrakturen, Mittelhandknochen, Gelenkbeteiligung, anatomiegerechte, Wiederherstellung, Gelenkflaeche, Kirschner - Draehte, Arthrose, Arthrodese, Belastbarkeit
Trauma+Berufskrankheit.0002s379.ger.abstr_task2
Sentence: Die in Fehlstellung verheilte intraartikulaere Basisfraktur des 1. Mittelhandknochens fuehrt zur Arthrose des Daumensattelgelenks mit erheblicher funktioneller Beeintraechtigung . Fuer die Therapie ist eine anatomiegerechte Wiederherstellung der Gelenkflaeche zu fordern . Im Regelfall ist hierzu die operative Behandlung erforderlich . Zur Stabilisierung werden Kirschner-Draehte oder , unter guenstigen Voraussetzungen , eine Schrauben- oder Plattenosteosynthese verwendet . Die Stabilitaet der Osteosynthese kann durch eine zusaetzliche Drahtfixation des 1. Strahls verbessert werden . Auch an den Langfingerstrahlen erfordern die hier selteneren Basisfrakturen der Mittelhandknochen mit Gelenkbeteiligung die anatomiegerechte Wiederherstellung der Gelenkflaeche . Zur Osteosynthese werden in der Regel Kirschner-Draehte , evtl. in Verbindung mit einer Transfixation , verwendet . Bei posttraumatischer Arthrose ermoeglicht hier die Arthrodese eine schmerzfreie Belastbarkeit ohne wesentlichen Funktionsverlust . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]
Die in Fehlstellung verheilte intraartikulaere Basisfraktur des 1. Mittelhandknochens fuehrt zur Arthrose des Daumensattelgelenks mit erheblicher funktioneller Beeintraechtigung . Fuer die Therapie ist eine anatomiegerechte Wiederherstellung der Gelenkflaeche zu fordern . Im Regelfall ist hierzu die operative Behandlung erforderlich . Zur Stabilisierung werden Kirschner-Draehte oder , unter guenstigen Voraussetzungen , eine Schrauben- oder Plattenosteosynthese verwendet . Die Stabilitaet der Osteosynthese kann durch eine zusaetzliche Drahtfixation des 1. Strahls verbessert werden . Auch an den Langfingerstrahlen erfordern die hier selteneren Basisfrakturen der Mittelhandknochen mit Gelenkbeteiligung die anatomiegerechte Wiederherstellung der Gelenkflaeche . Zur Osteosynthese werden in der Regel Kirschner-Draehte , evtl. in Verbindung mit einer Transfixation , verwendet . Bei posttraumatischer Arthrose ermoeglicht hier die Arthrodese eine schmerzfreie Belastbarkeit ohne wesentlichen Funktionsverlust .
[ "Die", "in", "Fehlstellung", "verheilte", "intraartikulaere", "Basisfraktur", "des", "1", ".", "Mittelhandknochens", "fuehrt", "zur", "Arthrose", "des", "Daumensattelgelenks", "mit", "erheblicher", "funktioneller", "Beeintraechtigung", ".", "Fuer", "die", "Therapie", "ist", "eine", "anatomiegerechte", "Wiederherstellung", "der", "Gelenkflaeche", "zu", "fordern", ".", "Im", "Regelfall", "ist", "hierzu", "die", "operative", "Behandlung", "erforderlich", ".", "Zur", "Stabilisierung", "werden", "Kirschner", "-", "Draehte", "oder", ",", "unter", "guenstigen", "Voraussetzungen", ",", "eine", "Schrauben-", "oder", "Plattenosteosynthese", "verwendet", ".", "Die", "Stabilitaet", "der", "Osteosynthese", "kann", "durch", "eine", "zusaetzliche", "Drahtfixation", "des", "1", ".", "Strahls", "verbessert", "werden", ".", "Auch", "an", "den", "Langfingerstrahlen", "erfordern", "die", "hier", "selteneren", "Basisfrakturen", "der", "Mittelhandknochen", "mit", "Gelenkbeteiligung", "die", "anatomiegerechte", "Wiederherstellung", "der", "Gelenkflaeche", ".", "Zur", "Osteosynthese", "werden", "in", "der", "Regel", "Kirschner", "-", "Draehte", ",", "evtl", ".", "in", "Verbindung", "mit", "einer", "Transfixation", ",", "verwendet", ".", "Bei", "posttraumatischer", "Arthrose", "ermoeglicht", "hier", "die", "Arthrodese", "eine", "schmerzfreie", "Belastbarkeit", "ohne", "wesentlichen", "Funktionsverlust", "." ]
[ "umlsterm" ]
Analgesic efficacy is a Outcome_Other, piroxicam is a Intervention_Pharmacological, postoperative pain . is a Outcome_Pain, analgesic efficacy and safety is a Outcome_Other, moderate or severe postoperative pain . is a Outcome_Pain, codeine sulfate is a Intervention_Pharmacological, placebo is a Intervention_Control, pain intensity and pain relief is a Outcome_Pain, Piroxicam is a Intervention_Pharmacological, efficacious is a Outcome_Other, sum of the pain intensity differences ( SPID ) , total pain relief ( TOTAL ) is a Outcome_Pain, percent SPID is a Outcome_Pain, duration of effect is a Outcome_Other, time to remedication is a Outcome_Other, Codeine is a Intervention_Pharmacological, hourly measures is a Outcome_Other, effective is a Outcome_Other, aspirin is a Intervention_Pharmacological, pain intensity and relief is a Outcome_Pain, pain intensity difference ( PID ) and relief scores is a Outcome_Pain, longer duration is a Outcome_Other, longer time to remedication is a Outcome_Other, duration of analgesic efficacy is a Outcome_Other
75275_task0
Sentence: Analgesic efficacy of piroxicam in the treatment of postoperative pain . Two randomized , double-blind , single-dose studies were conducted to assess the analgesic efficacy and safety of piroxicam for the treatment of moderate or severe postoperative pain . Study 1 evaluated the analgesic efficacy of piroxicam 20 mg compared with that of codeine sulfate 60 mg and placebo . A final patient population of 149 subjects rated pain intensity and pain relief at one half hour and one hour following treatment and then hourly for six hours , with a global assessment made at the completion of 24 hours . Piroxicam 20 mg was significantly more efficacious than placebo for all analgesic variables , including the sum of the pain intensity differences ( SPID ) , total pain relief ( TOTAL ) , percent SPID , duration of effect , and time to remedication . Codeine 60 mg was significantly superior to placebo for percent SPID and some hourly measures . Piroxicam 20 mg was significantly more effective than codeine 60 mg for percent SPID and a few hourly measures including time to remedication . Study 2 assessed the efficacy of piroxicam 20 mg or 40 mg compared with aspirin 648 mg and placebo . Sixty patients rated their pain intensity and relief hourly for 12 hours and at 24 hours after administration of study medication . Both doses of piroxicam were significantly more effective than placebo from Hours 2 to 12 for pain intensity difference ( PID ) and relief scores , as well as for SPID and TOTAL . Aspirin was significantly more effective than placebo from Hours 2 to 8 for relief and Hours 2 to 10 for PID as well as SPID and TOTAL . Piroxicam 40 mg was significantly more effective than aspirin 648 mg for SPID , TOTAL , and hourly measures beginning with Hour 6 through Hour 12 . Piroxicam 20 mg was significantly better than aspirin for a few hourly measures : Hours 7 to 9 for relief and Hour 7 for PID . In addition , effects of piroxicam 20 mg had a significantly longer duration than aspirin . Similarly , piroxicam 20 mg had a significantly longer time to remedication compared with aspirin and placebo . The results of these studies provide evidence in support of the longer duration of analgesic efficacy of piroxicam compared with codeine or aspirin in patients with postoperative pain . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Outcome_Other, Intervention_Pharmacological, Outcome_Pain, Intervention_Control
[ "B-Outcome_Other", "I-Outcome_Other", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "B-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "B-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "O", "B-Outcome_Pain", "I-Outcome_Pain", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Analgesic efficacy of piroxicam in the treatment of postoperative pain . Two randomized , double-blind , single-dose studies were conducted to assess the analgesic efficacy and safety of piroxicam for the treatment of moderate or severe postoperative pain . Study 1 evaluated the analgesic efficacy of piroxicam 20 mg compared with that of codeine sulfate 60 mg and placebo . A final patient population of 149 subjects rated pain intensity and pain relief at one half hour and one hour following treatment and then hourly for six hours , with a global assessment made at the completion of 24 hours . Piroxicam 20 mg was significantly more efficacious than placebo for all analgesic variables , including the sum of the pain intensity differences ( SPID ) , total pain relief ( TOTAL ) , percent SPID , duration of effect , and time to remedication . Codeine 60 mg was significantly superior to placebo for percent SPID and some hourly measures . Piroxicam 20 mg was significantly more effective than codeine 60 mg for percent SPID and a few hourly measures including time to remedication . Study 2 assessed the efficacy of piroxicam 20 mg or 40 mg compared with aspirin 648 mg and placebo . Sixty patients rated their pain intensity and relief hourly for 12 hours and at 24 hours after administration of study medication . Both doses of piroxicam were significantly more effective than placebo from Hours 2 to 12 for pain intensity difference ( PID ) and relief scores , as well as for SPID and TOTAL . Aspirin was significantly more effective than placebo from Hours 2 to 8 for relief and Hours 2 to 10 for PID as well as SPID and TOTAL . Piroxicam 40 mg was significantly more effective than aspirin 648 mg for SPID , TOTAL , and hourly measures beginning with Hour 6 through Hour 12 . Piroxicam 20 mg was significantly better than aspirin for a few hourly measures : Hours 7 to 9 for relief and Hour 7 for PID . In addition , effects of piroxicam 20 mg had a significantly longer duration than aspirin . Similarly , piroxicam 20 mg had a significantly longer time to remedication compared with aspirin and placebo . The results of these studies provide evidence in support of the longer duration of analgesic efficacy of piroxicam compared with codeine or aspirin in patients with postoperative pain .
[ "Analgesic", "efficacy", "of", "piroxicam", "in", "the", "treatment", "of", "postoperative", "pain", ".", "Two", "randomized", ",", "double", "-", "blind", ",", "single", "-", "dose", "studies", "were", "conducted", "to", "assess", "the", "analgesic", "efficacy", "and", "safety", "of", "piroxicam", "for", "the", "treatment", "of", "moderate", "or", "severe", "postoperative", "pain", ".", "Study", "1", "evaluated", "the", "analgesic", "efficacy", "of", "piroxicam", "20", "mg", "compared", "with", "that", "of", "codeine", "sulfate", "60", "mg", "and", "placebo", ".", "A", "final", "patient", "population", "of", "149", "subjects", "rated", "pain", "intensity", "and", "pain", "relief", "at", "one", "half", "hour", "and", "one", "hour", "following", "treatment", "and", "then", "hourly", "for", "six", "hours", ",", "with", "a", "global", "assessment", "made", "at", "the", "completion", "of", "24", "hours", ".", "Piroxicam", "20", "mg", "was", "significantly", "more", "efficacious", "than", "placebo", "for", "all", "analgesic", "variables", ",", "including", "the", "sum", "of", "the", "pain", "intensity", "differences", "(", "SPID", ")", ",", "total", "pain", "relief", "(", "TOTAL", ")", ",", "percent", "SPID", ",", "duration", "of", "effect", ",", "and", "time", "to", "remedication", ".", "Codeine", "60", "mg", "was", "significantly", "superior", "to", "placebo", "for", "percent", "SPID", "and", "some", "hourly", "measures", ".", "Piroxicam", "20", "mg", "was", "significantly", "more", "effective", "than", "codeine", "60", "mg", "for", "percent", "SPID", "and", "a", "few", "hourly", "measures", "including", "time", "to", "remedication", ".", "Study", "2", "assessed", "the", "efficacy", "of", "piroxicam", "20", "mg", "or", "40", "mg", "compared", "with", "aspirin", "648", "mg", "and", "placebo", ".", "Sixty", "patients", "rated", "their", "pain", "intensity", "and", "relief", "hourly", "for", "12", "hours", "and", "at", "24", "hours", "after", "administration", "of", "study", "medication", ".", "Both", "doses", "of", "piroxicam", "were", "significantly", "more", "effective", "than", "placebo", "from", "Hours", "2", "to", "12", "for", "pain", "intensity", "difference", "(", "PID", ")", "and", "relief", "scores", ",", "as", "well", "as", "for", "SPID", "and", "TOTAL", ".", "Aspirin", "was", "significantly", "more", "effective", "than", "placebo", "from", "Hours", "2", "to", "8", "for", "relief", "and", "Hours", "2", "to", "10", "for", "PID", "as", "well", "as", "SPID", "and", "TOTAL", ".", "Piroxicam", "40", "mg", "was", "significantly", "more", "effective", "than", "aspirin", "648", "mg", "for", "SPID", ",", "TOTAL", ",", "and", "hourly", "measures", "beginning", "with", "Hour", "6", "through", "Hour", "12", ".", "Piroxicam", "20", "mg", "was", "significantly", "better", "than", "aspirin", "for", "a", "few", "hourly", "measures", ":", "Hours", "7", "to", "9", "for", "relief", "and", "Hour", "7", "for", "PID", ".", "In", "addition", ",", "effects", "of", "piroxicam", "20", "mg", "had", "a", "significantly", "longer", "duration", "than", "aspirin", ".", "Similarly", ",", "piroxicam", "20", "mg", "had", "a", "significantly", "longer", "time", "to", "remedication", "compared", "with", "aspirin", "and", "placebo", ".", "The", "results", "of", "these", "studies", "provide", "evidence", "in", "support", "of", "the", "longer", "duration", "of", "analgesic", "efficacy", "of", "piroxicam", "compared", "with", "codeine", "or", "aspirin", "in", "patients", "with", "postoperative", "pain", "." ]
[ "Outcome_Pain", "Outcome_Other", "Intervention_Pharmacological", "Intervention_Control" ]
Analgesic efficacy is a Outcome_Other, piroxicam is a Intervention_Pharmacological, postoperative pain . is a Outcome_Pain, analgesic efficacy and safety is a Outcome_Other, moderate or severe postoperative pain . is a Outcome_Pain, codeine sulfate is a Intervention_Pharmacological, placebo is a Intervention_Control, pain intensity and pain relief is a Outcome_Pain, Piroxicam is a Intervention_Pharmacological, efficacious is a Outcome_Other, sum of the pain intensity differences ( SPID ) , total pain relief ( TOTAL ) is a Outcome_Pain, percent SPID is a Outcome_Pain, duration of effect is a Outcome_Other, time to remedication is a Outcome_Other, Codeine is a Intervention_Pharmacological, hourly measures is a Outcome_Other, effective is a Outcome_Other, aspirin is a Intervention_Pharmacological, pain intensity and relief is a Outcome_Pain, pain intensity difference ( PID ) and relief scores is a Outcome_Pain, longer duration is a Outcome_Other, longer time to remedication is a Outcome_Other, duration of analgesic efficacy is a Outcome_Other
75275_task1
Sentence: Analgesic efficacy of piroxicam in the treatment of postoperative pain . Two randomized , double-blind , single-dose studies were conducted to assess the analgesic efficacy and safety of piroxicam for the treatment of moderate or severe postoperative pain . Study 1 evaluated the analgesic efficacy of piroxicam 20 mg compared with that of codeine sulfate 60 mg and placebo . A final patient population of 149 subjects rated pain intensity and pain relief at one half hour and one hour following treatment and then hourly for six hours , with a global assessment made at the completion of 24 hours . Piroxicam 20 mg was significantly more efficacious than placebo for all analgesic variables , including the sum of the pain intensity differences ( SPID ) , total pain relief ( TOTAL ) , percent SPID , duration of effect , and time to remedication . Codeine 60 mg was significantly superior to placebo for percent SPID and some hourly measures . Piroxicam 20 mg was significantly more effective than codeine 60 mg for percent SPID and a few hourly measures including time to remedication . Study 2 assessed the efficacy of piroxicam 20 mg or 40 mg compared with aspirin 648 mg and placebo . Sixty patients rated their pain intensity and relief hourly for 12 hours and at 24 hours after administration of study medication . Both doses of piroxicam were significantly more effective than placebo from Hours 2 to 12 for pain intensity difference ( PID ) and relief scores , as well as for SPID and TOTAL . Aspirin was significantly more effective than placebo from Hours 2 to 8 for relief and Hours 2 to 10 for PID as well as SPID and TOTAL . Piroxicam 40 mg was significantly more effective than aspirin 648 mg for SPID , TOTAL , and hourly measures beginning with Hour 6 through Hour 12 . Piroxicam 20 mg was significantly better than aspirin for a few hourly measures : Hours 7 to 9 for relief and Hour 7 for PID . In addition , effects of piroxicam 20 mg had a significantly longer duration than aspirin . Similarly , piroxicam 20 mg had a significantly longer time to remedication compared with aspirin and placebo . The results of these studies provide evidence in support of the longer duration of analgesic efficacy of piroxicam compared with codeine or aspirin in patients with postoperative pain . Instructions: please typing these entity words according to sentence: Analgesic efficacy, piroxicam, postoperative pain ., analgesic efficacy and safety, moderate or severe postoperative pain ., codeine sulfate, placebo, pain intensity and pain relief, Piroxicam, efficacious, sum of the pain intensity differences ( SPID ) , total pain relief ( TOTAL ), percent SPID, duration of effect, time to remedication, Codeine, hourly measures, effective, aspirin, pain intensity and relief, pain intensity difference ( PID ) and relief scores, longer duration, longer time to remedication, duration of analgesic efficacy Options: Outcome_Other, Intervention_Pharmacological, Outcome_Pain, Intervention_Control
[ "B-Outcome_Other", "I-Outcome_Other", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "B-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "B-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "O", "B-Outcome_Pain", "I-Outcome_Pain", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Analgesic efficacy of piroxicam in the treatment of postoperative pain . Two randomized , double-blind , single-dose studies were conducted to assess the analgesic efficacy and safety of piroxicam for the treatment of moderate or severe postoperative pain . Study 1 evaluated the analgesic efficacy of piroxicam 20 mg compared with that of codeine sulfate 60 mg and placebo . A final patient population of 149 subjects rated pain intensity and pain relief at one half hour and one hour following treatment and then hourly for six hours , with a global assessment made at the completion of 24 hours . Piroxicam 20 mg was significantly more efficacious than placebo for all analgesic variables , including the sum of the pain intensity differences ( SPID ) , total pain relief ( TOTAL ) , percent SPID , duration of effect , and time to remedication . Codeine 60 mg was significantly superior to placebo for percent SPID and some hourly measures . Piroxicam 20 mg was significantly more effective than codeine 60 mg for percent SPID and a few hourly measures including time to remedication . Study 2 assessed the efficacy of piroxicam 20 mg or 40 mg compared with aspirin 648 mg and placebo . Sixty patients rated their pain intensity and relief hourly for 12 hours and at 24 hours after administration of study medication . Both doses of piroxicam were significantly more effective than placebo from Hours 2 to 12 for pain intensity difference ( PID ) and relief scores , as well as for SPID and TOTAL . Aspirin was significantly more effective than placebo from Hours 2 to 8 for relief and Hours 2 to 10 for PID as well as SPID and TOTAL . Piroxicam 40 mg was significantly more effective than aspirin 648 mg for SPID , TOTAL , and hourly measures beginning with Hour 6 through Hour 12 . Piroxicam 20 mg was significantly better than aspirin for a few hourly measures : Hours 7 to 9 for relief and Hour 7 for PID . In addition , effects of piroxicam 20 mg had a significantly longer duration than aspirin . Similarly , piroxicam 20 mg had a significantly longer time to remedication compared with aspirin and placebo . The results of these studies provide evidence in support of the longer duration of analgesic efficacy of piroxicam compared with codeine or aspirin in patients with postoperative pain .
[ "Analgesic", "efficacy", "of", "piroxicam", "in", "the", "treatment", "of", "postoperative", "pain", ".", "Two", "randomized", ",", "double", "-", "blind", ",", "single", "-", "dose", "studies", "were", "conducted", "to", "assess", "the", "analgesic", "efficacy", "and", "safety", "of", "piroxicam", "for", "the", "treatment", "of", "moderate", "or", "severe", "postoperative", "pain", ".", "Study", "1", "evaluated", "the", "analgesic", "efficacy", "of", "piroxicam", "20", "mg", "compared", "with", "that", "of", "codeine", "sulfate", "60", "mg", "and", "placebo", ".", "A", "final", "patient", "population", "of", "149", "subjects", "rated", "pain", "intensity", "and", "pain", "relief", "at", "one", "half", "hour", "and", "one", "hour", "following", "treatment", "and", "then", "hourly", "for", "six", "hours", ",", "with", "a", "global", "assessment", "made", "at", "the", "completion", "of", "24", "hours", ".", "Piroxicam", "20", "mg", "was", "significantly", "more", "efficacious", "than", "placebo", "for", "all", "analgesic", "variables", ",", "including", "the", "sum", "of", "the", "pain", "intensity", "differences", "(", "SPID", ")", ",", "total", "pain", "relief", "(", "TOTAL", ")", ",", "percent", "SPID", ",", "duration", "of", "effect", ",", "and", "time", "to", "remedication", ".", "Codeine", "60", "mg", "was", "significantly", "superior", "to", "placebo", "for", "percent", "SPID", "and", "some", "hourly", "measures", ".", "Piroxicam", "20", "mg", "was", "significantly", "more", "effective", "than", "codeine", "60", "mg", "for", "percent", "SPID", "and", "a", "few", "hourly", "measures", "including", "time", "to", "remedication", ".", "Study", "2", "assessed", "the", "efficacy", "of", "piroxicam", "20", "mg", "or", "40", "mg", "compared", "with", "aspirin", "648", "mg", "and", "placebo", ".", "Sixty", "patients", "rated", "their", "pain", "intensity", "and", "relief", "hourly", "for", "12", "hours", "and", "at", "24", "hours", "after", "administration", "of", "study", "medication", ".", "Both", "doses", "of", "piroxicam", "were", "significantly", "more", "effective", "than", "placebo", "from", "Hours", "2", "to", "12", "for", "pain", "intensity", "difference", "(", "PID", ")", "and", "relief", "scores", ",", "as", "well", "as", "for", "SPID", "and", "TOTAL", ".", "Aspirin", "was", "significantly", "more", "effective", "than", "placebo", "from", "Hours", "2", "to", "8", "for", "relief", "and", "Hours", "2", "to", "10", "for", "PID", "as", "well", "as", "SPID", "and", "TOTAL", ".", "Piroxicam", "40", "mg", "was", "significantly", "more", "effective", "than", "aspirin", "648", "mg", "for", "SPID", ",", "TOTAL", ",", "and", "hourly", "measures", "beginning", "with", "Hour", "6", "through", "Hour", "12", ".", "Piroxicam", "20", "mg", "was", "significantly", "better", "than", "aspirin", "for", "a", "few", "hourly", "measures", ":", "Hours", "7", "to", "9", "for", "relief", "and", "Hour", "7", "for", "PID", ".", "In", "addition", ",", "effects", "of", "piroxicam", "20", "mg", "had", "a", "significantly", "longer", "duration", "than", "aspirin", ".", "Similarly", ",", "piroxicam", "20", "mg", "had", "a", "significantly", "longer", "time", "to", "remedication", "compared", "with", "aspirin", "and", "placebo", ".", "The", "results", "of", "these", "studies", "provide", "evidence", "in", "support", "of", "the", "longer", "duration", "of", "analgesic", "efficacy", "of", "piroxicam", "compared", "with", "codeine", "or", "aspirin", "in", "patients", "with", "postoperative", "pain", "." ]
[ "Outcome_Pain", "Outcome_Other", "Intervention_Pharmacological", "Intervention_Control" ]
Analgesic efficacy, piroxicam, postoperative pain ., analgesic efficacy and safety, moderate or severe postoperative pain ., codeine sulfate, placebo, pain intensity and pain relief, Piroxicam, efficacious, sum of the pain intensity differences ( SPID ) , total pain relief ( TOTAL ), percent SPID, duration of effect, time to remedication, Codeine, hourly measures, effective, aspirin, pain intensity and relief, pain intensity difference ( PID ) and relief scores, longer duration, longer time to remedication, duration of analgesic efficacy
75275_task2
Sentence: Analgesic efficacy of piroxicam in the treatment of postoperative pain . Two randomized , double-blind , single-dose studies were conducted to assess the analgesic efficacy and safety of piroxicam for the treatment of moderate or severe postoperative pain . Study 1 evaluated the analgesic efficacy of piroxicam 20 mg compared with that of codeine sulfate 60 mg and placebo . A final patient population of 149 subjects rated pain intensity and pain relief at one half hour and one hour following treatment and then hourly for six hours , with a global assessment made at the completion of 24 hours . Piroxicam 20 mg was significantly more efficacious than placebo for all analgesic variables , including the sum of the pain intensity differences ( SPID ) , total pain relief ( TOTAL ) , percent SPID , duration of effect , and time to remedication . Codeine 60 mg was significantly superior to placebo for percent SPID and some hourly measures . Piroxicam 20 mg was significantly more effective than codeine 60 mg for percent SPID and a few hourly measures including time to remedication . Study 2 assessed the efficacy of piroxicam 20 mg or 40 mg compared with aspirin 648 mg and placebo . Sixty patients rated their pain intensity and relief hourly for 12 hours and at 24 hours after administration of study medication . Both doses of piroxicam were significantly more effective than placebo from Hours 2 to 12 for pain intensity difference ( PID ) and relief scores , as well as for SPID and TOTAL . Aspirin was significantly more effective than placebo from Hours 2 to 8 for relief and Hours 2 to 10 for PID as well as SPID and TOTAL . Piroxicam 40 mg was significantly more effective than aspirin 648 mg for SPID , TOTAL , and hourly measures beginning with Hour 6 through Hour 12 . Piroxicam 20 mg was significantly better than aspirin for a few hourly measures : Hours 7 to 9 for relief and Hour 7 for PID . In addition , effects of piroxicam 20 mg had a significantly longer duration than aspirin . Similarly , piroxicam 20 mg had a significantly longer time to remedication compared with aspirin and placebo . The results of these studies provide evidence in support of the longer duration of analgesic efficacy of piroxicam compared with codeine or aspirin in patients with postoperative pain . Instructions: please extract entity words from the input sentence
[ "B-Outcome_Other", "I-Outcome_Other", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "B-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "B-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "O", "B-Outcome_Pain", "I-Outcome_Pain", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "I-Outcome_Pain", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Analgesic efficacy of piroxicam in the treatment of postoperative pain . Two randomized , double-blind , single-dose studies were conducted to assess the analgesic efficacy and safety of piroxicam for the treatment of moderate or severe postoperative pain . Study 1 evaluated the analgesic efficacy of piroxicam 20 mg compared with that of codeine sulfate 60 mg and placebo . A final patient population of 149 subjects rated pain intensity and pain relief at one half hour and one hour following treatment and then hourly for six hours , with a global assessment made at the completion of 24 hours . Piroxicam 20 mg was significantly more efficacious than placebo for all analgesic variables , including the sum of the pain intensity differences ( SPID ) , total pain relief ( TOTAL ) , percent SPID , duration of effect , and time to remedication . Codeine 60 mg was significantly superior to placebo for percent SPID and some hourly measures . Piroxicam 20 mg was significantly more effective than codeine 60 mg for percent SPID and a few hourly measures including time to remedication . Study 2 assessed the efficacy of piroxicam 20 mg or 40 mg compared with aspirin 648 mg and placebo . Sixty patients rated their pain intensity and relief hourly for 12 hours and at 24 hours after administration of study medication . Both doses of piroxicam were significantly more effective than placebo from Hours 2 to 12 for pain intensity difference ( PID ) and relief scores , as well as for SPID and TOTAL . Aspirin was significantly more effective than placebo from Hours 2 to 8 for relief and Hours 2 to 10 for PID as well as SPID and TOTAL . Piroxicam 40 mg was significantly more effective than aspirin 648 mg for SPID , TOTAL , and hourly measures beginning with Hour 6 through Hour 12 . Piroxicam 20 mg was significantly better than aspirin for a few hourly measures : Hours 7 to 9 for relief and Hour 7 for PID . In addition , effects of piroxicam 20 mg had a significantly longer duration than aspirin . Similarly , piroxicam 20 mg had a significantly longer time to remedication compared with aspirin and placebo . The results of these studies provide evidence in support of the longer duration of analgesic efficacy of piroxicam compared with codeine or aspirin in patients with postoperative pain .
[ "Analgesic", "efficacy", "of", "piroxicam", "in", "the", "treatment", "of", "postoperative", "pain", ".", "Two", "randomized", ",", "double", "-", "blind", ",", "single", "-", "dose", "studies", "were", "conducted", "to", "assess", "the", "analgesic", "efficacy", "and", "safety", "of", "piroxicam", "for", "the", "treatment", "of", "moderate", "or", "severe", "postoperative", "pain", ".", "Study", "1", "evaluated", "the", "analgesic", "efficacy", "of", "piroxicam", "20", "mg", "compared", "with", "that", "of", "codeine", "sulfate", "60", "mg", "and", "placebo", ".", "A", "final", "patient", "population", "of", "149", "subjects", "rated", "pain", "intensity", "and", "pain", "relief", "at", "one", "half", "hour", "and", "one", "hour", "following", "treatment", "and", "then", "hourly", "for", "six", "hours", ",", "with", "a", "global", "assessment", "made", "at", "the", "completion", "of", "24", "hours", ".", "Piroxicam", "20", "mg", "was", "significantly", "more", "efficacious", "than", "placebo", "for", "all", "analgesic", "variables", ",", "including", "the", "sum", "of", "the", "pain", "intensity", "differences", "(", "SPID", ")", ",", "total", "pain", "relief", "(", "TOTAL", ")", ",", "percent", "SPID", ",", "duration", "of", "effect", ",", "and", "time", "to", "remedication", ".", "Codeine", "60", "mg", "was", "significantly", "superior", "to", "placebo", "for", "percent", "SPID", "and", "some", "hourly", "measures", ".", "Piroxicam", "20", "mg", "was", "significantly", "more", "effective", "than", "codeine", "60", "mg", "for", "percent", "SPID", "and", "a", "few", "hourly", "measures", "including", "time", "to", "remedication", ".", "Study", "2", "assessed", "the", "efficacy", "of", "piroxicam", "20", "mg", "or", "40", "mg", "compared", "with", "aspirin", "648", "mg", "and", "placebo", ".", "Sixty", "patients", "rated", "their", "pain", "intensity", "and", "relief", "hourly", "for", "12", "hours", "and", "at", "24", "hours", "after", "administration", "of", "study", "medication", ".", "Both", "doses", "of", "piroxicam", "were", "significantly", "more", "effective", "than", "placebo", "from", "Hours", "2", "to", "12", "for", "pain", "intensity", "difference", "(", "PID", ")", "and", "relief", "scores", ",", "as", "well", "as", "for", "SPID", "and", "TOTAL", ".", "Aspirin", "was", "significantly", "more", "effective", "than", "placebo", "from", "Hours", "2", "to", "8", "for", "relief", "and", "Hours", "2", "to", "10", "for", "PID", "as", "well", "as", "SPID", "and", "TOTAL", ".", "Piroxicam", "40", "mg", "was", "significantly", "more", "effective", "than", "aspirin", "648", "mg", "for", "SPID", ",", "TOTAL", ",", "and", "hourly", "measures", "beginning", "with", "Hour", "6", "through", "Hour", "12", ".", "Piroxicam", "20", "mg", "was", "significantly", "better", "than", "aspirin", "for", "a", "few", "hourly", "measures", ":", "Hours", "7", "to", "9", "for", "relief", "and", "Hour", "7", "for", "PID", ".", "In", "addition", ",", "effects", "of", "piroxicam", "20", "mg", "had", "a", "significantly", "longer", "duration", "than", "aspirin", ".", "Similarly", ",", "piroxicam", "20", "mg", "had", "a", "significantly", "longer", "time", "to", "remedication", "compared", "with", "aspirin", "and", "placebo", ".", "The", "results", "of", "these", "studies", "provide", "evidence", "in", "support", "of", "the", "longer", "duration", "of", "analgesic", "efficacy", "of", "piroxicam", "compared", "with", "codeine", "or", "aspirin", "in", "patients", "with", "postoperative", "pain", "." ]
[ "Outcome_Pain", "Outcome_Other", "Intervention_Pharmacological", "Intervention_Control" ]
Neurologie is an umlsterm, Zeit is an umlsterm, Nationalsozialismus is an umlsterm, Geschichte is an umlsterm, Neurologie is an umlsterm, Leistungen is an umlsterm, Ethik is an umlsterm
DerNervenarzt.80690728.ger.abstr_task0
Sentence: In einem Rueckblick auf die deutsche Neurologie waehrend der Zeit des Nationalsozialismus wird auf die Bedeutung der juedischen Fachkollegen fuer die Geschichte der Neurologie sowie auf den schweren Verlust durch die erzwungene Emigration hingewiesen . Darueber hinaus werden die wissenschaftlichen Leistungen waehrend der NS-Zeit , aber auch die Verstoesse gegen die aerztliche Ethik erwaehnt , dies am Beispiel von Prof. G. Schaltenbrand . Die Bedeutung der bedenklichen Einfluesse eines Zeitgeistes wird hervorgehoben . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
In einem Rueckblick auf die deutsche Neurologie waehrend der Zeit des Nationalsozialismus wird auf die Bedeutung der juedischen Fachkollegen fuer die Geschichte der Neurologie sowie auf den schweren Verlust durch die erzwungene Emigration hingewiesen . Darueber hinaus werden die wissenschaftlichen Leistungen waehrend der NS-Zeit , aber auch die Verstoesse gegen die aerztliche Ethik erwaehnt , dies am Beispiel von Prof. G. Schaltenbrand . Die Bedeutung der bedenklichen Einfluesse eines Zeitgeistes wird hervorgehoben .
[ "In", "einem", "Rueckblick", "auf", "die", "deutsche", "Neurologie", "waehrend", "der", "Zeit", "des", "Nationalsozialismus", "wird", "auf", "die", "Bedeutung", "der", "juedischen", "Fachkollegen", "fuer", "die", "Geschichte", "der", "Neurologie", "sowie", "auf", "den", "schweren", "Verlust", "durch", "die", "erzwungene", "Emigration", "hingewiesen", ".", "Darueber", "hinaus", "werden", "die", "wissenschaftlichen", "Leistungen", "waehrend", "der", "NS", "-", "Zeit", ",", "aber", "auch", "die", "Verstoesse", "gegen", "die", "aerztliche", "Ethik", "erwaehnt", ",", "dies", "am", "Beispiel", "von", "Prof", ".", "G.", "Schaltenbrand", ".", "Die", "Bedeutung", "der", "bedenklichen", "Einfluesse", "eines", "Zeitgeistes", "wird", "hervorgehoben", "." ]
[ "umlsterm" ]
Neurologie is an umlsterm, Zeit is an umlsterm, Nationalsozialismus is an umlsterm, Geschichte is an umlsterm, Neurologie is an umlsterm, Leistungen is an umlsterm, Ethik is an umlsterm
DerNervenarzt.80690728.ger.abstr_task1
Sentence: In einem Rueckblick auf die deutsche Neurologie waehrend der Zeit des Nationalsozialismus wird auf die Bedeutung der juedischen Fachkollegen fuer die Geschichte der Neurologie sowie auf den schweren Verlust durch die erzwungene Emigration hingewiesen . Darueber hinaus werden die wissenschaftlichen Leistungen waehrend der NS-Zeit , aber auch die Verstoesse gegen die aerztliche Ethik erwaehnt , dies am Beispiel von Prof. G. Schaltenbrand . Die Bedeutung der bedenklichen Einfluesse eines Zeitgeistes wird hervorgehoben . Instructions: please typing these entity words according to sentence: Neurologie, Zeit, Nationalsozialismus, Geschichte, Neurologie, Leistungen, Ethik Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
In einem Rueckblick auf die deutsche Neurologie waehrend der Zeit des Nationalsozialismus wird auf die Bedeutung der juedischen Fachkollegen fuer die Geschichte der Neurologie sowie auf den schweren Verlust durch die erzwungene Emigration hingewiesen . Darueber hinaus werden die wissenschaftlichen Leistungen waehrend der NS-Zeit , aber auch die Verstoesse gegen die aerztliche Ethik erwaehnt , dies am Beispiel von Prof. G. Schaltenbrand . Die Bedeutung der bedenklichen Einfluesse eines Zeitgeistes wird hervorgehoben .
[ "In", "einem", "Rueckblick", "auf", "die", "deutsche", "Neurologie", "waehrend", "der", "Zeit", "des", "Nationalsozialismus", "wird", "auf", "die", "Bedeutung", "der", "juedischen", "Fachkollegen", "fuer", "die", "Geschichte", "der", "Neurologie", "sowie", "auf", "den", "schweren", "Verlust", "durch", "die", "erzwungene", "Emigration", "hingewiesen", ".", "Darueber", "hinaus", "werden", "die", "wissenschaftlichen", "Leistungen", "waehrend", "der", "NS", "-", "Zeit", ",", "aber", "auch", "die", "Verstoesse", "gegen", "die", "aerztliche", "Ethik", "erwaehnt", ",", "dies", "am", "Beispiel", "von", "Prof", ".", "G.", "Schaltenbrand", ".", "Die", "Bedeutung", "der", "bedenklichen", "Einfluesse", "eines", "Zeitgeistes", "wird", "hervorgehoben", "." ]
[ "umlsterm" ]
Neurologie, Zeit, Nationalsozialismus, Geschichte, Neurologie, Leistungen, Ethik
DerNervenarzt.80690728.ger.abstr_task2
Sentence: In einem Rueckblick auf die deutsche Neurologie waehrend der Zeit des Nationalsozialismus wird auf die Bedeutung der juedischen Fachkollegen fuer die Geschichte der Neurologie sowie auf den schweren Verlust durch die erzwungene Emigration hingewiesen . Darueber hinaus werden die wissenschaftlichen Leistungen waehrend der NS-Zeit , aber auch die Verstoesse gegen die aerztliche Ethik erwaehnt , dies am Beispiel von Prof. G. Schaltenbrand . Die Bedeutung der bedenklichen Einfluesse eines Zeitgeistes wird hervorgehoben . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
In einem Rueckblick auf die deutsche Neurologie waehrend der Zeit des Nationalsozialismus wird auf die Bedeutung der juedischen Fachkollegen fuer die Geschichte der Neurologie sowie auf den schweren Verlust durch die erzwungene Emigration hingewiesen . Darueber hinaus werden die wissenschaftlichen Leistungen waehrend der NS-Zeit , aber auch die Verstoesse gegen die aerztliche Ethik erwaehnt , dies am Beispiel von Prof. G. Schaltenbrand . Die Bedeutung der bedenklichen Einfluesse eines Zeitgeistes wird hervorgehoben .
[ "In", "einem", "Rueckblick", "auf", "die", "deutsche", "Neurologie", "waehrend", "der", "Zeit", "des", "Nationalsozialismus", "wird", "auf", "die", "Bedeutung", "der", "juedischen", "Fachkollegen", "fuer", "die", "Geschichte", "der", "Neurologie", "sowie", "auf", "den", "schweren", "Verlust", "durch", "die", "erzwungene", "Emigration", "hingewiesen", ".", "Darueber", "hinaus", "werden", "die", "wissenschaftlichen", "Leistungen", "waehrend", "der", "NS", "-", "Zeit", ",", "aber", "auch", "die", "Verstoesse", "gegen", "die", "aerztliche", "Ethik", "erwaehnt", ",", "dies", "am", "Beispiel", "von", "Prof", ".", "G.", "Schaltenbrand", ".", "Die", "Bedeutung", "der", "bedenklichen", "Einfluesse", "eines", "Zeitgeistes", "wird", "hervorgehoben", "." ]
[ "umlsterm" ]